

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088106 A2

(51) International Patent Classification⁷: C07D 307/00

(21) International Application Number: PCT/IB01/02906

(22) International Filing Date:
16 November 2001 (16.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/252,802 17 November 2000 (17.11.2000) US
60/252,840 17 November 2000 (17.11.2000) US

(71) Applicant: **MEDIVIR AB** [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors: **QUIBELL, Martin**; Medivir UK Ltd., Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). **TAYLOR, Steven**; Medivir UK Ltd., Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). **GRABOWSKA, Urszula**; Medivir UK Ltd., Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). **NILSSON, Magnus**; Medivir UK Ltd., Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB). **MORISSON, Veronique**; Medivir UK Ltd., Peterhouse Technology Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB).

(74) Agent: **SVENSSON, Leonard, R.**; Birch, Stewart, Kolasch & Birch, LLP, P.O. Box 747, Falls Church, VA 22040-0747 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYSTEINE PROTEASE INHIBITORS



(IV)

(57) Abstract: In formula (IV) R1 = R'C(O), R'SO₂, R' = a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b), and c) below; or R' = a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b); R4 = H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7-alkenyl; R3 = C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar; R5 = C1-7-alkyl, halogen, Ar-C1-7-alkyl, C0-3-alkyl-CONR₃R₄ or a bulky amine, R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO₂-R^{ia}, C1-3-alkyl-C(O)-NHR^{ia} or CH₂XAr, q is 0 or 1, have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.

Cysteine Protease Inhibitors

Field of the invention.


This invention relates to inhibitors of cysteine proteases, especially those of the papain superfamily. The invention provides novel compounds useful in the prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K, or pathogenic proteases such as malarial falcipain.

Description of the related art.

The papain superfamily of cysteine proteases is widely distributed in diverse species including mammals, invertebrates, protozoa, plants and bacteria. A number of mammalian cathepsin enzymes, including cathepsins B, F, H, K, L, N and S, have been ascribed to this superfamily, and inappropriate regulation of their activity has been implicated in a number of metabolic disorders including arthritis, muscular dystrophy, inflammation, glomerulonephritis and tumour invasion. Pathogenic cathepsin like enzymes include the bacterial gingipains, the malarial falcipains I, II, III et seq and cysteine proteases from *Pneumocystis carinii*, *Trypanosoma cruzi* and *brucei*, *Crithidia fusiculata*, *Schistosoma* spp.

The inappropriate regulation of cathepsin K has been implicated in a number of disorders including osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's disease, hypercalcaemia of malignancy and metabolic bone disease. In view of its elevated levels in chondroclasts of osteoarthritic synovium, cathepsin K is implicated in diseases characterised by excessive cartilage or matrix degradation, such as osteoarthritis and rheumatoid arthritis. Metastatic neoplastic cells typically express high levels of proteolytic enzymes that degrade the surrounding matrix and inhibition of cathepsin K may thus assist in treating neoplasias.

WO 98/50533 describes the use of compounds according to the formula (I).



(I)

It is suggested the compounds of this formula, are useful as inhibitors to proteases, in particular the papain superfamily; specifically those of the Cathepsin family; and particularly Cathepsin K. The ketone bearing ring structure in these compounds has a tendency to spontaneously racemise, limiting their clinical utility. Other SKB applications describing ketone cathepsin K inhibitors include WO 98 46582, WO9964399, WO0029408, WO0038687 and WO0049011. However, none of these applications disclose α -ring substituents adjacent the linkage to the peptidomimetic chain.


Shenai et al, J Biol. Chem. 275 37 29000-29010 describes the isolation of a major cysteine protease, denoted falcipain 2 from trophozoites of *Plasmodium falciparum*. The enzyme appears inter alia to hydrolyse erythrocyte haemoglobin in acidic food vacuoles. This publication also describes the isolation of the corresponding gene using an N-terminus tag, which is autocatalytically removed during folding.

SmithKline Beecham's WO 99/53039 describes the cysteine protease inhibitory activity of a diverse range of peptidomimetics on a trophozoite preparation from *Plasmodium falciparum*. No guidance is provided as to which cysteine protease is being inhibited. Although most of the peptidomimetics are linear structures, one compound (R,S)-3-[N-(3-benzyloxybenzoyl)-L-leucinylamino]tetrahydrofuran-4-one belongs to the furanones of formula I depicted above. As would be expected of such structures, the ketone bearing ring is racemic.

Our copending PCT application WO00/69855 published after the present priority date, discloses cathepsin S inhibitors comprising a monocyclic P3 filling group.

5 Summary of the invention

A first aspect of the invention provides compounds of the formula (IV):



where:

10 R1 = R'C(O) R' SO2 ,

R' = a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which ring system is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or

15 R' = a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c), and which may optionally bear one or two further substituents selected from group b);

20 a) a cyclic group which may be linked direct to the R' ring or via an alkyl, alkylether, alkylthioether, alkylamine, alkylamide, alkylsulphonamide, alkylsulphone, alkylurea, alkylketone or alkylester linker; or

b) H, C1-7alkyl, C3-6cycloalkyl, OH, SH, NH₂ , NHC1-3alkyl, N(C1-3alkyl)₂, halogen; or

25 c) O-C1-4alkyl, S-C1-4alkyl, SOC1-4alkyl, SO₂C1-4alkyl, CO₂C0-4alkyl, NHCOC0-4alkyl, CONHC0-4alkyl, COC0-4alkyl, NHC(=NH)NH₂;


R4 = H, C1-7-alkyl, Ar-C1-7 alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl ;

R3 = C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl,

30 Ar;

R⁵ = C1-7-alkyl, halogen, Ar- C1-7-alkyl, C0-3-alkyl-CONR³R⁴ or R^{iv};

R^{iv} =



where n = 1-3, m = 1-3;

5 R^v, R^{vi} = H, C1-7-alkyl;

A = N, CH; B = N, O, S, CH;

R^{vii} = absent when B = O, S; or R^{vii} = H, C1-7-alkyl when B = N, CH;

R^{viii} = O, C1-7-alkyl;

R⁶ = H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO₂-R^{ix}, C1-3-alkyl-C(O)-NHR^{ix}

10 or CH₂XAr;

R^{ix} is C1-7-alkyl, C3-C6-cycloalkyl or Ar-C1-7-alkyl;

q is zero (ie -C(R₆)- is a bond) or 1

and pharmaceutically acceptable salts thereof.

15 Compounds of the invention have utility in the treatment or prophylaxis of various disorders characterised by the presence or inappropriate activity of cysteine proteases of the papain superfamily, such as cathepsins B, F, L, S and especially cathepsin K or falcipain.

20 'C1-7-alkyl' as applied herein is meant to include straight and branched chain aliphatic carbon chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, hexyl, heptyl and any simple isomers thereof. Additionally, any C1-7-alkyl may optionally be substituted by one or two halogens and/or a heteroatom S, O, NH. If the heteroatom is located at a
25 chain terminus then it is appropriately substituted with one or 2 hydrogen atoms, for example hydroxymethyl. Sulphur heteroatoms may further be oxidised to sulphones.

'C1-3-alkyl' as applied herein includes methyl, ethyl, propyl, isopropyl, cyclopropyl, any of which may be optionally substituted as described in the paragraph above.

5 'Amine' includes NH₂, NHC1-3-alkyl or N(C1-3-alkyl)₂.

'Halogen' as applied herein is meant to include F, Cl, Br, I, particularly chloro and preferably fluoro.

10 'C3-6-cycloalkyl' (or C3-7-cycloalkyl) as applied herein is meant to include any variation of 'C1-7-alkyl' which additionally contains a C3-6 (or C3-7) carbocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl. Alternatively the C3-6 or C3-7 cyclopropyl may be spiro bound to the adjacent carbon without an intervening C1-C7 alkyl.

15

'Ar- C1-7-alkyl' as applied herein is meant to include a phenyl, pyrazolyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazinyl, isothiazinyl, thiazolyl, oxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, furanyl or thienyl aromatic ring (Ar) attached through a 'C1-7-alkyl' (defined above) to the dihydro-(3H)-furanone
20 ring system or in the case of R₂, R₃ or R₄ linked directly to the molecule backbone. Optionally, the aromatic ring Ar may be substituted with halogen, C1-3-alkyl, OH, OC1-3-alkyl, SH, SC1-3-alkyl, amine and the like.

The cyclic substituent a) to R' may be saturated, unsaturated or aromatic and
25 have 0 to 4 hetero atoms including monocyclic rings such as phenyl, cycloalkenyl, such as cyclohexenyl or cyclopentenyl, furyl, thienyl, pyranlyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl,
30 morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, and the like or bicyclic rings such as naphthyl and especially any of the above fused to a phenyl ring such as indolyl, quinolynyl, isoquinolynyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzothienyl etc. The carbo or heterocyclic ring substituent may be bonded via a carbon or via a hetero atom, typically a

nitrogen atom, such as N-piperidyl, N-morpholinyl etc. The ring substituent a) may itself be substituted with substituents as for Ar above. The ring substituent a) excludes cycloalkyl as defined in subgroup b).

- 5 The optional alkyl, alkylether, alkylthioether, alkylamine, alkylamide, alkylsulphonamide, alkylsulphone, alkylurea, alkylketone or alkylester linkage between R' and ring substituent a) may comprise up to 6 carbon atoms, typically up to four carbon atoms, for instance 1 or 2. If present, the ether, thioether, amine, amide, sulphonamide, sulphone, urea, ketone or ester
- 10 component may be located adjacent the R' ring, (for example a morpholinoethoxy substituent) adjacent the substituent ring (for example a phenylsulphonethyl substituent) or intermediate two alkyl groups, (for example a benzoyloxymethyl substituent).
- 15 'C1-3-alkyl-CONR'''', R^{iv} as applied herein is meant to include straight or branched carbon chain substituted with a 1°, 2° or 3° carboxamide wherein R''', R^{iv} includes H and Me.

- 'C1-3-alkyl-SO₂-R^{ix}', as applied herein is meant to include straight or branched
- 20 carbon chain substituted with a sulphone wherein R^{ix} includes 'C1-7-alkyl', 'Ar-C1-7-alkyl', 'C3-6-cycloalkyl'.

- 'C1-3-alkyl-C(O)-NHR^{ix}', as applied herein is meant to include straight or branched carbon chain substituted with a secondary carboxamide wherein R^{ix}
- 25 includes 'C1-7-alkyl', 'Ar-C1-7-alkyl', 'C3-6-cycloalkyl'.

Preferred R' groups include bicyclic rings such as naphthyl, quinoloyl, benzofuranyl, benzothienyl, indolyl and indoliny, particularly where the linkage is to the 2 position of the R' ring.

- 30 Additional bicyclic groups include naphthalenyl, especially naphthylen-2-yl; benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl, benzofuranyl, especially benzofuran-2-yl, and especially C1-6 alkoxy substituted benzofuranyl, more especially 5-(2-piperazin-4-carboxylic acid

- tert-butyl ester- ethoxy) benzofuran-2-yl,
5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-yl, 5-(2-piperazin-1-yl-ethoxy)benzofuran-2-yl, 5-(2-cyclohexyl-ethoxy)-benzofuran-2-yl;
7-methoxy-benzofuran-2-yl, 5-methoxy-benzofuran-2-yl,
5 5,6-dimethoxy-benzofuran-2-yl, especially halogen substituted benzofuranyl, more especially 5-fluoro-benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl, especially C 1-6alkyl substituted benzofuranyl, most especially 3-methyl-benzofuran-2-yl;
benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl; especially C1-6alkoxy
10 substituted benzo[b]thiophenyl, more especially 5,6-dimethoxy-benzo[b]thiophen-2-yl
quinoliny, especially quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-6-yl, and quinolin-5-yl;
quinoxaliny, especially quinoxalin-2-yl;
15 1,8 naphthyridiny, especially 1,8 naphthyridin-2-yl;
indoly, especially indol-2-yl, especially indol-6-yl, indol-5-yl, especially C1-6alkyl substituted indoly, more especially N-methylindol-2-yl;
furo[3,2-b]pyridiny, especially furo[3,2-b]pyridin-2-yl, and C1-6alkyl substituted furo[3,2-b]pyridiny, especially 3-methyl-furo[3,2-b]pyridin-2-yl;
20 thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl, more especially C1-6alkyl substituted thieno[3,2-b]thiophene-2-yl, more especially 5-tert-butyl-3-methylthieno[3,2-b]thiophene-2-yl.

- Monocyclic R' groups include substituted pyridyl, substitute pyrimidyl,
25 substituted phenyl, particularly phenyl substituted with a cyclic group such as pyrrolidine-1-yl, piperidine-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 2-morpholin-4-yl-ethylamino, and piperazin-1-yl. A phenyl R' is conveniently substituted at the 3 or 4 position with such a cyclic group.
- 30 If a chiral centre is present, all isomeric forms are intended to be covered. Both (R) and (S) stereochemistries at the position corresponding to the furan 5-position (ie R5 adjacent the linkage to the peptidomimetic chain) are encompassed by the invention with (R) being convenient in some cases, for instance in cathepsin K or falcipain inhibitors, particularly in conjunction with R

stereochemistry at the pyranone 4 bond. Alternatively R5 and the furanone/pyranone C4-bond conveniently both have the S stereochemistry.

The compounds of the invention are cysteine protease inhibitors, notably
5 against cathepsins or cathepsin-like proteases of the papain superfamily. Ideally the compound displays selective inhibition of a single protease in the complex mixture of proteolytic enzymes characterising the physiological environment, for example a greater than 10-fold selectivity, preferably greater than 100 fold. Most preferably inhibitory specificity is exhibited over other
10 members of the same enzyme class or family, such as the Cathepsin family, which have a high degree of homology, as incorrect regulation of proteolytic activity can lead to unwanted pathological conditions such as hypertension, blood clotting or worse. This is especially desirable for disorders such as autoimmune disorders where administration of the drug is likely to be
15 protracted.

However, compounds can be useful notwithstanding that they exhibit a degree of promiscuity in relation to inhibition of physiological proteases. For example the physiological functions of many cathepsins are redundant, that is
20 inhibition of a particular cysteine protease can be compensated by the presence or upregulation of other non-inhibited proteases or alternative metabolic routes. Alternatively, treatments of short duration can result only in transient toxicity or other side effects.

25 The cross-specificity of cysteine proteases for a given putative inhibitor (ie the selectivity of the inhibitor) is readily ascertained with conventional enzyme and cell culture assays performed in parallel with the respective enzymes.

A further aspect of the invention comprises a method employing the
30 compounds of formula IV for the treatment of diseases wherein cathepsin K is a factor, ie diseases or conditions alleviated or modified by inhibition of cathepsin K, preferably without substantial concomitant inhibition of other human members of the papain superfamily.

The invention further provides the use of the compounds of formula IV in therapy and in the manufacture of a medicament for the treatment of diseases or conditions alleviated or moderated by inhibition of cathepsin K

- 5 A further aspect of the invention provides methods for the treatment or prophylaxis of a parasitical infection such as a protozoal or bacterial infection comprising the administration of a compound of formula IV, to a mammal in need thereof. A still further aspect provides a method for the control of protozoal parasites comprising the administration of a compound of formula IV
10 but without the proviso, to an invertebrate vector and/or to a locus prone to infestation of such a vector.

Conveniently the protozoal or bacterial parasite is a Plasmodium, Leishmania, Schistosoma, Giardia, Entamoeba, Trypanosoma, Crithidia, Pneumocystis or
15 Porphyromonas species.

Suitably, the treatment or prophylaxis of Plasmodium falciparum comprises inhibition of a falcipain II enzyme.

- 20 Preferred R3 groups for parasite treatment and prophylaxis include 2-methylpropen-1-yl; or isobutyl or benzyl, especially with the stereochemistry corresponding to the side chain of L-leucine and L-phenylalanine.

Preferred R3 groups for cathepsin K inhibition include the sidechain
25 corresponding to L-leucine.

The R5 substituent confers many beneficial qualities to molecules of general formula (II) including improvements in potency and offers the potential to append inhibitor molecules with a basic functionality to improve solubility and
30 pharmacokinetic properties. It should be remembered that many cathepsins such as cathepsin K and falcipain are active in acidic vacuoles or physiological microenvironments which may favour basic functionality at this position. Additionally, molecules of formula (IV) where R5 is alkyl or other substituent and not simply hydrogen tend to show good chiral stability at the

furanone (or corresponding for the pyranone) α -carbon (denoted ring position 4 or C4 herein, unless the context requires otherwise). By chirally stable is meant that the compounds of the invention exist as a predominant stereoisomer rather than an equal mixture of stereoisomers differing in stereochemistry at C4. Preferably the compounds of the invention are at least 90% diastereomically pure.

Note particularly the presence of the substituent R5 in formula (II) in comparison with the absence of any substituent in the same position in formula (I) according to WO 98/50533, WO 98/46582, WO99/64399, WO00/29408, WO00/38687 and WO00/49011.

Interesting compounds of formula II, particularly in the context of cathepsin K inhibition include:

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-2-phenethyl-benzamide

Benzofuran-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-pentyl]-amide

Benzofuran-2-carboxylic acid [1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-cyclohexyl]-amide

Benzofuran-2-carboxylic-acid-[1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-cyclopentyl]-amide

Naphthalene-2-carboxylic-acid-[1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-cyclohexyl]-amide

Benzofuran-2-carboxylic-acid-[2-cyclopropyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-ethyl]-amide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-pyrrol-1-yl-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-piperidin-1-yl-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-morpholin-4-yl-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-piperazin-1-yl-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-(4-methyl-piperazin-1-yl)-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-pyrrolidin-1-yl-benzamide

4-(3,3-Dimethyl-piperazin-1-yl)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-(2,2-Dimethyl-piperazin-1-yl)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-(4-Allyl-piperazin-1-yl)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-(4-Cyclopropylmethyl-piperazin-1-yl)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

1,2,3,4-Tetrahydro-quinoline-6-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

Benzothiazole-5-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

4-Azepan-1-yl-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-[1,4]Diazepan-1-yl-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-(2-Methylamino-ethylamino)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

Naphthalene-1-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

Benzo-furan-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

Benzo[*b*]thiophene-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

5-Methoxy-benzofuran-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

5-Methoxy-benzofuran-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-but-3*S*-enyl]-amide

4-Acetyl-amino-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-morpholin-4-ylmethyl-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-piperidin-1-ylmethyl-benzamide

Piperidine-1-carboxylic-acid-{4-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butylcarbamoyl]-phenyl}-amide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-but-3-enyl]-*N'*-phenyl-terephthalamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-*N'*-phenyl-terephthalamide

N-Ethyl-*N'*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-but-3-enyl]-terephthalamide

N-Ethyl-*N'*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-terephthalamide

4-Hydroxy-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-3-morpholin-4-ylmethyl-benzamide

4-Hydroxy-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-but-3-enyl]-3-morpholin-4-ylmethyl-benzamide

Biphenyl-4-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

4-*tert*-Butyl-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-*tert*-Butyl-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-but-3-enyl]-benzamide

4-Guanidino-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-Guanidino-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-but-3-enyl]-benzamide

5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylicacid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-but-3-enyl]-amide

Naphthalene-2-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

4-Benzenesulfonylamino-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

3,4,5,6-Tetrahydro-2*H*-[1,4']bipyridinyl-4-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

4-(1-Methyl-4,5-dihydro-1*H*-imidazol-2-yl)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

4-(Benzyl-methyl-amino)-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

N-[3-Methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-4-phenylamino-benzamide

4-Benzylamino-*N*-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-benzamide

1-Methyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic-acid-[3-methyl-1*S*-(2*R*-methyl-4-oxo-tetrahydro-furan-3*S*-ylcarbamoyl)-butyl]-amide

and the corresponding *R*5 hydroxymethyl compounds;
and pharmaceutically acceptable salts thereof

- 5 Additional preferred compounds include
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-pyrrolidin-1-yl-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-piperidin-1-yl-benzamide
- 10 *N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-morpholin-4-yl-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-(4-methyl-piperazin-1-yl)-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-
- 15 (2-morpholin-4-yl-ethylamino)-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-piperazin-1-yl-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-4-[(piperidin-4-ylmethyl)-amino]-benzamide
- 20 4-Hydroxy-*N*-[3-methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-3-morpholin-4-ylmethyl-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-3-pyrrolidin-1-yl-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-3-
- 25 piperidin-1-yl-benzamide
- N*-[3-Methyl-1*S*-(3*S*-methyl-5-oxo-tetrahydro-pyran-4*S*-ylcarbamoyl)-butyl]-3-morpholin-4-yl-benzamide

- N-[3-Methyl-1S-(3S-methyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-(4-methyl-piperazin-1-yl)-benzamide
N-[3-Methyl-1S-(3S-methyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-(2-morpholin-4-yl-ethylamino)-benzamide
- 5 N-[3-Methyl-1S-(3S-methyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-piperazin-1-yl-benzamide
N-[3-Methyl-1S-(3S-methyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-[(piperidin-4-ylmethyl)-amino]-benzamide
N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-pyrrolidin-1-yl-benzamide
- 10 N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-piperidin-1-yl-benzamide
N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-morpholin-4-yl-benzamide
- 15 N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-(4-methyl-piperazin-1-yl)-benzamide
N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-(2-morpholin-4-yl-ethylamino)-benzamide
N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-piperazin-1-yl-benzamide
- 20 N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-[(piperidin-4-ylmethyl)-amino]-benzamide
N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-4-hydroxy-3-morpholin-4-ylmethyl-benzamide
- 25 N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-pyrrolidin-1-yl-benzamide
N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-piperidin-1-yl-benzamide

- N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-morpholin-4-yl-benzamide
- N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-(4-methyl-piperazin-1-yl)-benzamide
- 5 N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-(2-morpholin-4-yl-ethylamino)-benzamide
- N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-piperazin-1-yl-benzamide
- N-[1S-(3S-Ethyl-5-oxo-tetrahydro-pyran-4S-ylcarbamoyl)-3-methyl-butyl]-3-
10 [(piperidin-4-ylmethyl)-amino]-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-pyrrolidin-1-yl-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-piperidin-1-yl-benzamide
- 15 N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-morpholin-4-yl-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-(4-methyl-piperazin-1-yl)-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-
20 (2-morpholin-4-yl-ethylamino)-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-piperazin-1-yl-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-4-
[(piperidin-4-ylmethyl)-amino]-benzamide
- 25 4-Hydroxy-N-[3-methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-morpholin-4-ylmethyl-benzamide
- N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-pyrrolidin-1-yl-benzamide

N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-piperidin-1-yl-benzamide

N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-morpholin-4-yl-benzamide

5 N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-(4-methyl-piperazin-1-yl)-benzamide

N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-(2-morpholin-4-yl-ethylamino)-benzamide

10 N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-piperazin-1-yl-benzamide

N-[3-Methyl-1S-(3S-oxo-5-propyl-tetrahydro-pyran-4S-ylcarbamoyl)-butyl]-3-[(piperidin-4-ylmethyl)-amino]-benzamide;

the corresponding 3R,4R stereoisomers of the respective compounds enumerated above;

15 and pharmaceutically acceptable salts thereof

The compounds of the invention can form salts which form an additional aspect of the invention. Appropriate pharmaceutically acceptable salts of the compounds of Formula II include salts of organic acids, especially carboxylic acids, including but not limited to acetate, trifluoroacetate, lactate, gluconate, 20 citrate, tartrate, maleate, malate, pantothenate, isethionate, adipate, alginate, aspartate, benzoate, butyrate, digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate, hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, proprionate, 25 tartrate, lactobionate, pivalate, camphorate, undecanoate and succinate, organic sulphonic acids such as methanesulphonate, ethanesulphonate, 2-hydroxyethane sulphonate, camphorsulphonate, 2-napthalenesulphonate, benzenesulphonate, p-chlorobenzenesulphonate and p-toluenesulphonate; and inorganic acids such as hydrochloride, hydrobromide, hydroiodide, 30 sulphate, bisulphate, hemisulphate, thiocyanate, persulphate, phosphoric and sulphonic acids. The compounds of Formula II may in some cases be isolated as the hydrate.

It will be appreciated that the invention extends to prodrugs solvates, complexes and other forms releasing a compound of formula II in vivo.

- 5 While it is possible for the active agent to be administered alone, it is preferable to present it as part of a pharmaceutical formulation. Such a formulation will comprise the above defined active agent together with one or more acceptable carriers/excipients and optionally other therapeutic ingredients. The carrier(s) must be acceptable in the sense of being
10 compatible with the other ingredients of the formulation and not deleterious to the recipient.

The formulations include those suitable for rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous,
15 intramuscular, intravenous and intradermal) administration, but preferably the formulation is an orally administered formulation. The formulations may conveniently be presented in unit dosage form, e.g. tablets and sustained release capsules, and may be prepared by any methods well known in the art of pharmacy.

- 20 Such methods include the step of bringing into association the above defined active agent with the carrier. In general, the formulations are prepared by uniformly and intimately bringing into association the active agent with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. The invention extends to methods for preparing a pharmaceutical
25 composition comprising bringing a compound of Formula II or its pharmaceutically acceptable salt in conjunction or association with a pharmaceutically acceptable carrier or vehicle. If the manufacture of pharmaceutical formulations involves intimate mixing of pharmaceutical
30 excipients and the active ingredient in salt form, then it is often preferred to use excipients which are non-basic in nature, i.e. either acidic or neutral.

Formulations for oral administration in the present invention may be presented as discrete units such as capsules, cachets or tablets each containing a

predetermined amount of the active agent; as a powder or granules; as a solution or a suspension of the active agent in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water in oil liquid emulsion and as a bolus etc.

5

With regard to compositions for oral administration (e.g. tablets and capsules), the term suitable carrier includes vehicles such as common excipients e.g. binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone (Povidone), methylcellulose, ethylcellulose, sodium
10 carboxymethylcellulose, hydroxypropylmethylcellulose, sucrose and starch; fillers and carriers, for example corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride and alginic acid; and lubricants such as magnesium stearate, sodium stearate and other metallic stearates, glycerol stearate stearic acid, silicone
15 fluid, talc waxes, oils and colloidal silica. Flavouring agents such as peppermint, oil of wintergreen, cherry flavouring or the like can also be used. It may be desirable to add a colouring agent to make the dosage form readily identifiable. Tablets may also be coated by methods well known in the art.

20 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active agent in a free flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Moulded tablets may
25 be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active agent.

30 Other formulations suitable for oral administration include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active agent in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active agent in a suitable liquid carrier.

The appropriate dosage for the compounds or formulations of the invention will depend upon the indication and the patient and is readily determined by conventional animal trials. Dosages providing intracellular (for inhibition of physiological proteases of the papain superfamily) concentrations of the order 0.01-100 μ M, more preferably .01-10 μ M, such as 0.1-25 μ M are typically desirable and achievable. Ex vivo or topical administration against parasites will typically involve higher concentrations.



10 The term "N-protecting group" or "N-protected" and the like as used herein refers to those groups intended to protect the N-terminus of an amino acid or peptide or to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis" (John Wiley & Sons, New York, 1981), which is hereby incorporated by reference. N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxycetyl, α -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonyl groups such as benzenesulfonyl, p-toluenesulfonyl, and the like, carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butoxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexylloxycarbonyl, phenylthiocarbonyl, and the like; alkyl groups such as benzyl, triphenylmethyl, benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the

like. Favoured N-protecting groups include formyl, acetyl, allyl, Fmoc, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, t-butoxycarbonyl (Boc) and benzyloxycarbonyl (Cbz).

- 5 Hydroxy and/or carboxy protecting groups are also extensively reviewed in Greene *ibid* and include ethers such as methyl, substituted methyl ethers such as methoxymethyl, methylthiomethyl, benzyloxymethyl, t-butoxymethyl, 2-methoxyethoxymethyl and the like, silyl ethers such as trimethylsilyl (TMS), t-butyldimethylsilyl (TBDMS) tribenzylsilyl, triphenylsilyl, t-butyldiphenylsilyl
10 (TBDPS), triisopropyl silyl and the like, substituted ethyl ethers such as 1-ethoxymethyl, 1-methyl-1-methoxyethyl, t-butyl, allyl, benzyl, p-methoxybenzyl, diphenylmethyl, triphenylmethyl and the like, aralkyl groups such as trityl, and pixyl (9-hydroxy-9-phenylxanthene derivatives, especially the chloride). Ester hydroxy protecting groups include esters such as formate,
15 benzylformate, chloroacetate, methoxyacetate, phenoxyacetate, pivaloate, adamantate, mesitoate, benzoate and the like. Carbonate hydroxy protecting groups include methyl vinyl, allyl, cinnamyl, benzyl and the like.



- Compounds of the invention are synthesised by a combination of chemistries,
20 performed either in solution or on the solid phase. The synthesis methodology described in schemes 1-8 of our copending PCT/GB00/01894 but employing the appropriate R' capping group is convenient for the compounds of the invention.

- 25 Scheme 1 . Preparation of dihydro-2(3H)-5-alkyl furanone ring system

Scheme 1

where
 R = H or ^tBu
 R' = R5 in general formula (II)
 R'' = Boc or Fmoc


18, 23
 where
 R'' = Fmoc
 18 R' = Ethyl
 23 R' = Methyl




where
 R = H or ^tBu
 R' = R5 in general formula (II)
 R'' = Boc or Fmoc

22
 where
 R'' = Fmoc
 22 R' = Methyl


a) Fmoc-Cl, Na₂CO₃ or Boc₂O; b) ^tBuOCOC₂H₅, NMM, THF; c) CH₂N₂ in Et₂O; d) AcOH; e) LiCl in 80% AcOH



Scheme 2. Preparation of chiral β -alkylserine aminoacids, exemplified by (2S, 3S)- β -ethylserine (15)




Scheme 3. Sugar route for the preparation of chiral α -alkylserine aminoacids, exemplified by (2S, 3S)- β -ethylserine (15)




Scheme 4. Novel P2 hybrids by the CuCN catalysed cross coupling of Zn activated α -iodoalanine with allyl bromides (with permission from Dexter &


5 Jackson *ibid*)



Scheme 5. Solid phase synthesis of dihydro-2(3H)-5-alkyl furanone inhibitors of cathepsin (also applicable to the corresponding pyranones)



5 Scheme 6. Solution phase preparation of 3(2H)-furanone inhibitors



Scheme 6A solution phase N-terminal extension and capping of a pyranone building block


5

10

15

Additional routes to building blocks include:

Scheme 7




a) $i\text{BuOCOC}\text{Cl}$, NMM; b) diazomethane in Et_2O ; c) LiCl (10eq) in 80 % acetic acid; d) 4M HCl in dioxane; e) Boc-Leu-Opfp, HOBt, NMM, DMF; f) 4M HCl in dioxane; g) 2-naphthoic acid, HBTU, HOBt, NMM, DMF.

- 10 Compounds of the general formula (IV), wherein $q = 0$, are prepared by methods shown in Scheme 7. Activation of the known Boc-aminoacid 1-Scheme-7 with isobutyl chloroformate and 4-methylmorpholine provides 2-Scheme-7. Subsequent treatment of 2-Scheme-7 with diazomethane provides the diazoketone 3-Scheme-7. Cyclization of diazoketone 3-Scheme-7 can be
- 15 effected by lithium chloride/aqueous acetic acid to give the dihydro-3(2H)-furanone 4-Scheme-7. The *tert*-butoxycarbonyl group may be removed from 4-Scheme-7, by treatment with acid, and provides the amine salt 5-Scheme-7. The amine salt 5-Scheme-7 may be coupled with a carboxylic acid by methods that are known in the art, such as coupling with a pentafluorophenol
- 20 derivative in the presence of HOBt and NMM, to provide the amide 6-Scheme-7. The *tert*-butoxycarbonyl group may be removed from 6-Scheme-7 by treatment with an acid, such as hydrogen chloride in dioxane, to provide the amine salt 7-Scheme-7. The amine salt 7-Scheme-7 may be coupled with a carboxylic acid by methods that are known in the art, such as coupling with

an acid in the presence of HBTU and HOBT, to provide the amide 8-Scheme-7.

Scheme 8




- 5 a) OsO_4 , NMM; b) TBDPSCl, imidazole, DMF/ CH_2Cl_2 ; c) allyl bromide, TBAF, Bu_2SnO ; d) LiOH in THF/ H_2O ; e) $^t\text{BuOCOC}$ l, NMM; f) diazomethane in Et_2O ;
 10 g) LiCl (10eq) in 80 % acetic acid; h) $(\text{Ph}_3\text{P})_4\text{Pd}$, CHCl_3 , AcOH, NMM; i) $(\text{MeO})_3\text{CH}$, *p*-toluenesulphonic acid, MeOH; j) TsCl, pyridine; k) $\text{Me}_2\text{CuCNLi}_2$;
 l) 10 % Pd on carbon, H_2 ; m) Boc-Leu-Opfp, HOBT, NMM, DMF; n) 4M HCl in dioxane; o) 2-naphthoic acid, HBTU, HOBT, NMM, DMF; p) TFA, NaHCO_3

Compounds of the general formula (IV), wherein $q = 1$, are prepared by methods shown in Scheme 8. Treatment of the known Cbz-ethyl ester 1-Scheme-8 with osmium tetroxide and 4-methylmorpholine provides the diol 2-

- Scheme-8. Protection of the primary alcohol may be effected with *tert*-butyldiphenylsilylchloride and imidazole to provide 3-Scheme-8. Protection of the secondary alcohol 3-Scheme-8 may be achieved with allyl bromide and subsequent base hydrolysis of the ethyl ester provides 4-Scheme-8.
- 5 Activation of the acid 4-Scheme-8 may be achieved with isobutyl chloroformate and 4-methylmorpholine to provide 5-Scheme-8. Subsequent treatment of 5-Scheme-8 with diazomethane provides the diazoketone 6-Scheme-8. Cyclization of diazoketone 6-Scheme-8 can be effected by lithium chloride/aqueous acetic acid to give the 3-pyranone 7-Scheme-8. The allyl
- 10 protection may be removed from 7-Scheme-8, by treatment with palladium(0) and acid, to provide alcohol 8-Scheme-8. Ketal formation from ketone 8-Scheme-8 may be effected by treatment with trimethylorthoformate and *p*-toluenesulphonic acid to provide 9-Scheme-8. Conversion of the alcohol 9-Scheme-8 to the methyl derivative 10-Scheme 8 can be achieved utilising
- 15 methods that are known in the art, such as tosylation with tosylchloride and pyridine, with subsequent reaction with the higher order cuprate prepared from methyl lithium. Removal of the Cbz protecting group from 10-Scheme 8 may be achieved with 10% Pd on carbon in the presence of hydrogen to provide 11-Scheme-8. The amine 11-Scheme-8 can be coupled with a
- 20 carboxylic acid by methods that are known in the art, such as coupling with a pentafluorophenol derivative in the presence of HOBT and NMM, to provide the amide 12-Scheme-8. The *tert*-butoxycarbonyl group may be removed by treatment with an acid, such as hydrogen chloride in dioxane and the amine salt subsequently coupled with a carboxylic acid by methods that are known in
- 25 the art, such as coupling with an acid in the presence of HBTU and HOBT, to provide the amide 13-Scheme-8. Removal of the ketal functionality from 13-Scheme-8 may be achieved with trifluoroacetic acid in the presence of sodium hydrogen carbonate to provide 14-Scheme-8.
- 30 Compounds of the general formula II wherein q = 1 can alternatively be prepared by the methods shown in Scheme 9.

Scheme 9



- a) pyridine, acetic anhydride; b) triethylsilane, trimethylsilyl triflate; c) sodium methoxide, methanol; d) cyclohexanone diethylacetal; e) Swern oxidation; f) $\text{PPh}_3\text{CHCH}_3$, THF; g) H_2 , palladium on carbon, sodium bicarbonate; h) 80% aqueous acetic acid; i) sodium hydride, benzyl bromide; j) mesyl chloride, pyridine; k) sodium azide, DMF; l) H_2 , palladium on carbon, di-(*tert*-butyloxy)carbonyl; m) Dess-Martin periodinane

10

Lyxose 1-scheme-9 can be peracetylated to give 2-scheme-9 with acetic anhydride in pyridine at room temperature overnight. Reduction at the anomeric centre to afford 3-scheme-9 may be achieved using triethylsilane in the presence of trimethylsilyl triflate. Hydrolysis of the triacetate 3-scheme-9 affords 4-scheme-9 whereupon the vicinal diol can be protected as the

15

cyclohexanone acetal 5-scheme-9. Swern oxidation of the unprotected alcohol functionality gives 6-scheme-9, a key intermediate for the introduction of the required C5 pyranone substitution. Ethyl substitution is achieved here by treatment with ethyl triphenylphosphonium bromide with potassium *tert*-butoxide in THF at 0°C to produce 7-scheme-9. Hydrogenation of 7-scheme-9 in ethyl acetate with sodium bicarbonate gives the ethyl derivative 8-scheme-9 with the stereochemistry shown. Deprotection of the cyclohexanone acetal 8-scheme-9 can be achieved with aqueous acetic acid overnight to afford the diol 9-scheme-9. Selective benzylation of the equatorial hydroxyl group gives 10-scheme-9, which can then be mesylated using mesyl chloride in pyridine at 50°C to produce 11-scheme-9. Azide displacement of mesylate anion using sodium azide in DMF at 80°C affords 12-scheme-9, from which the pyranol 13-scheme-9 can be obtained by hydrogenolysis in the presence of BOC-anhydride. Oxidation to the pyranone 14-scheme-1 is achieved using the Dess-Martin periodinane.


In scheme 9, the C5 substitution is introduced using Wittig chemistry followed by hydrogenation, and hence compound 6-scheme-9 is converted to the C5 ethyl derivative 8-scheme-9. Alternative C5 substitution can be achieved using this route. For example, alternative Wittig or Horner-Emmons chemistry will lead to different alkyl substituents. In an analogous manner, the C5 hydroxymethyl group can be prepared and this itself can be further derivatised to other groups such as halogen, amino and other basic groups and sulfhydryl.

25

A general methodology starting from L-lyxose has been established for the preparation of various 5-substituted 4-amino 3-hydroxy pyranols with all four possible combinations of configuration at position 4 and 5 *i.e.* 4S,5S; 4S,5R; 4R,5S and 4R,5R. This methodology is exemplified in Scheme 9A. The pyranols can then be N-extended and capped as described herein and subsequently oxidised to the keto compounds, for example by Dess Martin periodination.

30

Scheme 9A



L-Lyxose can be acylated with a suitable acylating agent such as acid anhydride, acyl halide in an organic solvent like pyridine or other mixed organic solvents, to give the peracylated compound 1-scheme-9A. This compound can then be subjected to anomeric reduction with a trialkyl silane together with a Lewis acid such as triethyl silane and trimethylsilyl trifluoromethanesulphonate. Transforming the compound into the corresponding halo-, sulfo- or thiocarbo-glycoside followed by a radical reduction, using known methodology, can also bring about the anomeric reduction. Deacylation under basic condition provides the triol 3-scheme-9A, which can be selectively protected on the 2,3-hydroxyl groups forming a ketal

4-scheme 9A by using standard protecting group methodology. Oxidation of the 4-OH group into the keto function 5-scheme-9A can be performed with the Swern procedure, Dess-Martin or any other suitable oxidation method.


Various 4-substituted alkenes 6-scheme-9A can be achieved by using
5 appropriate Wittig reagents for example triphenylalkylphosphonium halide or triphenylalkylarylphosphonium halide together with a base. Catalytic hydrogenation of the Wittig product in the presence of a buffer provides predominantly compound 8-scheme-9A. Alternatively, the compound with the other configuration at this position 10-scheme-9A can be obtained by removal
10 of the ketal protecting group prior to the hydrogenation. The alkene compound can also be subjected to hydroboration, which will introduce a hydroxyl group, suitable for further modifications.

Another possibility to achieve the 4-alkyl compounds is to transform the 4-OH group into a leaving group for example a sulphonate followed by displacement
15 by a cuprous or Grignard reagent of the desired alkylgroup.

The ketal protecting group can be removed under acidic conditions such as 1M HCl/THF 1:1 at room temperature or heating to 80 °C in aqueous acetic acid which will give the diol 8-scheme-9A. Selective protection of the 2-OH group with an alkylating agent such as benzyl halide or any other similar
20 reagent in the presence of a base can give exclusively or predominantly the 2-O-protected compound 11,12-scheme-9A. The 3-OH can be converted to a suitable leaving group such as a sulphonate, which subsequently can be displaced by an azide 13,14-scheme-9A. Alternatively, a Mitsunobu reaction can be used to produce the azide-substituted compound. Hydrogenation of
25 the azide-compound in the presence of a carbamoylating agent like di-*tert*-butyl dicarbonate provides the desired 1,5-anhydro-3-[(*tert*-butoxycarbonyl)amino]-3,4-dideoxy-4-ethyl-D-xylitol and 1,5-anhydro-3-[(*tert*-butoxycarbonyl)amino]-2,3-dideoxy-2-ethyl-L-arabinitol.

The series of compounds with the other configuration at carbon 3 can be
30 prepared by inversion of the configuration of the 3-OH in compound 11,12-scheme-9A by methods that are known in the art, followed by the above procedure *i.e.* putting on a leaving group and azide displacement. They can also be prepared by the following sequence. Oxidation of the 3-OH into a ketone, using the oxidation reagents previously described, transformation of

the ketone into an oxime, utilising reagents such as benzyloxyamine halide and finally reduction of the oxime into the aminofunction. This will provide a mixture of the compounds with the two different configurations, which can be separated using known methodology. Boc-protection of the aminogroup and reductive removal of the benzyl protecting group provides the compounds with the remaining two configurations 4R,5S and 4R,5R.

Scheme 10

- 10 a) TFA; b) Me_3Al , HCl.HNMe(OMe) , DCM; c) $\text{CCl}_3(\text{NH})\text{O}^t\text{Bu}$, $\text{BF}_3 \cdot \text{Et}_2\text{O}$, DCM, cyclohexane; d) LAH in Et_2O ; e) $^t\text{BuOH}$, 2-methyl-2-butene, NaClO_2 , NaH_2PO_4 , H_2O ; f) $^t\text{BuOK}$, Et_2O , H_2O ; g) $^t\text{BuOCOC}$, NMM, THF; h) diazomethane in Et_2O ; i) LiCl (10eq) in 80 % acetic acid.


- 15 Compounds of the general formula (IV), wherein q is 1 are alternatively prepared by methods shown in Scheme 10. Alcohol 2-Scheme-10 can be prepared following the literature procedure reported by J. E. Baldwin *et al* (Tetrahedron, 1995, 51 (43), 11581). Removal of the ester functionality from

2-Scheme-10 can be achieved with trifluoroacetic acid to provide the lactone 3-Scheme-10. Lactone 3-Scheme-10 can be ring opened by MeONHMe in the presence of Me₃Al to provide the alcohol 4-Scheme-10. The *tert*-butoxycarbonyl group may be introduced onto alcohol 4-Scheme-10 to provide 5-Scheme-10. The Weinreb amide 5-Scheme-10 can then be treated with lithium aluminum hydride to provide the aldehyde 6-Scheme-10. Oxidation of the aldehyde 6-Scheme-10 can be effected by sodium chlorite to provide the acid 7-Scheme-2. Alternatively, the Weinreb amide 5-Scheme-10 can then be treated with potassium-*tert*-butoxide to directly provide the acid 7-Scheme-10. Activation of the acid 7-Scheme-10 with isobutyl chloroformate and 4-methylmorpholine provides 8-Scheme-10. Subsequent treatment of 8-Scheme-10 with diazomethane provides the diazoketone 9-Scheme-10. Cyclization of diazoketone 9-Scheme-10 can be effected by lithium chloride/aqueous acetic acid to give the dihydro-3(2H)-furanone 10-Scheme-10.

In Scheme 10, the C5 substitution of the pyranone is introduced via stereoselective alkylation of a beta-lactam derived from aspartic acid, as outlined by J. E. Balwin *et al* (Tetrahedron 1995, **51**, 11581). Alternative substitution of the pyranone using this methodology can be achieved by varying the electrophilic component in the alkylation step. Hence, various alkyl or aryl-C1-7 alkyl substitutions can be made in this manner.

An alternative ring closing route to compound of Formula II wherein q is 1 is depicted in scheme 11 below with respect to a model compound wherein the R5 functionality is duplicated:

Scheme 11




- a) $(\text{CF}_3\text{SO}_2)_2\text{O}$, pyridine, DCM; b) $(\text{nBu})_4\text{NN}_3$, toluene; c) H_2 , 10% Pd/C, pTsoH, MeOH; d) Boc_2O , NEt_3 , THF; e) 1M LiOH, THF; f) TBDMSCl, NEt_3 , cat DMAP, DCM; g) $^t\text{BuOCOCl}$, NMM, THF; h) diazomethane in Et_2O ; i) LiCl (10eq) in 80 % acetic acid.

Pantolactone 1-Scheme-11 is commercially available and is first converted to the triflate 2-Scheme-11. The triflate 2-Scheme-11 may be displaced with tetrabutylammonium azide to provide the corresponding azide 3-Scheme-11. Azide 3-Scheme-11 may be reduced to provide the amine salt 4-Scheme-11. Protection of the amine salt 4-Scheme-11 provides 5-Scheme-11. Ring opening of the lactone 5-Scheme-11 with lithium hydroxide provides the acid 6-Scheme-11. Protection of the primary alcohol 6-Scheme-11 with tetrabutyltrimethylsilyl chloride in the presence of base provides acid 7-Scheme-11. Activation of the acid 7-Scheme-11 with isobutyl chloroformate and 4-methylmorpholine provides 8-Scheme-11. Subsequent treatment of 8-Scheme-11 with diazomethane provides the diazoketone 9-Scheme-11. Cyclization of diazoketone 9-Scheme-11 can be effected by lithium chloride/aqueous acetic acid to give the model dihydro-3(2H)-pyranone 10-Scheme-11. The ring closing methodology demonstrated in this example is also applicable to compounds of formula II with various R5 functionalities.

Additional routes to 5-methyl and ethyl furanones as building blocks toward inhibitors or as intermediates to access other R5 functionalities are as shown in schemes 12 and 13.


5 Scheme 12



a) *p*-TolCl, pyridine; b) (CF₃SO₂)₂O, pyridine, DCM; c) NaN₃, DMF; d) 75% HCOOH; e) Ac₂O, pyridine; f) TMSOTf, Et₃SiH; g) K₂CO₃, MeOH; h) H₂, 10% Pd/C, MeOH, Boc₂O; i) TsCl, pyridine; j) LiAlH₄, Et₂O

- 10 An alternative synthesis of methyl furanones is shown in Scheme 12. 1,2-Isopropylidene-D-xylofuranoside 1-Scheme-12 is first converted to the *p*-toluoyl ester 2-Scheme-12 with *p*-toluoyl chloride and pyridine. The secondary alcohol 2-Scheme-12 may be converted to the triflate 3-Scheme-12. The triflate 3-Scheme-12 may be displaced with sodium azide to provide the corresponding azide 4-Scheme-12. Deprotection of the 1,2-isopropylidene of 4-Scheme-12 and subsequent acetylation of the residue provides diacetate 5-Scheme-12. Reduction of the anomeric centre of 5-Scheme-12 with trimethylsilyl triflate and triethylsilane provides monoacetate 6-Scheme-12. Removal of the two ester groups from 6-Scheme-12 with potassium carbonate

affords alcohol 7-Scheme-12. Reduction of the azide 7-Scheme-12 in the presence of Boc anhydride affords the key intermediate furanol 8-Scheme-12. Furanol 8-Scheme-12 can be transformed to the methyl furanol 10-Scheme-12 by converting the primary alcohol functionality of 8-Scheme-12 to the tosylate 9-Scheme-12, which in turn can be reduced with lithium aluminium hydride to provide the methyl furanol 10-Scheme-12. As described herein, furanol 10-Scheme-12 can be used to build up inhibitors of the invention in solution or on solid phase. Solid phase chemistry would typically require conversion of the Boc protection to Fmoc chemistry. The ultimate synthetic step involves oxidation of the furanol functionality to the corresponding furanone using an oxidant such as Dess-Martin periodinane. Alternatively, the oxidation may be carried out prior to subsequent modifications at the N-terminus. Importantly, furanol 8-Scheme-12 also provides an opportunity for introduction of diverse functionality at C-5 as the hydroxymethylene can be used for subsequent transformations known to those skilled in the art.

Scheme 13

a) TsCl, pyridine; b) Me_2CuLi , Et_2O , THF; c) $(\text{CF}_3\text{SO}_2)_2\text{O}$, pyridine, DCM; d) NaN_3 , DMF; e) TMSOTf, Et_3SiH ; f) H_2 , 10% Pd/C, MeOH; g) Boc_2O

An alternative synthesis of ethyl furanones is shown in Scheme 13. 1,2-Isopropylidene-L-xylofuranoside 1-Scheme-13 is used as the starting material and is first converted to the tosylate 2-Scheme-13. The tosylate 2-Scheme-13

is readily displaced using cuprate chemistry to provide the ethyl furanoside 3-Scheme-13. The secondary alcohol 3-Scheme-13 may be converted to the triflate 4-Scheme-13 using triflic anhydride and pyridine. The triflate 4-Scheme-13 may be displaced with sodium azide to provide the corresponding
5 azide 5-Scheme-13. Reduction of the anomeric centre of 5-Scheme-13 with trimethylsilyl triflate and triethylsilane provides alcohol 6-Scheme-13. Reduction of the azide 6-Scheme-13 with hydrogen in the presence of 10% palladium on carbon provides amine 7-Scheme-13. Protection of the amine 7-Scheme-13 with Boc anhydride provides the ethyl furanol 8-Scheme-13. As
10 described previously, furanol 8-Scheme-13 can be used to build up potential inhibitors in solution or on solid phase. Solid phase chemistry would require conversion of the Boc protection to Fmoc chemistry. The ultimate synthetic step involves oxidation of the furanol functionality to the corresponding furanone using an oxidant such as Dess-Martin periodinane. Alternatively, the
15 oxidation may be carried out prior to subsequent modifications at the N-terminus.

Many R3 groups are accessed from commercially available amino acid residues such as L-leucine, L-norleucine, L-phenylalanine etc. Other
20 branched and unsaturated amino acid building blocks are as shown in Medivir UK's PCT/GB01/02162 claiming priority from British patent application GB 00025386-4 filed 17 May 2000 the contents of which are incorporated by reference.

25 Access to sulphonyl bearing C1-C7alkyl or ArC1-C7alkyl R3 groups, for instance arylalkylC0-2sulphonylmethyl functionalities can come from the suitably protected amino acid cysteine. Mitsunobu coupling of the cysteinyl thiol with aryl alcohols such as phenol yield the protected amino acid containing the phenylthiomethyl R3 sidechain that is readily oxidised using *m*-
30 chloroperbenzoic acid to provide the R3 sidechain phenylsulphonylmethyl. The benzylsulphonylmethyl and phenethylsulphonylmethyl R3 sidechain containing amino acids can be prepared by nucleophilic substitution of the cysteinyl thiol with benzyl bromide and phenethyl bromide respectively.

Oxidation of the resulting sulphides with *m*-chloroperbenzoic acid provides the suitably protected amino acids with the benzylsulphonylmethyl and phenethylsulphonylmethyl R3 sidechain.


5 Detailed Description of the Embodiments

Solution phase chemistry

Example 1

Following general chemistry scheme 14:

10



(a) General method for the synthesis of N-Boc protected diazoketones, exemplified by (2S, 3S)-N-Boc-O-t-butyl-L-threonyldiazomethane (1)

- 15 (2S, 3S)- N-Boc-O-t-butyl-L-threonine (1.2g, 4.2mmol) was dissolved in dry DCM (20mL) and N-methylmorpholine (1mL, 2.2eq) added. The reaction mixture was cooled to -15°C and stirred under an atmosphere of argon. Isobutyl chloroformate (0.56mL, 4.3mmol) was added and the mixture stirred for 10mins at -15°C . A solution of diazomethane in diethyl ether (45mL,
- 20 approx 40mmol) was added and the reaction allowed to warm to room temperature over 1hr, then acetic acid was added dropwise until effervescence had ceased. The reaction mixture was diluted with DCM

(100mL) and washed successively with saturated aqueous sodium bicarbonate (2 x 75mL), water (75mL) and brine (75mL) and dried over sodium sulphate. The solvent was removed *in vacuo* to give crude (2S, 3S)-N-Boc-O-t-butyl-L-threonyldiazomethane (1.2g, ~100%) as a pale yellow oil. The above synthesis was repeated 9 times and the total crude product pooled (12g) and used without purification for the next stage.

(b) General method for the synthesis of Boc-3(2H)-furanones, exemplified by dihydro-(4S-amino-[N-Boc])-5S-methyl-3(2H)-furanone (2)

A solution of lithium chloride (13.6g, 320mmol) in 80% aqueous acetic acid (400mL) was cooled to 5°C and added to crude (2S, 3S)-N-Boc-O-t-butyl-L-threonyldiazomethane (1) (9.6g) with stirring. The oil dissolved over 10mins and stirring continued for a further 1hr slowly warming to room temperature, with evolution of gas. The solvents were removed *in vacuo* and the residue taken into EtOAc (250mL) and washed successively with water (250mL), saturated aqueous sodium bicarbonate (2 x 100mL) and brine (75mL), then dried over sodium sulphate. The solvent was removed *in vacuo* and the crude product purified by flash chromatography over silica gel (150g) eluting with EtOAc / heptane (1:2, v/v). Two fractions were pooled and the quicker eluting fraction reduced *in vacuo* to approx 50mL heptane and left to crystallise to give dihydro-(4S-amino-[N-Boc])-5S-methyl-3(2H)-furanone (2) as a white solid, yield 4.05g, 18.8mmol, 58%. Electrospray-MS m/z 216 (MH^+), 160 ($MH^+ - 56$), elemental analysis $C_{10}H_{17}O_4N$ (req) %C 55.80, %H 7.96, %N 6.51, (fnd) %C 55.82, %H 7.86, %N 6.44.

δ_H (500 MHz; $CDCl_3$); 1.41 (9H, s, $C(CH_3)_3$), 1.49 (3H, d, J 6, 5S- CH_3), 3.72 (1H, bm, furanone $CH\alpha$), 3.90-4.02 (2H, 5S-H + 1 x furanone $COCH_2O$), 4.22 (1H, d, J 17.4, 1 x furanone $COCH_2O$), 4.85 (1H, bs, furanone, NH). δ_C (125 MHz; $CDCl_3$); 19.34 (5S- CH_3), 28.45 ($C(CH_3)_3$), 62.79 (furanone $CH\alpha$), 71.06 (furanone $COCH_2O$), 77.96 (5S- $CHCH_3$), 80.88 ($C(CH_3)_3$), 155.6 ($(CH_3)_3 CO-CO$), 212.6 (furanone CO).

(c) General method for N-terminal extension, exemplified by dihydro-(4S-amino-[N-Boc-L-tert-butylalanyl])-5S-methyl-3(2H)-furanone (3)

Dihydro-(4S-amino-[N-Boc])-5S-methyl-3(2H)-furanone (**2**) (1.0g, 4.6mmol) was treated with a solution of 4.0M HCl in dioxan (25mL) at room temperature for 1hr. The solvents were removed *in vacuo* and the residue azeotroped with 2 x toluene to give the hydrochloride salt as a white solid.

- 5 Boc-L-*tert*-butylalanine pentafluorophenyl ester (2.0g, 1.05eq) and 1-hydroxybenzotriazole hydrate (0.735g, 1.05eq) were dissolved in DMF (20mL) and after 5mins added to the above salt. The clear solution was then treated with N-methylmorpholine (0.51g, 0.56mL, 1.1eq) and left at room temperature for 2hrs. The solvents were removed *in vacuo* and the crude product purified
- 10 by flash chromatography over silica gel (50g) eluting with EtOAc / heptane (1:3, v/v), then EtOAc / heptane (1:2, v/v). Fractions were pooled and reduced *in vacuo* to give dihydro-(4S-amino-[N-Boc-L-*tert*-butylalanyl])-5S-methyl-3(2H)-furanone (**3**) as a white solid, yield 1.31g, 3.82mmol, 83%.
Electrospray-MS m/z 343 (MH⁺), 287 (MH⁺ - 56).

15

This methodology is readily applicable to the corresponding N-Boc-protected pyranone or (1,5-anhydro-3-[(*tert*-butoxycarbonyl)amino]-3,4-dideoxy-4-ethyl-D-xylitol

- 20 (d) General method for addition of capping group, exemplified by benzofuran-2-carboxylic acid [3,3-dimethyl-1S-(2S-methyl-4-oxo-tetrahydrofuran-3S-ylcarbamoyl)butyl]amide (**4**)

- Dihydro-(4S-amino-[N-Boc-L-*tert*-butylalanyl])-5S-methyl-3(2H)-furanone (**3**) (1.03g, 3.0mmol)) was treated with a solution of 4.0M HCl in dioxan (25mL)
- 25 at room temperature for 1hr. The solvents were removed *in vacuo* and the residue azeotroped with 2 x toluene to give the hydrochloride salt as a white solid.
- Benzofuran-2-carboxypentafluorophenyl ester (1.05eq) and 1-hydroxybenzotriazole hydrate (1.05eq) are dissolved in DMF (15mL) and after
- 30 5mins added to the above salt. The clear solution was then treated with N-methylmorpholine (1.1eq) and left at room temperature for 2hrs.. The solvents are removed *in vacuo* and the crude product purified by flash chromatography over silica gel (50g) eluting with EtOAc / heptane (3:2, v/v). Fractions are pooled and reduced *in vacuo* to give the title compound.

Example 2. 4,4-Dimethyl-2S-(benzofuran-2-sulfonylamino)pentanoic acid (2S-methyl-4-oxo-tetrahydrofuran-3S-yl)amide (5)

(a) General method for addition of sulphonyl capping group, exemplified by
5 4,4-Dimethyl-2S-(benzofuran-2-sulfonylamino)pentanoic acid (2S-methyl-4-oxo-tetrahydrofuran-3S-yl)amide (5)

Dihydro-(4S-amino-[N-Boc-L-*tert*-butylalanyl])-5S-methyl-3(2H)-furanone (3) (34mg, 0.1mmol) was treated with a solution of 4.0M HCl in dioxan (5mL) at room temperature for 1hr. The solvents were removed *in vacuo* and the
10 residue azeotrope with 2 x toluene to give the hydrochloride salt as a white solid.

Hydrochloride salt was dissolved in dry DCM (2mL) and benzofuran-2-sulphonylchloride added followed by diisopropylethylamine (3eq) and catalytic N,N-dimethylaminopyridine (2mg). After 2hr at room temperature, the solution
15 was diluted with DCM (15mL) and washed successively with 0.1N HCl (25mL), water (2 x 25mL) and brine (25mL), then dried over sodium sulphate. The solvent was removed *in vacuo* and the crude product purified by flash chromatography over silica gel (15g) eluting with EtOAc / heptane (1:1, v/v). Fractions were pooled and reduced *in vacuo* to give the title compound.

20

General Synthesis of Chiral β -alkyl serine aminoacids

Adapted from Blaskovich, M.A., Evinder, G., Rose, N. G. W., Wilkinson, S., Luo, Y. and Lajoie, G. A. *J. Org. Chem*, 63, 3631-3646, 1998. (Following scheme 2).

25 Example 5. (2S, 3S) β -hydroxynorvaline (15)

(a) N-Benzoyloxycarbonyl-L-serine 3-methyl-3-(hydroxymethyl)oxetane ester (8)

N-Cbz-L-serine (10 g, 41.8 mmol) was dissolved in DCM (450 mL) and DMF (14 mL) and added dropwise over 2.5 h to a stirred solution of WSC. HCl (12
30 g, 62.7 mmol), N,N-dimethylaminopyridine (260 mg, 2.1 mmol) and 3-methyl-3-oxetane methanol (84 mL, 0.84 mmol) cooled to 0 °C. The reaction was warmed to room temperature and allowed to stir overnight. The mixture was washed with 0.1M HCl (200 mL), water (200 mL), 10 % Na₂CO₃ (200 mL x 2)

and water (200mL x 2), dried (Na₂SO₄) and the solvent evaporated *in vacuo* to afford a pale yellow oil. Purification by column chromatography (4:1, EtOAc:heptane) and subsequent recrystallisation (1:1, EtOAc:heptane) yielded the target intermediate as a white crystalline solid, 8.07 g, 60 %; TLC (4:1, EtOAc:heptane), R_f = 0.28, electrospray-MS m/z 324.1 (MH⁺).

δ (400 MHz; CDCl₃) 1.28 (3H, s, CH₃), 3.04 (1H, t, J 6.2, CHNH), 3.90-3.91 (1H, br m, OH), 4.10-4.13 (2H, m, CH₂OH), 4.41-4.55 (6H, m, 3 x CH₂), 5.13 (2H, s, OCH₂), 5.82 (1H, d, J 7.7, NH), 7.35-7.36 (5H, m, C₆H₅).

δ_c (100 MHz; CDCl₃) 20.75 (CH₃), 39.67 (CH₂OH), 56.39 (CHNH), 63.37 (CH₂), 67.19 (CH₂), 68.94 (CH₂), 79.50 (OCH₂), 128.16 (C₆H₅), 128.27 (C₆H₅), 128.58 (C₆H₅), 136.14 (C₆H₅), 156.25 (CO₂NH), 170.74 (CO₂).

(b) 1-[N-Benzyloxycarbonyl-(1S)-1-amino-2-hydroxyethyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2]oxetane (9).

Compound (8) (10.23 g, 28.6 mmol) was dissolved in anhydrous DCM (150 mL) and cooled to 0 °C under N₂. A solution of boron trifluoride etherate (0.10 mL, 0.77 mmol) in anhydrous DCM (10 mL) was added and the mixture stirred for 30 minutes at 0 °C, then at room temperature overnight. Triethylamine (1.2 mL, 8.30 mmol) was added and the reaction mixture stirred for 30 minutes before being concentrated to a thick colourless oil. Purification by column chromatography (4:1, EtOAc:heptane) and subsequent recrystallisation (1:1, EtOAc:heptane) yielded (9) as a white crystalline solid, 8.06 g, 80 %; TLC (4:1, EtOAc:heptane) R_f = 0.27, electrospray-MS m/z 324.1 (MH⁺).

δ (400 MHz; CDCl₃) 0.78 (3H, s, CH₃), 2.67 (1H, m, CHNH), 3.64-3.69 (1H, m, CH₂OH), 3.80-3.83 (1H, m, CH₂OH), 3.88 (6H, s, CH₂ x 3), 5.09 (2H, dd, J 18.9, 12.3, OCH₂), 5.38 (1H, d, J 8.7, NH), 7.26-7.34 (5H, m, C₆H₅).

δ_c (100 MHz; CDCl₃) 14.11 (CH₃), 30.39 (CCH₃), 55.26 (CHNH), 61.75 (CH₂OH), 66.76 (CH₂O), 72.53 (CH₂ x 3), 108.29 (CO₃), 127.98 (C₆H₅), 128.32 (C₆H₅), 136.31 (C₆H₅), 156.31 (CO₂NH).

(c) 1-[*N*-Benzyloxycarbonyl-(1*S*)-1-amino-2-oxoethyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2]oxetane (**10**).

Compound (**9**) (6.45 g, 20.0 mmol) was dissolved in anhydrous DCM (55 mL) under N₂ and cooled to -78 °C in flask 1. Oxalyl chloride (2.8 mL, 31.9 mmol) was added to anhydrous DCM (85 mL) in a separate flask (flask 2) under N₂ and cooled to -78 °C. Anhydrous dimethylsulphoxide (4.7 mL, 65.8 mmol) was added to the oxalyl chloride solution and the mixture stirred at -78 °C for 15 minutes. The alcohol solution was transferred over 20 minutes by cannula to flask 2 and rinsed with anhydrous DCM (35 mL). The resulting cloudy, white mixture was stirred for 1.5 hours at -78 °C. Diisopropylethylamine (17.4 mL, 99.7 mmol) was added and the solution stirred for 30 minutes at -78 °C and 10 minutes at 0 °C. Ice-cold DCM (140 mL) was added and the solution washed with ice-cold NH₄Cl (20 % saturated solution; 3 x 140 mL) and saturated NaCl (140 mL), dried (MgSO₄) and the solvent evaporated *in vacuo* to afford a yellow solid (**10**), 5.08 g, 79 %; TLC (3:1, EtOAc:heptane), R_f = 0.56, electrospray-MS m/z 322.1 (40%) (MH⁺), 340.2 (100%) (MH⁺+H₂O).

δ_H (400 MHz; CDCl₃): 0.82 (3H, s, CH₃), 3.93 (6H, s, CH₂ x 3), 4.60 (1H, d, J 8.8, CHNH), 5.12 (2H, dd, J 14.9, 12.4, OCH₂), 5.35 (1H, br d, J 8.0, NH), 7.30-7.36 (5H, m, C₆H₅), 9.68 (1H, s, HCO).

δ_C (100 MHz; CDCl₃) 14.25 (CH₃), 30.86 (CCH₃), 63.25 (CHNH), 67.22 (CH₂O), 72.88 (CH₂ x 3), 107.16 (CO₃), 128.13 (C₆H₅), 128.46 (C₆H₅), 136.13 (C₆H₅), 156.17 (CO₂NH), 195.66 (CHO).

(d) 1-[*N*-(Benzyloxycarbonyl)-(1*S*,2*R*)-1-amino-2-hydroxybutyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2]oxetane (**11**).

Compound (**10**) (2 g, 5.73 mmol) was dissolved in anhydrous DCM:Et₂O (1:1) under N₂. A solution of EtMgBr (3M solution in Et₂O; 7.6 mL, 22.9 mmol) was added quickly at -78 °C and stirred vigorously. After 30 minutes the reaction was quenched by pouring into 5 % NH₄Cl (500 mL). DCM (500 mL) was added, the organic layer separated and washed with 3 % NH₄Cl (500 mL) and brine (500 mL), dried (Na₂SO₄) and the solvent evaporated *in vacuo* to afford

a yellow oil. Purification by column chromatography (1:10, EtOAc:DCM) and subsequent recrystallisation (EtOAc:heptane) yielded a white crystalline solid (**11**), 1.32 g, 60 %; TLC (1:10, EtOAc:DCM) R_f = 0.25, electrospray-MS m/z 352.2 (20%) (MH^+), 370.3 (100%) ($MH^+ + H_2O$).

5 δ (400 MHz; $CDCl_3$) 0.82 (3H, s, CH_3), 0.94 (3H, t, J 7.4, CH_2CH_3), 1.36-1.53 (2H, m, CH_2CH_3), 3.85 (1H, d, J 10.3, CH), 3.93 (6H, s, $CH_2 \times 3$), 4.05 (1H, t, J 6.8, CH), 5.13-5.14 (2H, dd, J 16.4, 12.7, OCH_2), 5.32 (1H, d, J 10.2, NH), 7.30-7.36 (5H, m, C_6H_5).
 δ_c (100 MHz; $CDCl_3$) 10.11 (CH_2CH_3), 14.34 (CH_3), 25.98 (CH_2CH_3), 30.65
 10 (CCH_3), 56.05 ($CHOH$), 66.83 (CH_2O), 70.81 ($CHNH$), 72.76 ($CH_2 \times 3$), 108.93 (CO_3), 127.65 (C_6H_5), 128.45 (C_6H_5), 136.65 (C_6H_5), 156.83 (CO_2NH).

(e) 1-[*N*-Benzyloxycarbonyl-(1*S*)-1-amino-2-oxobutyl]-4-methyl-2,6,7-trioxabicyclo[2.2.2]oxetane (**12**).

15 Compound (**11**) (1.32 g, 3.8 mmol) was dissolved in anhydrous DCM (10 mL) under N_2 and cooled to $-78^\circ C$ in flask 1. Oxalyl chloride (2M solution in DCM; 3 mL, 6.0 mmol) was diluted with anhydrous DCM (10 mL) in a separate flask (flask 2) under N_2 and cooled to $-78^\circ C$. Anhydrous dimethylsulphoxide (0.88 mL, 12.4 mmol) was added to the oxalyl chloride
 20 solution and the mixture stirred at $-78^\circ C$ for 15 minutes. The alcohol solution was transferred over 20 minutes by cannula to flask 2 and rinsed with anhydrous DCM (10 mL). The resulting cloudy, white mixture was stirred for 2 hr 15 min at $-78^\circ C$. DIPEA (3.3 mL, 18.8 mmol) was added and the solution stirred for 30 minutes at $-78^\circ C$ and 10 minutes at $0^\circ C$. Ice-cold DCM (25
 25 mL) was added and the solution washed with ice-cold NH_4Cl (5 % saturated solution; 3 x 25 mL) and saturated NaCl (25 mL), dried (Na_2SO_4) and the solvent evaporated *in vacuo* to afford an orange oil. Purification by column chromatography (2:3, EtOAc:heptane) yielded a colourless oil (**12**), 556 mg, 45 %; TLC (2:3, EtOAc:heptane) R_f = 0.25, electrospray-MS m/z 350.2
 30 (60%) (MH^+), 368.2 (100%) ($MH^+ + H_2O$).

δ (400 MHz; $CDCl_3$) 0.80 (3H, s, CH_3), 1.06 (3H, t, J 7.2, CH_2CH_3), 2.48-2.56 (1H, m, $CHCH_3$), 2.80-2.88 (1H, m, $CHCH_3$), 3.90 (6H, s, $CH_2 \times 3$), 4.60

(1H, d, *J* 8.8, CHNH), 5.09 (2H, s, OCH₂), 5.66 (1H, d, *J* 8.5, NH), 7.30-7.35 (5H, m, C₆H₅).

δ_c (100 MHz; CDCl₃) 7.53 (CH₂CH₃), 14.25 (CH₃), 30.57 (CCH₃), 35.74 (CH₂CH₃), 62.33 (CHNH), 67.05 (CH₂O), 72.94 (CH₂ x 3), 106.98 (CO₃),
 5 128.10 (C₆H₅), 128.46 (C₆H₅), 136.31 (C₆H₅), 155.99 (CO₂NH).

(f) 1-[N-(Benzyloxycarbonyl)-(1S,2S)-1-amino-2-hydroxybutyl]-4-methyl-2,6,7- trioxabicyclo[2.2.2]oxetane (**13**).

Compound (**12**) (2.77 g, 7.9 mmol) and LiBH₄ (1.73 g, 79 mmol) were cooled
 10 to -78 °C under N₂. A solution of DCM:CH₃OH (1.5:1; 332 mL cooled to -78 °C) was added and the solution stirred at -78 °C overnight. After being warmed to room temperature, the solution was poured into 5% NH₄Cl solution (500 mL) and DCM (300 mL) added. The organic layer was separated, washed with 5 % NH₄Cl solution (500 mL) and brine (400 mL), dried (Na₂SO₄)
 15 and the solvent evaporated *in vacuo* to afford a white solid (**13**), 2.51 g, 90 %; TLC (1:1, EtOAc:heptane) R_f = 0.23, electrospray-MS *m/z* 352.2 (40%) (MH⁺), 370.3 (100%) (MH⁺+H₂O).

δ (400 MHz; CDCl₃) 0.82 (3H, s, CH₃), 0.97 (3H, t, *J* 7.4, CH₂CH₃), 1.44-1.45 (1H, m, CHCH₃), 1.63-1.68 (1H, m, CHCH₃), 3.44 (1H, d, *J* 4.0, CHOH),
 20 3.66-3.69 (1H, m, CHNH), 3.92 (6H, s, CH₂ x 3), 5.04 (1H, d, *J* 9.8, NH), 5.16 (2H, d, *J* 6.1, OCH₂), 7.36 (5H, d, *J* 4.3, C₆H₅),

δ_c (100 MHz; CDCl₃) 9.79 (CH₂CH₃), 14.27 (CH₃), 26.10 (CH₂CH₃), 30.56 (CCH₃), 57.57 (CHOH), 66.94 (CH₂O), 69.80 (CHNH), 72.66 (CH₂ x 3),
 108.89 (CO₃), 128.06 (C₆H₅), 128.47 (C₆H₅), 136.51 (C₆H₅), 156.49 (CO₂NH).

25

(g) (1S,2S)-(1-amino-2-hydroxybutyl)-4-methyl-2,6,7- trioxabicyclo[2.2.2]oxetane (**14**).

Compound (**13**) (2.51g, 7.1mmol) was dissolved in ethanol (220 mL) and 10 % Pd/C (218 mg) added. The reaction mixture was stirred overnight in the
 30 presence of H₂. The catalyst was removed by filtration through celite and the solvent evaporated *in vacuo* to afford a thick oil. Purification by column chromatography (20:1, DCM:MeOH) yielded a pale yellow oil (**14**), 1.24 g, 92

%, which crystallised on standing; TLC (5:1, DCM:MeOH) R_f = 0.51, electrospray-MS m/z 218.1 (MH^+).

(400 MHz; $CDCl_3$) 0.83 (3H, s, \underline{CH}_3), 0.98 (3H, t, J 7.4, $\underline{CH}_2\underline{CH}_3$), 1.38-1.48 (1H, m, \underline{CHCH}_3), 1.71-1.78 (1H, m, \underline{CHCH}_3), 2.77 (1H, d, J 7.1, \underline{CHNH}_2),
 5 3.62-3.66 (1H, m, \underline{CHOH}), 3.93 (6H, s, $\underline{CH}_2 \times 3$).
 δ_c (100 MHz; $CDCl_3$) 9.57 ($\underline{CH}_2\underline{CH}_3$), 14.37 (\underline{CH}_3), 26.01 ($\underline{CH}_2\underline{CH}_3$), 30.52 (\underline{CCH}_3), 58.52 (\underline{CHOH}), 72.59 (\underline{CHNH}_2), 72.67 ($\underline{CH}_2 \times 3$), 109.62 (\underline{CO}_3).

(h) (2S,3S) β -hydroxynorvaline (**15**)

10 Compound (**14**) (1.24 g, 5.5 mmol) was dissolved in DCM (68 mL) and trifluoroacetic acid (1.58 mL) and H_2O (1.13 mL) added. The resulting cloudy, white solution was stirred at room temperature for 30 minutes and the solvent evaporated *in vacuo*. The colourless residue was dissolved in MeOH (66 mL) and H_2O (17 mL) and 10 % Cs_2CO_3 (9.2 g in 92 mL H_2O) added. After stirring
 15 overnight at room temperature, the solution was acidified with 2 M HCl (~35 mL) to pH <3. The solution was loaded onto a cation exchange column (Bio-Rad AG 50W-X8 100-200 mesh, hydrogen form, 4.5 x 20 cm) washed with 0.01 M HCl (500 mL) and H_2O (500 mL) and eluted with 2M NH_4OH (2 L) then lyophilised to afford a pale yellow solid. The solid was washed with MeOH to
 20 yield an off-white solid (**15**), 227 mg, 30 %; TLC (4:1:1, butan-2-ol : AcOH : H_2O) R_f = 0.26, electrospray-MS m/z 134.1 (MH^+), elemental analysis $C_5H_{11}O_3N$ (req) %C 45.10, %H 8.33, %N 10.52, (fnd) %C 44.67, %H 8.03, %N 9.92.

δ (400 MHz; $CDCl_3$) 92:8 *erythro* (2S, 3S) : *threo* (2S, 3R), 1.00 (3H, t, J
 25 7.4, \underline{CH}_3), 1.40-1.54 (2H, m, \underline{CH}_2), 3.41 (0.08H, d, J 4.2, \underline{CH}), 3.61 (0.92H, d, J 4.2, \underline{CH}), 3.60-3.65 (0.08H, m, \underline{CH}), 3.66-3.69 (0.92H, m, \underline{CH}).
 δ_c (100 MHz; $CDCl_3$) 11.02 ($\underline{CH}_2\underline{CH}_3$), 25.26 ($\underline{CH}_2\underline{CH}_3$), 61.26 (\underline{CHOH}), 72.09 (\underline{CHNH}_2), 172.03 (\underline{CO}_2H).

30 **General method for the synthesis of Fmoc-3(2H)-furanones**

Exemplified by dihydro-(4S-amino-[N-Fmoc])-5S-ethyl-3(2H)-furanone (**18**), following the general chemistry detailed in scheme 1.

(a) Preparation of Fmoc-(2S,3S)- β -ethylserine (**16**)

(2S,3S) -hydroxynorvaline (**15**) (277mg, 2.07mmol) and sodium carbonate (2.1eq, 460mg) were dissolved with stirring and ice-cooling in water (25mL) and THF (10mL). 9-Fluorenylmethyl chloroformate (1.05eq, 560mg) in THF (15mL) was added over 45mins and the mixture stirred for a further 1hr at
5 room temperature. Chloroform (100mL) and water (50mL) were added and the mixture acidified to pH2 with 0.1N HCl. The organic layer was collected and the aqueous washed with a further 2 x 100mL chloroform. The combined organics were backwashed with brine (1 x 300mL) and dried over magnesium sulphate. The chloroform was reduced *in vacuo* to yield a fine white solid. The
10 solid was dissolved in *tert*-butyl methylether (25mL) with heating and heptane (75mL) added to give a cloudy solution. The mixture was cooled to -20°C and each 30mins further heptane (75mL) added for 4 cycles. The precipitate was filtered off and dried *in vacuo* to a fine white solid (**16**) 590mg, 80.6 %; TLC (CHCl₃ ; MeOH 3:1) R_f = 0.40, electrospray-MS m/z 356.2 (MH⁺).

15

(b) Preparation of (2S, 3S)-N-Fmoc-β-ethylserinyldiazomethane (**17**)

Following the general method detailed in example 1.(a) for compound (**1**), Fmoc-(2S, 3S)- -ethylserine (**16**) (560mg) was converted to a yellow solid (600mg) (**17**) used without purification.

20

(c) Preparation of dihydro-(4S-amino-[N-Fmoc])-5S-ethyl-3(2H)-furanone (**18**)

A solution of lithium chloride (1.0g, 23.5mmol) in 80% aqueous acetic acid (10mL) was cooled to 5°C and added to crude (2S, 3S)-N-Fmoc- -ethylserinyldiazomethane (**17**) (0.6g) with stirring. The oil dissolved over
25 10mins and stirring continued for a further 1hr slowly warming to room temperature, with evolution of gas. The solvents were removed *in vacuo* and the residue taken into EtOAc (50mL) and washed successively with water (50mL), saturated aqueous sodium bicarbonate (2 x 100mL) and brine (75mL), then dried over sodium sulphate. The solvent was removed *in vacuo*
30 and the crude product purified by flash chromatography over silica gel (25g) eluting with EtOAc / heptane (1:3, v/v). Desired fractions were pooled and reduced *in vacuo* to give dihydro-(4S-amino-[N-Fmoc])-5S-ethyl-3(2H)-furanone (**18**) as a white solid, yield 320mg, 0.91mmol, 58%. Electrospray-MS

m/z 352 (MH^+), HRMS $C_{21}H_{21}O_4NNa$ requires M , 374.1368, found: MNa^+ , 374.1368. (δ - 1.49 ppm), analytical HPLC R_t = 13.61mins (98.4%), elemental analysis $C_{21}H_{21}O_4N$ (req) %C 71.78, %H 6.02, %N 3.99, (fnd) %C 70.95, %H 6.22, %N 3.81.

- 5 δ (500 MHz; $CDCl_3$); 1.05 (3H, m, CH_2CH_3), 1.76, 1.94 (2H, bm, CH_2CH_3), 3.83 (1H, bm, furanone $CH\beta$), 3.88 (1H, bm, furanone $CH\alpha$), 4.02 (1H, d, J 17.3, 1 x furanone $COCH_2O$), 4.23 (2H, m, 1 x furanone $COCH_2O$ + Fmoc $CHCH_2O$), 4.42 (2H, b, Fmoc $CHCH_2O$), 5.05 (1H, b, furanone, NH), 7.35 (2H, t, J 7.4, Fmoc aromatic), 7.42 (2H, t, J 7.3, Fmoc aromatic), 7.58 (2H, t, J 7.4, Fmoc aromatic), 7.77 (2H, t, J 7.4, Fmoc aromatic).
- 10 δ_c (125 MHz; $CDCl_3$); 8.90 (5S- CH_2CH_3), 26.14 (5S- CH_2CH_3), 46.90 (Fmoc $CHCH_2O$), 60.50 (furanone $CH\alpha$), 66.99 (Fmoc $CHCH_2O$), 70.43 (furanone $COCH_2O$), 81.65 (furanone $CH\beta$), 119.76 (Fmoc aromatic), 124.72 (Fmoc aromatic), 126.85 (Fmoc aromatic), 127.53 (Fmoc aromatic), 141.09 (Fmoc aromatic), 143.37 (Fmoc aromatic), 155.76 ($OCONH$), 211.72 (furanone CO).
- 15

(d) Preparation of (2S, 3R)-N-Fmoc-O-*t*-butyl-L-threonyldiazomethane (**19**)

- Following the general method detailed in example 1. (a) for compound (**1**), Fmoc-(2S,3R)-O-*t*-butyl-L-threonine (1.99 g, 5 mmol) was converted to (2S, 3R)-N-Fmoc-O-*t*-butyl-L-threonyldiazomethane (**19**) (2.11g, 100%) as a pale yellow immobile oil. This compound was carried through to the next stage without further purification. Electrospray-MS m/z 444 (MNa^+ , 20%), 394 ($MH^+ - N_2$, 70%) and 338 ($MH^+ - t\text{-butyl} - N_2$, 100%).
- 20

25 (e) Preparation of (2R, 3S)-N-Fmoc-O-*t*-butyl-D-threonyldiazomethane (**20**)

- Following the general method detailed in example 1. (a) for compound (**1**), Fmoc-(2R,3S)-O-*t*-butyl-D-threonine (0.4 g, 1 mmol) was converted to (2S, 3R)-N-Fmoc-O-*t*-butyl-L-threonyldiazomethane (**20**) (0.48g, 111%) as a pale yellow immobile oil. This compound was carried through to the next stage without further purification. Electrospray-MS m/z 394 ($MH^+ - N_2$, 60%) and 338 ($MH^+ - t\text{-butyl} - N_2$, 100%).
- 30

(f) Preparation of (2S, 3S)-N-Fmoc-O-*t*-butyl-L-*allo*-threonyldiazomethane (**21**)

Following the general method detailed in example 1.(a) for compound (1), Fmoc-(2S,3S)-O-*t*-butyl-L-*allo*-threonine (0.4 g, 1 mmol) was converted to (2S, 3S)-N-Fmoc-O-*t*-butyl-L-*allo*-threonyldiazomethane (21) (0.53g, 123%) as a pale yellow immobile oil.. Electrospray-MS m/z 394 ($MH^+ - N_2$, 90%) and 338 ($MH^+ - t\text{butyl} - N_2$, 60%).

(i) Preparation of dihydro-(4R-amino-[N-Fmoc])-5R-methyl-3(2H)-furanone (22)

Following the general method detailed for cyclisation of (17) to (18), diazoketone (19) cyclised to give dihydro-(4R-amino-[N-Fmoc])-5R-methyl-3(2H)-furanone (22) isolated as a white solid, yield 69%, electrospray-MS m/z 338 (MH^+ , 100%), analytical HPLC R_t = 14.59 mins (97.7%).

δ (500 MHz; $CDCl_3$); 1.50 (3H, brd, \underline{CH}_3), 3.80 (1H, brt, furanone \underline{CH}_α), 3.97 (1H, brm, furanone \underline{CH}), 3.99 (1H, d, J 17.7, 1 x furanone \underline{COCH}_2O), 4.22 (1H, t, J 6.7, Fmoc \underline{CHCH}_2O), 4.25 (1H, d, J 17.7, 1 x furanone \underline{COCH}_2O), 4.44 (2H, b, Fmoc \underline{CHCH}_2O), 5.11 (1H, b, \underline{NH}), 7.32 (2H, t, J 7.4, Fmoc aromatic), 7.41 (2H, t, J 7.4, Fmoc aromatic), 7.58 (2H, t, J 7.4, Fmoc aromatic), 7.76 (2H, t, J 7.4, Fmoc aromatic).
 δ_c (125 MHz; $CDCl_3$); 19.1 (\underline{CH}_3), 47.2 (Fmoc \underline{CHCH}_2O), 62.7 (furanone \underline{CH}_α), 67.3 (Fmoc \underline{CHCH}_2O), 70.8 (furanone \underline{COCH}_2O), 77.4 (furanone \underline{CH}_β), 120.1 (Fmoc aromatic), 125.0 (Fmoc aromatic), 127.1 (Fmoc aromatic), 127.8 (Fmoc aromatic), 141.4 (Fmoc aromatic), 143.7 (Fmoc aromatic), 156.1 (\underline{OCONH}), 211.8 (furanone \underline{CO}).

(j) Preparation of dihydro-(4S-amino-[N-Fmoc])-5S-methyl-3(2H)-furanone (23)

Following the general method detailed for cyclisation of (17) to (18), diazoketone (20) cyclised to give dihydro-(4S-amino-[N-Fmoc])-5S-methyl-3(2H)-furanone (23) isolated as a white solid, yield 70%, electrospray-MS m/z 338 (MH^+ , 75%), analytical HPLC R_t = 14.62 mins (98.9%).


(k) Preparation of dihydro-(4S-amino-[N-Fmoc])-5S-methyl-3(2H)-furanone (23)

Following the general method detailed for cyclisation of (17) to (18), diazoketone (21) cyclised to give dihydro-(4R-amino-[N-Fmoc])-5R-methyl-3(2H)-furanone (23) isolated as a white solid, yield 64%, electrospray-MS m/z 338 (MH^+ , 100%), analytical HPLC R_t = 14.68 mins (97.5%).

5

General method for preparation of N-protected- 4-aminopyranol building blocks

10 This route is exemplified by the 4S 5S enantiomer, but is applicable to other configurations as discussed above.



1,2,3,4-Tetra-O-acetyl-L-lyxopyranose (1).

15 L-Lyxopyranose (25.0 g, 166 mmol) was dissolved in pyridine (150 ml) and cooled on an icebath, acetic anhydride (75 ml) was added and the solution was stirred at room temperature. After 2 hours tlc (pentane:ethyl acetate 1:1)

indicated complete conversion of the starting material into a higher migrating spot. The solution was concentrated and co-evaporated three times with toluene which gave a pale yellow syrup.

NMR data 400 MHz (CDCl₃): ¹H, δ 2.06 (s, 3H), 2.08 (s, 3H), 2.14 (s, 3H),

5 2.16 (s, 3H), 3.71 (dd, 1H), 4.01 (dd, J=5.0, 11.7 Hz, 1H), 5.17-5.26 (m, 2H), 5.37 (dd, J=3.5, 8.8 Hz, 1H), 6.0 (d, J=3.2 Hz, 1H).

¹³C, δ 20.9, 20.9, 21.0, 21.0, 62.2, 66.7, 68.4, 68.4, 90.8, 168.8, 169.9, 170.0, 170.1.

10 **2,3,4-Tri-O-acetyl-1,5-anhydro-L-arabinitol (2).**

Trimethylsilyl trifluoromethanesulphonate (60 ml, 333 mmol) was added to a solution of crude 1,2,3,4-tetra-O-acetyl-L-lyxopyroanose constituting the yield from the step above in acetonitrile (200 ml), the solution was cooled on an ice bath and triethylsilane (80 ml, 500 mmol) was added dropwise. The solution

15 was stirred at room temperature and the reaction was monitored by GC.

When the reaction was completed (after 3 hours) the solution was neutralised with sodium hydrogen carbonate (s), diluted with dichloromethane and washed with water. The organic phase was dried with magnesium sulphate, filtered and concentrated. The obtained oil was purified by silica gel flash

20 column chromatography (pentane:ethyl acetate 5:1, 4:1, 3:1) which gave 32 g, 74 % (from free lyxose) of the reduced compound.

NMR data 400 MHz (CDCl₃): ¹H, δ 2.06 (s, 3H), 2.07 (s, 3H), 2.11 (s, 3H), 3.36-3.41 (m, 1H), 3.64 (dd, J=2.4, 12.2 Hz, 1H), 3.87 (m, 1H), 4.03 (m, 1H), 5.10-5.15 (m, 2H), 5.28-5.31 (m, 1H).

25

1,5-Anhydro-3,4-O-cyclohexylidene-L-arabinitol (3).

A solution of 1-deoxy-2,3,4-tri-O-acetyl-L-lyxopyroanose (20.8 g, 80 mmol) in methanol (125 ml) was treated with a catalytic amount of 1M methanolic sodium methoxide. After stirring for 1 hour at room temperature tlc (ethyl acetate:methanol 3:1) indicated complete conversion into a lower migrating spot. The solution was neutralised with Dowex H⁺, filtered and concentrated, which gave a colourless oil.

30

The oil was suspended in dichloromethane (70 ml) and cyclohexanone diethyl ketal (41 g, 240 mmol) was added followed by *p*.toluenesulphonic acid until acidic pH. After a few minutes the suspension became a clear solution that was stirred at room temperature. After 18 hours, when tlc (pentane:ethyl acetate 1:2) indicated complete conversion into a higher migrating spot, the solution was neutralised with triethyl amine, concentrated and the residue was purified by silica gel flash column chromatography (toluene:ethyl acetate 3:2, 1:1) which gave 9.6 g, 56% of the title compound as white crystals.

NMR data 400 MHz (CDCl₃): ¹H, δ 1.38-1.43 (m, 2H), 1.56-1.75 (m, 8H), 2.43 (d, J=4.9 Hz, 1H), 3.28 (m, 1H), 3.75 (dd, J=3.9, 12.7 Hz, 1H), 3.82-3.94 (m, 3H), 4.05 (t, J=5.4 Hz, 1H), 4.22 (m, 1H).

¹³C, δ 23.9, 24.3, 25.2, 35.7, 38.3, 67.8, 68.7, 69.1, 71.9, 77.5, 110.5.

1,5-Anhydro-3,4-O-cyclohexylidene-L-ribulose (4).

A solution of dimethyl sulfoxide (2.65 ml, 37.3 mmol) in dichloromethane (30 ml) was added dropwise at -60 °C under nitrogen to a stirred solution of oxalyl chloride (1.79 ml, 20.5 mmol) in dichloromethane (30 ml) during a period of 15 min. To this solution a solution of 2,3-O-cyclohexylidene-1-deoxy-L-lyxopyranose (4 g, 18.7 mmol) in dichloromethane (20 ml) was added dropwise during a period of 5 min. A white suspension was obtained and additional dichloromethane was added twice (10+30 ml). The temperature was allowed to rise to -25 °C where the suspension became a colourless solution. The temperature was again lowered to -45 °C and a solution of triethyl amine (12.9 ml, 93.3 mmol) in dichloromethane (20 ml) was added.

After 10 min, when tlc (toluene:ethyl acetate 1:1) indicated complete conversion of the alcohol into the ketone, the reaction mixture was poured into water (100 ml), the water layer was extracted once with dichloromethane (50 ml), the combined organic phases were dried with sodium sulphate, filtered and concentrated. Flash column chromatography on silica gel (eluent pentane:diethyl ether 1:1) of the residue gave a colourless solid. 3.4 g, 86%.

The oxidation was also performed by the Dess-Martin procedure:

A suspension of 2,3-*O*-cyclohexylidene-1-deoxy-L-lyxopyranose (0.5 g, 2.33 mmol) and Dess-Martin periodinane (1.39 g, 3.29 mmol) in dichloromethane (5 ml) was stirred for 10 min then "wet dichloromethane" (46 ml water in 10 ml dichloromethane) was added dropwise during 15 min. After 1h tlc (toluene:ethyl acetate 1:1) indicated complete conversion of the starting material into a higher migrating spot. The reaction mixture was diluted with diethyl ether (100 ml) and washed with an aqueous solution of sodium hydrogen carbonate/sodium thiosulphate 1:1 (50 ml), dried with sodium sulphate, filtered and concentrated. Purification of the residue by flash column chromatography on silica gel (eluent pentane:diethyl ether 1:1) gave the title compound, 0.42 g, 84%, as a crystalline solid.

NMR data 400 MHz (CDCl₃): ¹H, δ 1.39-1.43 (m, 2H), 1.56-1.72 (m, 8H), 3.92-4.07 (m, 3H), 4.18-4.23 (m, 1H), 4.45 (d, J=6.8 Hz, 1H), 4.64-4.67 (m, 1H).

¹³Cδ 23.9, 24.1, 25.1, 35.3, 36.8, 68.5, 74.1, 75.1, 76.3, 112.4, 205.0.

1,5-Anhydro-4-deoxy-4-ethylidene-2,3-*O*-cyclohexylidene-*D*-erythro-pentitol (5).

Potassium-*t*-butoxide (3.41 g, 30.4 mmol) was added in one portion to a stirred suspension of ethyltriphenylphosphonium bromide (11.9 g, 32.0 mmol) in THF (60 ml) at -10 °C under nitrogen. The obtained orange-red mixture was allowed to reach room temperature, then cooled again to -10 °C and a solution of 1,5-anhydro-3,4-*O*-cyclohexylidene-L-ribulose (3.4 g, 16.0 mmol) in THF (40 ml) was added dropwise. The mixture was allowed to attain room temperature. 20 minutes after final addition, when tlc (toluene:ethyl acetate 1:1) indicated complete conversion of the starting material into a higher migrating spot, the reaction mixture was partitioned between diethyl ether (400 ml) and water (200 ml). The organic layer was washed with water (1x200 ml) and brine (1x200 ml), dried with sodium sulphate, filtered and concentrated into a 10-ml residue. The residue was purified by flash column chromatography on silica gel (eluent pentane:ethyl acetate 95:5, 9:1) and appropriate fractions were carefully concentrated (bath temperature 25 °C) into a 10 g solution that was used directly in the next step.

1,5-Anhydro-4-deoxy-4-ethyl-2,3-O-cyclohexylidene-D-ribitol (6).

The above solution was diluted with ethyl acetate (30 ml), Pd/C (10%, 0.2 g) was added and the mixture was hydrogenated at atmospheric pressure.

- 5 Additional Pd/C was added (0.16 g + 0.20 g) after 40 and 90 minutes. After 100 minutes tlc indicated almost complete consumption of the starting material. The reaction mixture was filtered through celite, concentrated into a liquid (5 ml) and purified by flash column chromatography on silica gel (eluent pentane:ethyl acetate 95:5, 9:1). Appropriate fractions were concentrated to
- 10 2.08 g and this solution was used directly in the next step.

NMR data 400 MHz (CDCl₃): ¹H, δ 0.98 (t, 3H), 1.31-1.74 (m, 12H), 1.82-1.92 (m, 1H), 3.18-3.26 (m, 2H), 3.64-3.68 (m, 1H), 3.84 (dd, J=6.4, 11.4 Hz, 1H), 4.08-4.14 (m, 1H), 4.27-4.29 (m, 1H).

- ¹³C, δ 11.3, 20.9, 24.0, 24.3, 25.3, 35.7, 38.3, 38.7, 67.7, 68.3, 70.8, 72.6,
- 15 109.5.

1,5-Anhydro-4-deoxy-4-ethyl-D-ribitol (7).

- The above 1,5-anhydro-4-deoxy-4-ethyl-2,3-O-cyclohexylidene-D-ribitol was dissolved in aqueous acetic acid (80 %, 25 ml) and the solution was stirred at
- 20 70 °C. After 18 hours, when tlc (pentane ethyl acetate 9:1 and 1:1) indicated almost complete consumption of the starting material (~5% left), the solution was concentrated. Purification of the residue by flash column chromatography on silica gel (eluent pentane:ethyl acetate 1:1, 2:3) gave 0.91 g 39 % (from the keto compound) of a colourless solid.

- 25 NMR data 400 MHz (CDCl₃): ¹H, δ 0.94 (t, 3H), 1.24-1.42 (m, 2H), 1.58-1.67 (m, 1H), 3.35 (t, 1H), 3.43 (t, 1H), 3.56 (dd, 1H), 3.67-3.71 (m, 2H).

¹³C, δ 11.4, 20.1, 42.1, 66.1, 66.3, 68.3, 68.7.

1,5-anhydro-2-O-benzyl-4-deoxy-4-ethyl-D-ribitol (8).

- 30 Sodium hydride (60%, 0.27 g, 6.84 mmol) was added in one portion, at room temperature, under nitrogen, to a stirred solution of 1,5-anhydro-4-deoxy-4-ethyl-D-ribitol (0.5 g, 3.42 mmol) in dimethylformamide (7 ml). After 30 minutes benzyl bromide (0.53 ml, 4.45 mmol) was added dropwise during 30

minutes. After 20 minutes, when tlc (p.ether:ethyl acetate 4:1) indicated complete conversion of the diol, methanol (1 ml) was added and the mixture was stirred for 20 minutes. The reaction mixture was diluted with ethyl acetate (100 ml), washed with water (3x50 ml), dried with sodium sulphate, filtered
5 and concentrated. Purification of residue by flash column chromatography on silica gel (eluent pentane:ethyl acetate 9:1, 4:1) gave 0.52 g, 64% of a colourless solid.

NMR data 400 MHz (CDCl₃): ¹H, δ 0.94 (t, 3H), 1.25-1.36 (m, 1H), 1.37-1.48 (m, 1H), 1.54-1.62 (m, 1H), 2.14 (s, 1H), 3.40 (t, 1H), 3.51-3.56 (m, 3H), 3.72-
10 3.79 (m, 1H), 4.13 (s, 1H), 4.58 (d, J=11.7 Hz, 1H), 4.63 (d, J=11.7 Hz, 1H), 7.29-7.38 (m, 5H).

¹³C, δ 11.5, 20.1, 42.0, 64.1, 66.5, 66.6, 71.1, 75.6, 127.9, 128.2, 128.8, 138.1.

15 **1,5-Anhydro-3-azido-2-O-benzyl-3,4-dideoxy-4-ethyl-D-xylitol (9).**

Methanesulphonyl chloride (0.34 g, 2.96 mmol) was added to a stirred solution of 1,5-anhydro-2-O-benzyl-4-deoxy-4-ethyl-D-ribitol (0.28 g, 1.18 mmol) in pyridine (5 ml). The reaction mixture was warmed to 50 °C and stirred for one hour. Dichloromethane (100 ml) was added and the reaction
20 mixture was washed successively with 1M aqueous sulphuric acid (2x50 ml), 1M aqueous sodium hydrogen carbonate, dried with sodium sulphate, filtered and concentrated. The residue was dissolved in dimethylformamide (10 ml) and sodium azide (0.31 g, 4.74 mmol) was added. The obtained mixture was stirred at 80 °C over night, diluted with ethyl acetate (100 ml), washed with
25 water (3x50 ml), dried with sodium sulphate, filtered and concentrated.

Purification of residue by flash column chromatography on silica gel (eluent toluene:ethyl acetate 95:5) gave 0.25 g, 81% of a colourless oil.

NMR data 400 MHz (CDCl₃): ¹H, δ 0.90 (t, 3H), 1.12-1.24 (m, 1H), 1.44-1.54 (m, 1H), 1.69-1.79 (m, 1H), 3.01 (t, 1H), 3.08-3.16 (m, 2H), 3.44-3.50 (m, 1H),
30 3.92 (dd, J=4.9, 11.7 Hz, 1H), 4.04 (ddd, J=1.0, 4.9, 11.2 Hz, 1H), 4.62 (d, J=11.7 Hz, 1H), 4.71 (d, J=11.2 Hz, 1H) 7.29-7.37 (m, 5H).

¹³C, δ 11.3, 22.0, 42.4, 68.5, 69.2, 70.9, 73.1, 78.2, 128.2, 128.2, 128.7, 138.0.

1,5-anhydro-3-[(tert-butoxycarbonyl)amino]-3,4-dideoxy-4-ethyl-D-xylitol (10).


Pd/C (10%, 30 mg) was added to solution of 1,5-anhydro-3-azido-2-O-benzyl-3,4-dideoxy-4-ethyl-D-xylitol (88 mg, 0.34 mmol) and di-*tert*-butyl dicarbonate (77 mg, 0.35 mmol) in ethyl acetate (4 ml) and the mixture was stirred under hydrogen. After 18 hours, when tlc (pentane: ethyl acetate 9:1, ninhydrine) indicated complete consumption of the starting material, the mixture was filtered through celite and concentrated. The residue was purified by flash column chromatography on silica gel (eluent toluene:ethyl acetate 4:1) which gave a colourless solid that still contained a benzyl group according to ¹H-nmr. The solid was dissolved in ethyl acetate:ethanol 1:1 and hydrogenated over Pd/C (10% 20 mg). After 1 hour, when tlc (toluene ethyl acetate 1:1, ninhydrine) indicated complete conversion of the starting material into a lower migrating spot, the mixture was filtered through celite and concentrated. Purification of residue by flash column chromatography on silica gel (eluent toluene:ethyl acetate 1:1, 2:3) gave 59 mg, 71% of the desired monool as a colourless solid. This monool is N-extended and capped as described herein and then oxidised to the corresponding pyranone. Alternatively the monool is first oxidised and then N-extended and capped.

NMR data (CDCl₃): ¹H, δ 0.90 (t, 3H), 1.12-1.24 (m, 1H), 1.42-1.52 (m, 10H), 1.59-1.70 (m, 1H), 3.05-3.16 (m, 2H), 3.26-3.30 (m, 1H), 3.43-3.48 (m, 2H), 3.96-4.05 (m, 2H).

¹³C, δ 11.5, 21.2, 28.5, 42.4, 59.2, 71.4, 71.8, 72.7.


Alternative method for the preparation of 5-methyl pyranones as building blocks and intermediates towards 5-functionalised pyranones

2-Benzyloxycarbonylamino-4-hydroxy-3-methyl-butyric acid tert-butyl ester




2-Benzyloxycarbonylamino-4-hydroxy-3-methyl-butyric acid *tert*-butyl ester was prepared following procedures reported by J.E. Baldwin *et al* (*Tetrahedron* 1995, 51(42), 11581).

5 (4-Methyl-2-oxo-tetrahydro-furan-3-yl)-carbamic acid benzyl ester




2-Benzyloxycarbonylamino-4-hydroxy-3-methyl-butyric acid *tert*-butyl ester (1.00g, 3 mmol) was dissolved in TFA (30 mL). This solution was stirred for 45 minutes and then concentrated *in vacuo*. The residual TFA was removed
 10 azeotropically with toluene. This residue was purified by flash column chromatography to yield the title compound as a crystalline solid (750mg, 80%), MS (ES⁺) 250 (M+H).

15 [3-Hydroxy-1-(methoxy-methyl-carbamoyl)-2-methyl-propyl]-carbamic acid benzyl ester 4




The lactone ring of (4-methyl-2-oxo-tetrahydro-furan-3-yl)-carbamic acid benzyl ester can be opened using *N,O*-dimethylhydroxylamine hydrochloride in the presence of Me₃Al to give the title compound.

20 [3-*tert*-Butoxy-1-(methoxy-methyl-carbamoyl)-2-methyl-propyl]-carbamic acid benzyl ester 5




The primary alcohol of [3-hydroxy-1-(methoxy-methyl-carbamoyl)-2-methyl-propyl]-carbamic acid benzyl ester can be protected using *tert*-butyl-2,2,2-trichloroacetimidate and boron trifluoride etherate to give the title compound.
 25

(3-*tert*-Butoxy-1-formyl-2-methyl-propyl)-carbamic acid benzyl ester 6



The Weinreb amide function of [3-*tert*-butoxy-1-(methoxy-methyl-carbamoyl)-2-methyl-propyl]-carbamic acid benzyl ester can be reduced using lithium aluminium hydride in ether to provide the title compound.


- 5 2-Benzyloxycarbonylamino-4-*tert*-butoxy-3-methyl-butyric acid 7



- 10 (3-*tert*-butoxy-1-formyl-2-methyl-propyl)-carbamic acid benzyl ester in *tert*-butyl alcohol in the presence of 2-methyl-2-butene can be oxidised using a solution of sodium chlorite and monobasic sodium phosphate in water to give the title compound.


[3-*tert*-Butoxy-1-(2-diazo-acetyl)-2-methyl-propyl]-carbamic acid benzyl ester

9



- 15 Activation of 2-benzyloxycarbonylamino-4-*tert*-butoxy-3-methyl-butyric acid with isobutyl chloroformate and 4-methylmorpholine, and subsequent treatment of the activated acid with diazomethane allows for the preparation of the title compound.

- 20 (3-Methyl-5-oxo-tetrahydro-pyran-4-yl)-carbamic acid benzyl ester 10




- 25 Cyclisation of *tert*-butoxy-1-(2-diazo-acetyl)-2-methyl-propyl]-carbamic acid benzyl ester using lithium chloride in aqueous acetic acid gives the title compound. The CBz protecting group is readily replaced with Boc or Fmoc etc by conventional protecting group manipulation.

Alternative Route Towards Chiral β -Alkyl Serines


Following the chemistry detailed in scheme 3. Exemplified by the synthesis of (2S, 3S)- β -hydroxynorvaline (15) (also termed of (2S, 3S)- β -ethylserine)

(a) Tri-acetone-D-mannitol




D-Mannitol (49.5g, 0.27mol) was suspended in acetone (600mL, 99.9% purity). To the suspension H_2SO_4 (4.95mL) was added and the mixture
 5 shaken at 21°C overnight. The solution was then filtered and the clear solution neutralised with a saturated solution of NaHCO_3 until $\text{pH}=6$. The solvent was concentrated *in vacuo*, affording tri-acetone-D-mannitol as a white solid, yield 78g, 96%. Electrospray-MS m/z 303 (MH^+).

10 (b) 3,4-Isopropylidene-D-mannitol



Tri-acetone-D-mannitol (78g, 0.26mol) was dissolved in the minimum amount of 70% acetic acid (400mL) and stirred in water bath at 42.7°C for 1.5hrs. The solvent was quickly evaporated *in vacuo* to give 3,4-Isopropylidene-D-mannitol
 15 as a colourless oil, yield 57.6g, 99.8%. Electrospray-MS m/z 223 (MH^+).

(c) 1,2,5,6-tetra-O-benzyl-3,4-O-isopropylidene-D-mannitol (35)




3,4-Isopropylidene-D-mannitol (57.64g, 0.26mol) was dissolved in
 20 benzylchloride (543mL). To the stirred solution powdered KOH (500g) was added and the solution heated in an oil bath at 133°C for 2hrs. The mixture

was allowed to cool to room temperature and poured into a 3000mL beaker. Ice and water (1400mL) were carefully added, the mixture extracted with DCM (800mL) and the aqueous phase further extracted with DCM (300mL). The organic extracts were dried over sodium sulphate and the filtered solution concentrated *in vacuo*. The residue was purified by flash chromatography over silica gel eluting with EtOAc/heptane (1:15 to 1:10, v/v) to afford compound (35) as a colourless oil, yield 77g, 51%.

Electrospray-MS m/z 583 (MH^+). Analytical HPLC R_t = 29.16mins (91.8%).

1H (500 MHz, $CDCl_3$) 1.35 (6H, s, $C(CH_3)_2$), 3.62 (2H, dd, J 6, 10, 2 x $CHOC$), 3.75 (4H, m, 2 x CH_2OBn), 4.15–4.20 (1H, m, $CHOBn$), 4.46 (1H, dd, J 12.5, 14.5, $CHOBn$), 4.77 (4H, d, J 11.5, 4 x $CH_2AC_6H_5$), 4.73 (4H, d, J 11.5, 4 x $CH_2BC_6H_5$) and 7.25–7.34 (20H, m, 4 x C_6H_5).

(d) 1,2,5,6-Tetra-O-benzyl-D-mannitol (36)



15


In a 2000mL flask fitted with a condenser compound (35) (41.11g, 0.071mol) was dissolved in 70% acetic acid (700mL) and the solution stirred at 100°C in an oil bath for 1.5hrs. After concentration *in vacuo*, the residue was purified by flash chromatography over silica gel eluting with EtOAc/heptane (3:7, v/v) to afford compound (36) as a pale yellow oil, yield 21.8g, 57%.

Electrospray-MS m/z 543 (MH^+). Analytical HPLC R_t = 25.8 (100%).

δ_H (500 MHz, $CDCl_3$) 3.01 (2H, d, J 6.0, 2 x OH), 3.65–3.70 (2H, m, 2 x $CHOBn$), 3.72–3.78 (4H, m, 2 x CH_2OBn), 3.93–3.97 (2H, m, 2 x $CHOH$), 4.55 (4H, s, 2 x $CH_2C_6H_5$), 4.73 (2H, d, J 11.5, 2 x $CH_2AC_6H_5$), 4.77 (2H, d, J 11.5, 2 x $CH_2BC_6H_5$) and 7.25–7.34 (20H, m, 4 x C_6H_5).

25

(e) (2R)-2,3-Di-O-benzylglyceraldehyde (37)




Compound (36) (10.78g, 0.02mol) was dissolved in anhydrous toluene (150mL). While vigorously stirring lead tetraacetate (9.83g, 0.023mol, 1.1eq) was added as a solid and the mixture stirred for 3hrs at room temperature.

The mixture was then filtered and the filtered concentrated *in vacuo* to afford compound (37) as a colourless oil, yield 10.2g, 95%.

δ_H (500 MHz, $CDCl_3$) 3.75-3.83 (2H, m, CH_2OBn), 3.97 (1H, t, J 4, $CHOBn$), 4.55 (2H, d, J 5.5, 2 x $CH_{2A}C_6H_5$), 4.70 (2H, d, J 12, 2 x $CH_{2B}C_6H_5$), 7.20-7.40 (10H, m, 2 x C_6H_5) and 9.70 (1H, s, CHO).


(f) (2S)-N-(2,3-Dibenzyloxypropylidene)benzylamine (38)



Benzylamine (4.06mL, 0.037mol, 1eq) was dissolved in anhydrous diethyl ether (150mL) and the solution cooled to 0°C. To a solution of compound (37) (9.9g, 0.037mol, 1eq) in anhydrous diethyl ether (100mL) at 0°C, was added anhydrous magnesium sulphate (7.3g) and the solution transferred *via* cannula under argon to the solution of the amine. After stirring for 3 hrs the reaction mixture was concentrated *in vacuo* to give compound (38) as a crude colourless oil, yield 12.2g, 96%.

δ_H (500 MHz, $CDCl_3$) 3.75-3.83 (2H, m, CH_2OBn), 4.17-4.25 (1H, m, $CHOBn$), 4.57 (2H, s, $NCH_2C_6H_5$), 4.62 (2H, m, 2 x $CH_{2A}C_6H_5$), 4.70 (2H, m, $CH_{2B}C_6H_5$), 7.20-7.40 (15H, m, 3 x C_6H_5) and 7.70 (1H, m, CHN).

(g) (1R,2S)-N-Benzyl-2,3-dibenzyloxy-1-phenyl-1-propylamine (39)




Phenylmagnesium bromide (29.17mL, 0.087mol, 3.0M, 2.5eq) was dissolved in anhydrous diethyl ether (124mL) and the solution cooled to 0°C under argon. A solution of compound (38) (12.5g, 0.035mol) in anhydrous diethyl ether (140mL) was transferred *via* cannula to the solution of the

phenylmagnesium bromide and the reaction mixture stirred at room temperature for 2hrs. The solution was poured into an aqueous solution of NH_4Cl (200mL) and extracted with *tert*-butyl methyl ether (2 x 100mL). The combined extracts, dried over anhydrous sodium sulphate, were concentrated *in vacuo*. The crude oil obtained was purified by flash chromatography over silica gel eluting with EtOAc/heptane (1:4, v/v) to afford compound (39) as a pale yellow oil, yield 8.5g, 56%. Electrospray-MS m/z 438 (MH^+). Analytical HPLC R_t = 24.0mins (98%).

δ_{H} (500 MHz, CDCl_3) 2.45 (1H, br s, NH), 3.32 (1H, dd, J 10, 4.5, $\text{CH}_2\text{A}\text{OBn}$), 3.43 (1H, d, J 13, $\text{C}_6\text{H}_5\text{CH}_2\text{A}\text{NH}$) 3.50-3.54 (1H, dd, J 10, 3, $\text{CH}_2\text{B}\text{OBn}$), 3.55-3.61 (1H, d, J 13, $\text{C}_6\text{H}_5\text{CH}_2\text{B}\text{NH}$), 3.65-3.78 (1H, m, CHOBn), 3.90 (1H, d, J 7, $\text{C}_6\text{H}_5\text{CHNH}$), 4.40 (2H, s, $\text{OCH}_2\text{C}_6\text{H}_5$), 4.62 (1H, d, J 11, $\text{OCH}_2\text{A}\text{C}_6\text{H}_5$), 4.70 (1H, d, J 11, $\text{OCH}_2\text{B}\text{C}_6\text{H}_5$) and 7.18-7.40 (20H, m, 4 x C_6H_5).

(h) (1R,2S)-N-Benzyl-*tert*-butoxycarbonyl-2,3-dibenzyloxy-1-phenyl-1-propylamine
(40)




Compound (39) (9.26g, 0.02mol) was dissolved in dioxane (66mL) and diisopropylamine (0.37mL, 0.0021mol, 0.11eq) was added. To the stirred solution di-*tert*-butyl dicarbonate (11.25g, 0.0516mol, 2.6eq) was added as a solid and the solution stirred at 50°C in an oil bath overnight. The mixture was treated with *tert*-butyl methyl ether (300mL), washed with 1.0M KHSO_4 aqueous solution (60mL) and the organic extracts were dried over anhydrous sodium sulphate and concentrated *in vacuo*. The crude oil was purified by flash chromatography over silica gel eluting with EtOAc/heptane (1:9, v/v) to afford compound (40) as a colourless oil, yield 7.7g, 71%. Electrospray-MS m/z 538 (MH^+). Analytical HPLC R_t = 30.0mins (95%).

δ_{H} (500 MHz, CDCl_3) 1.30 (9H, s, $\text{C}(\text{CH}_3)_3$), 3.44 (1H, dd, J 10, 4.5, $\text{CH}_2\text{A}\text{OBn}$), 3.61 (1H, dd, J 10, 2, $\text{CH}_2\text{B}\text{OBn}$), 4.30 (1H, m, CH_2AN) 4.37 (2H, d, J 12, $\text{OCH}_2\text{A}\text{C}_6\text{H}_5$), 4.43 (2H, d, J 12, $\text{OCH}_2\text{B}\text{C}_6\text{H}_5$), 4.50-4.63 (1H, m, CH_2BN),

4.85 (1H, m, CHOBN) 5.25 (1H, d, J 9, $\text{C}_6\text{H}_5\text{CHN}$) and 7.00-7.45 (20H, m, 4 x C_6H_5).

(i) (1R,2S)-N-*tert*-Butoxycarbonyl-2,3-hydroxy-1-phenyl-1-propylamine (**41**)




5

Compound (**40**) (7.67g, 0.014mol) was dissolved in anhydrous methanol (80mL). After having flushed the flask with argon, 20%Pd(OH)₂/C (10.00g, Degussa type, E101 NE/W, wet) was carefully added and the mixture stirred under H₂ for 48 hrs. The mixture was carefully filtered through a pad of Celite and the catalyst washed with a solution of aqueous methanol (10:100 H₂O:CH₃OH, v/v). The filtered solution was concentrated *in vacuo* and the residue purified by flash chromatography over silica gel eluting with EtOAc/heptane (3:1, v/v) to afford compound (**41**) as a colourless oil, yield 2.7g, 72%. Electrospray-MS *m/z* 268 (MH⁺). Analytical HPLC *R*_t = 15.3mins (100%).

15

δ_{H} (500 MHz, CDCl₃) 1.44 (9H, s, C(CH₃)₃), 2.6 (2H, br s, OH), 3.56 (2H, d, J 5.5, CH_2OH), 3.97 (1H, s, $\text{C}_6\text{H}_5\text{CHNH}$), 4.83 (1H, s, $\text{C}_6\text{H}_5\text{CHCHOH}$), 5.28 (1H, d, J 8, NH) and 7.20-7.45 (5H, m, C_6H_5).

(j) (1R,2S)-N-*tert*-Butoxycarbonyl-3-*tert*-butyldimethylsilyloxy-2-hydroxy-1-phenyl-1-propylamine (**42**)




Compound (**41**) (2.67g, 0.01mol) was dissolved in anhydrous DMF (60mL) and stirred under argon. Imidazole (1.5g, 0.022mol, 2.2eq) was added followed by the addition of TBDMSCl (1.66g, 0.011mol, 1.1eq). The reaction mixture was stirred overnight at room temperature. The mixture was diluted with ether (240mL), washed with saturated NH₄Cl (120mL) and H₂O (40mL) and the aqueous layer extracted with ether (4 x 100mL). The combined extracts were dried over anhydrous sodium sulphate, filtered and

30

concentrated *in vacuo*. Purification of the residue by flash chromatography over silica gel eluting with EtOAc/heptane (3:1, v/v) afforded compound **(42)** as a colourless oil, yield 3.31g, 87%. Electrospray-MS m/z 382 (MH^+).

δ_H (500 MHz, $CDCl_3$) 0.05 (3H, s, $CH_{3A}SiCH_3$), 0.06 (3H, s, CH_3SiCH_{3B}), 0.89 (9H, s, $Si(CH_3)_3$), 1.39 (9H, br s, $C(CH_3)_3$), 2.45 (1H, br s, OH), 3.51 (1H, dd, J 10, 7, $TBDMSOCH_{2A}$), 3.65 (1H, dd, J 10, 4.5, $TBDMSOCH_{2B}$), 3.85 (1H, m, $CHOH$), 4.66 (1H, m, C_6H_5CHNH), 5.45 (1H, br s, NH) and 7.23-7.35 (5H, m, C_6H_5).


- 10 (k) (1R,2S)-N-*tert*-butoxycarbonyl-3-*tert*-butyldimethylsilyloxy-2-mesyloxy-1-phenyl-1-propylamine **(43)**



- 15 Compound **(42)** (1.30g, 3.40mmol, 1.0eq) was dissolved in anhydrous DCM (30mL). To the solution TEA (0.57mL, 4.09mmol, 1.2eq) was added and the mixture was cooled to 0°C in an ice-water bath. At this temperature and under argon, a solution of MsCl (0.32ml, 4.09mmol, 1.2eq) in anhydrous DCM (3mL) was added. The mixture was stirred for 1.5hrs. The reaction mixture was
- 20 treated with water (20mL) and extracted with DCM (20mL). The aqueous phase was further extracted with DCM (4 x 60mL) and the combined organic layers were dried over anhydrous sodium sulphate and concentrated *in vacuo*. The residue was purified by flash chromatography over silica gel eluting with EtOAc/heptane (1:3, v/v) affording compound **(43)** as a
- 25 colourless oil, yield 1.30g, 83%. Electrospray-MS m/z 460 (MH^+). Analytical HPLC Rt: 27.1mins (98%).

δ_H (500 MHz, $CDCl_3$) 0.06 (3H, s, $CH_{3A}SiCH_3$), 0.07 (3H, s, CH_3SiCH_{3B}), 0.91 (9H, s, $Si(CH_3)_3$), 1.42 (9H, br s, $C(CH_3)_3$), 2.54 (3H, s, SO_2CH_3), 3.77 (2H, d, J 6.0, $TBDMSOCH_2$), 4.7 (1H, m, $CHOH$), 5.1 (1H, m, C_6H_5CHNH), 5.4 (1H, br s, NH) and 7.26-7.38 (5H, m, C_6H_5).


- (l) (1R,2R)-N-*tert*-Butoxycarbonyl-2,3-epoxy-1-propylamine **(44)**



Compound **(43)** (3.79g, 8.26mmol, 1.0eq) was dissolved in THF anhydrous (78mL) and the solution cooled to 0°C in an ice water bath. TBAF (16.52mL, 1.0M sol in THF, 16.52mmol, 2eq) was added dropwise *via* syringe and once
 5 the addition was complete the ice bath was removed. The reaction mixture was stirred at room temperature overnight and then treated with water (40mL), extracted with diethyl ether (40mL) and the aqueous phase further extracted with diethyl ether (3 x 75mL). The combined extracts were dried over anhydrous sodium sulphate, filtered and concentrated *in vacuo*. The
 10 residue was purified by flash chromatography over silica gel eluting with TBME /heptane (1:6 to 2:1, v/v) affording compound **(44)** a white solid, yield 1.0g, 48%. Electrospray-MS *m/z* 250 (MH⁺).

δ_H (500 MHz, CDCl₃) 1.42 (9H, s, C(CH₃)₃), 2.50 (1H, dd, *J* 5, 2.2, CHCH_{2A}O),
 2.76 (1H, dd, *J* 5, 4, CHCH_{2B}O), 3.20-3.30 (1H, m, CHCH₂O), 4.72 (1H, br s,
 15 C₆H₅CHCHO), 5.00 (1H, br s, NH) and 7.27-7.38 (5H, m, C₆H₅).

(*m*) (1*R*,2*S*)-*N*-tert-butoxycarbonyl-2-hydroxy-1-phenyl-1-butylamine (**45**)




Copper(I)iodide (0.574g, 3.01mmol, 5eq) was dispersed in anhydrous diethyl
 20 ether (17mL). After cooling the suspension to -35°C under argon, CH₃Li in diethyl ether (3.76mL, 1.6M, 6.02mmol, 10eq) was added dropwise. After stirring at -35°C for 30 mins a solution of compound **(44)** (0.15g, 0.60mmol, 1.0eq) dissolved in diethyl ether (1.5mL) was added dropwise to the solution of the organocuprate and the reaction mixture was stirred at -35°C for 1.5 hrs.
 25 Ethyl acetate (12.5mL) was added followed by the careful addition of a saturated solution of NH₄Cl (10mL) and water (3mL). The mixture was allowed to warm up to room temperature and the organic phase extracted. The aqueous phase was further extracted with ethyl acetate (3 x 15mL) and the combined extracts dried over anhydrous sodium sulphate, filtered and
 30 concentrated *in vacuo*. The crude oil was purified by flash chromatography

over silica gel eluting with TBME /heptane (2:3, v/v) affording compound **(45)** as a white solid, yield 0.14g, 88%. Electrospray-MS m/z 266 (MH^+). Analytical HPLC R_t = 17.6mins (100%).

δ_H (500 MHz, $CDCl_3$) 0.97 (3H, t, J 7.5, CH_3CH_2), 1.10-1.25 (1H, m, CH_3CH_{2A}), 1.25-1.50 (1H, m, CH_3CH_{2B}), 1.50 (9H, s, $C(CH_3)_3$), 3.78 (1H, br s, $CHOH$), 4.73 (1H, br s, C_6H_5CHNH), 5.28 (1H, br s, NH) and 7.25-7.38 (5H, m, C_6H_5).

(n) (1R,2S)-N-*tert*-Butoxycarbonyl-2-*tert*-butoxy-1-phenyl-1-butylamine **(46)**




10

In a sealed tube, compound **(45)** (0.114g, 0.43mmol) was dissolved in anhydrous DCM (11mL). Whilst stirring was maintained, the tube was immersed in a dry ice-acetone bath and cooled to $-60^\circ C$. Isobutylene (11mL) was condensed into the tube and methyltriflate (55 μ L) was carefully added.

The tube was capped tightly and the bath removed to allow the reaction to proceed at room temperature for 4 days. The tube was cooled to $-60^\circ C$, the lid removed and then the bath removed to allow the excess of isobutylene to slowly evaporate whilst warming up to room temperature. At about $10^\circ C$, TEA (0.7mL) was added to neutralise the excess acid. The residue obtained after removal of the solvents *in vacuo* was purified by flash chromatography over silica gel eluting with EtOAc/heptane (2:8, v/v) affording compound **(46)** as a white solid, yield 0.02g, 14.%. Electrospray-MS m/z 322 (MH^+). Analytical HPLC R_t = 24.1mins (90%).

δ_H (500 MHz, $CDCl_3$) 0.84 (3H, t, J 7.5, CH_3CH_2), 1.15-1.30 (1H, m, CH_3CH_{2A}), 1.24 (9H, s, $CHOC(CH_3)_3$), 1.35-1.40 (1H, m, CH_3CH_{2B}), 1.41 (9H, s, $CO_2C(CH_3)_3$), 3.72 (1H, m, $CHO(CH_3)_3$), 4.78 (1H, m, C_6H_5CHNH), 5.15 (1H, br s, NH) and 7.22-7.38 (5H, m, C_6H_5).


(o) (2S,3S)-N-*tert*-Butoxycarbonyl- -*tert*-butoxy-norvaline **(47)**



30

Compound (46) (0.024g, 0.074mmol, 1eq), was dissolved in a mixture of CCl₄/CH₃CN/H₂O (1:1:2, v/v/v, 2.4mL). To the stirred biphasic solution NaHCO₃ (0.104g, 1.25mmol, 16.9eq) was added as a solid, followed by the careful addition of NaIO₄ (0.284g, 1.33mmol, 18eq). After 10 minutes
 5 RuCl₃·3H₂O (1.5mg, 7.23 μmol, 0.1eq) was added and the reaction mixture stirred for 48hrs. The solution was treated with EtOAc (15mL) and acidified to pH =3 by dropwise addition of citric acid (10%). The organic phase was further extracted with EtOAc (3 x 15mL) and the combined extracts were dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo*. The
 10 crude residue was purified by flash chromatography over silica gel eluting with a gradient of MeOH /CH₃Cl (0.1:10 to 1.0:10, v/v) to give compound (47) as a white solid, yield 0.009g, 42%.
 Electrospray-MS m/z 290 (MH⁺).

15 (p) (2S,3S)-β-Hydroxy-norvaline (15)



Compound (47) (9mg, 0.03mmol) was dissolved in a solution HCl in dioxane (1mL, 4.0M). After stirring for 3hrs at room temperature, the solvent was removed *in vacuo* and the residue was lyophilised using CH₃CN/H₂O (4:1, v/v)
 20 to yield (2S,3S)-β-hydroxynorvaline (15) as a white solid, 3.0 mg, 75%.Electrospray-MS m/z 134 (MH⁺).

¹H (500 MHz; CD₃OD) 1.00 (3H, t, J 7.5, CH₃CH₂), 1.50-1.65 (2H, m, CH₃CH₂), 3.88-3.95 (1H, m, CHOH) and 3.98 (1H, d, J 3, C₆H₅CHNH₂).

25

Chemistry Towards P2 Hybrid Aminoacids

30 The general chemistry depicted in scheme 4 will shortly be published in full in the academic literature, by its inventors CS Dexter and RFW Jackson at the University of Newcastle, England.

(a) General Procedure for the zinc coupling reactions

(b) Zinc activation

Zinc dust (150mg, 2.3mmol, 3.0eq, Aldrich) was weighed into a 25mL round bottom flask with a side arm and fitted with a three way tap. The zinc powder
5 was heated with a heat gun under vacuum and the flask was flushed with nitrogen and evacuated and flushed a further three times. With the flask filled with nitrogen, dry DMF (1mL) was added. Trimethylsilylchloride (30μl, 0.23mmol, 0.3eq) was added and the zinc slurry was vigorously stirred for a further 30mins.

10

(c) Zinc insertion; N-(*tert*-Butoxycarbonyl)-3-iodozinc-L-alanine methyl ester (61)

N-(*tert*-Butoxycarbonyl)-3-iodo-L-alanine methyl ester (247mg, 0.75mmol, 1.0eq) dissolved in dry DMF (0.5mL) was added dropwise, *via* cannula, to the
15 activated zinc slurry at 0°C prepared as described above. The reaction mixture was then allowed to warm up to room temperature and stirred for 1hr to give the organozinc reagent.

(d) CuBr.SMe₂ preparation

20 Whilst the zinc insertion reaction was in progress, CuBr.SMe₂ (20mg, 0.1mmol, 0.13eq) was weighed into a 25ml round bottom flask fitted with a three way tap and dried "gently" with a heat gun under vacuum until CuBr.SMe₂ changed appearance from a brown powder to give a light green powder. Dry DMF (0.5mL) was then added followed by addition of the
25 electrophile (either 1-bromo-2-methylbut-2-ene, toluene-4-sulfonic acid-(E)-2-methyl-but-2-enyl ester or 1-bromo-2,3-dimethylbut-2-ene) (1.0mmol, 1.3eq). The reaction mixture was then cooled to -15°C.

(e) Coupling Reaction

30 Stirring of the organozinc reagent solution was stopped to allow the zinc powder to settle and the supernatant was carefully removed *via* cannula (care taken to avoid transferring too much zinc powder) and added dropwise to the solution of electrophile and copper catalyst. The cooling bath was removed and the solution was stirred at room temperature overnight. Ethyl acetate

(20mL) was added and stirring was continued for a further 15mins. The reaction mixture was transferred to a separating funnel and a further aliquot of EtOAc (30mL) was added. The organic phase was washed successively with 1M Na₂S₂O₃ (20mL), water (2 x 20mL), brine (40mL), dried over sodium sulphate and filtered. The solvent was removed *in vacuo* and the crude product purified by flash chromatography on silica gel as described.

(f) Hydrogenation of alkene

The alkene (1.0mmol) was dissolved in ethanol (10mL), 10% palladium on carbon (80mg) added and hydrogen introduced. Once the reaction had been deemed to have reached completion, the hydrogen was removed, the reaction filtered through Celite and the catalyst washed with ethanol (30mL). The combined organic filtrate was concentrated *in vacuo* and the alkane used directly in the subsequent reaction.

(g) Saponification of methyl ester

The methyl ester (1.0mmol) was dissolved in THF (6mL) and whilst stirring, a solution of LiOH (1.2mmol, 1.2eq) in water (6mL) was added dropwise. Once the reaction was deemed to have reached completion, the THF was removed *in vacuo* and diethyl ether (10mL) added to the residue. The reaction mixture was then acidified with 1.0M HCl until pH =3. The organic phase was then removed and the aqueous layer extracted with diethyl ether (2 x 10mL). The combined organic extracts were dried over magnesium sulphate, filtered and the solvent removed *in vacuo* to give the carboxylic acid used directly in the subsequent reaction.

(h) Removal of N-Boc protecting group

The N-Boc protected material (1.0mmol) was dissolved in DCM (2mL) and cooled to 0°C. Trifluoroacetic acid (2mL) was added dropwise and when the reaction was deemed to have reached completion, the solvents were removed *in vacuo* to yield the amine used directly in the subsequent reaction.

Alternatively, the N-Boc protected material (1.0mmol) was cooled to 0°C and 4M HCl in dioxane (5mL) added dropwise and when the reaction was deemed

to have reached completion, the solvents were removed *in vacuo* to yield the amine used directly in the subsequent reaction.

(i) Fmoc protection of amine


- 5 The amine (1.0mmol) in 1,4-dioxane (2mL) was cooled to 0°C and 10% sodium carbonate (2.2mmol, 2.2eq, 2mL) added. The biphasic reaction mixture was stirred vigorously and Fmoc-Cl (1.1mmol, 1.1eq) added. Once the reaction was deemed to have reached completion, diethyl ether (10mL) added and the reaction mixture acidified to pH = 3 with 1M HCl. The organic
- 10 phase was removed and the aqueous layer extracted with diethyl ether (2 x 10mL). The combined organic extracts were dried over sodium sulphate, filtered, the solvent removed *in vacuo* and the residue purified by flash chromatography over silica gel.

15

Example Synthesis 1

Preparation of 2S-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4,4-dimethylhexanoic acid (**68**)

- The following scheme explains how optically pure (S)-2-*tert*-
- 20 Butoxycarbonylamino-4,4-dimethyl-hex-5-enoic acid methyl ester (**62**) was prepared and isolated.



- (a) 2S-2-*tert*-Butoxycarbonylamino-4, 4-dimethyl-hex-5-enoic acid methyl ester (62), 2S-2-*tert*-butoxycarbonylamino-4-(2S-3,3-dimethyl-oxiranyl)-butyric acid methyl ester (63) and 2S-2-*tert*-butoxycarbonylamino-4-(2R-3,3-dimethyl-oxiranyl)-butyric acid methyl ester (64)

Following the general procedure for zinc coupling reactions, 1-bromo-3-methylbut-2-ene (115 μ L, 1.0mmol) was coupled to compound (61) (247mg, 0.75mmol) in the presence of CuBr.SMe₂ (20mg, 0.1mmol) to give a residue which was purified by flash column chromatography over silica gel eluting with EtOAc / 40:60 petroleum ether (1:9, v/v). Fractions were pooled and reduced *in vacuo* to give a mixture of regioisomers (2:1 formal SN2' vs SN2), inseparable by column chromatography, as a colourless oil, yield 190mg, 93%.

To a mixture of regioisomers (190mg, 0.7mmol) in chloroform (3mL) was added dropwise over 5mins, 3-chloroperbenzoic acid (156mg, 85% pure, 0.8mmol, 1.1eq) in chloroform (2mL). The reaction mixture was stirred at room temperature for a further 2hr. The reaction mixture was then washed successively with 1M Na₂S₂O₅ (5mL), saturated sodium bicarbonate solution (5mL) and brine (10mL). The organic phase was dried over sodium sulfate, filtered, the solvent removed *in vacuo* and the residue was purified by flash chromatography over silica gel eluting with EtOAc / 40:60 petroleum ether (2:8, v/v). Three products were obtained; compound (62) was eluted first and further elution afforded an inseparable mixture of compound (63) and compound (64). Fractions of the initial component were pooled and reduced *in vacuo* to give 2S-2-*tert*-butoxycarbonylamino-4,4-dimethyl-hex-5-enoic acid methyl ester (62) as a clear oil, yield 93mg, 49%. Electrospray-MS *m/z* 272 (MH⁺). Analytical HPLC Rt = 21.45mins (95%), HRMS C₁₀H₁₇O₄N requires *M*, 215.1158, found: M⁺-C₄H₈ 215.1152 (- 2.8 ppm); IR (cap. film)/cm⁻¹ 3369 (s), 3084 (m), 2965 (s), 1748 (s), 1715 (s), 1517 (s), 1167 (s), 1007 (s), 914 (s)

δ_H (500 MHz; $CDCl_3$) 1.06 (6H, s, $CH_2=CHC(CH_3)_2$), 1.42 (9H, s, $C(CH_3)_3$)
 1.55 (1H, dd, J 14, 9, $CH_2=CHC(CH_3)_2CH_{2A}$), 1.82 (1H, dd, J 14, 3,
 $CH_2=CHC(CH_3)_2CH_{2B}$), 3.69 (3H, s, OCH_3), 4.30 (1H, m, $NHCHCO_2CH_3$),
 4.83 (1H, br d, J 7, NH), 4.97 (2H, m, $CH_2=CH$) and 5.78 (1H, dd, J_{trans} 17.5,
 5 J_{cis} 11, $CH_2=CH$)
 δ_C (125 MHz; $CDCl_3$) 26.93 ($CH_2=CHC(CH_3)_2$), 28.34 ($C(CH_3)_3$), 36.33
 ($CH_2=CHC(CH_3)_2CH_2$), 45.06 ($CH_2=CHC(CH_3)_2$), 51.25 ($NHCHCO_2CH_3$),
 52.15 (OCH_3), 79.77 ($C(CH_3)_3$), 111.39 ($CH_2=CH$), 146.87 ($CH_2=CH$), 154.97
 ($NHCO_2Bu^t$) and 174.04 (CO_2CH_3).

10

(b) 2S-2-*tert*-Butoxycarbonylamino-4,4-dimethyl-hexanoic acid methyl ester
 (65)

Following the general procedure for alkene hydrogenation, compound (62)
 (93mg, 0.3mmol) yielded compound (65) as a colourless oil, yield 90mg, 96%
 15 and used directly in the subsequent reaction. Electrospray-MS m/z 274 (MH^+).
 Analytical HPLC R_t = 22.55mins (100%).

(c) 2S-2-*tert*-Butoxycarbonylamino-4,4-dimethyl-hexanoic acid (66)

Following the general procedure for methyl ester saponification, compound
 20 (65) (90mg, 0.3mmol) gave compound (66) as crystals, yield 79mg, 92% and
 used directly in the subsequent reaction. Electrospray-MS m/z 260 (MH^+).
 Analytical HPLC R_t = 20.90mins (100%).

(d) 2S-2-Amino-4,4-dimethyl-hexanoic acid trifluoroacetic acid salt (67)

25 Following the general procedure of N-Boc removal using TFA, compound (66)
 (79mg, 0.3mmol) gave compound (67) as a solid, yield 80mg, 96% and used
 directly in the subsequent reaction. Electrospray-MS m/z 274 (MH^+).

(e) 2S-2-(9*H*-Fluoren-9-ylmethoxycarbonylamino)-4,4-dimethyl-hexanoic acid
 30 (68)

Following the general procedure for Fmoc protection of an amine, compound
 (67) (80mg, 0.3mmol) gave on purification by flash chromatography over silica
 gel eluting with $CHCl_3$ / CH_3OH (100:0 to 96:4, v/v) 2S-2-(9*H*-fluoren-9-


ylmethoxycarbonylamino)-4,4-dimethyl-hexanoic acid (**68**) as a solid, yield 60mg, 54%. Electrospray-MS m/z 382(MH^+). Analytical HPLC R_t = 23.63mins (100%); $[\alpha]_D^{17}$ -18.4 (c 0.25 in EtOH)

- 5 δ_H (500MHz, $CDCl_3$) 0.88 (3H, t, J 7, CH_3CH_2), 0.95 (6H, s, $CH_3CH_2C(CH_3)_2$), 1.31 (2H, m, CH_3CH_2), 1.46 (1H, dd, J 14.5, 10, $CH_3CH_2C(CH_3)_2CH_2A$), 1.85 (1H, br d, J 14.5, $CH_3CH_2C(CH_3)_2CH_2B$), 4.21 (1H, t, J 6.5, $CH-Fmoc$), 4.41 (3H, m, $NHCHCO_2H$ and CH_2O), 5.02 (1H, br d, J 8, $NH-Fmoc$), 7.29 (2H, m, H-2' and H-7'), 7.38 (2H, m, H-3' and H-6'), 7.58 (2H, m, H-1' and H-8') and
10 7.74 (2H, d, J 7, H-4' and H-5').

Example Synthesis 2

Preparation of 2S,4RS-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4,5-dimethyl-hexanoic acid (**74**)

- 15 Optically pure 2S,4S-2-*tert*-Butoxycarbonylamino-4,5-dimethyl-hex-5-enoic acid methyl ester (**69**) and 2S,4R-2-*tert*-Butoxy-carbonylamino-4,5-dimethyl-hex-5-enoic acid methyl ester (**70**) were obtained directly after zinc coupling reaction by flash chromatography.



- (a) 2S,4S-2-*tert*-Butoxycarbonylamino-4,5-dimethyl-hex-5-enoic acid methyl ester (**69**) and 2S,4R-2-*tert*-butoxy-carbonylamino-4,5-dimethyl-hex-5-enoic acid methyl ester (**70**)

- 25 Following the general procedure for zinc coupling reactions, toluene-4-sulfonic acid (E)-2-methyl-but-2-enyl ester (1.45mL, 1.0mmol) was coupled to compound (**61**) (247mg, 0.75mmol) in the presence of CuBr.SMe_2 (20mg, 0.10mmol) to give a residue which was purified by flash chromatography over
30 silica gel eluting with EtOAc / 40:60 petroleum ether (1:9, v/v) to give two diastereoisomers. Analytical HPLC R_t = 22.49mins (60%) and R_t = 22.52mins

(40%). Fractions of the first eluted component were pooled to give one of the diastereoisomers obtained as a colourless oil, yield 36mg, 18%. Next a mixture of the diastereomers as a colourless oil, yield 75mg, 37% was obtained. Pure fractions containing the later eluted component were pooled to
 5 give the other diastereoisomer as a colourless oil, yield 19mg, 9%. (The stereochemistry at the 4 position was not investigated). Spectral data obtained for the fast running diastereomer: Electrospray-MS m/z 272 (MH^+); $[\alpha]_D^{20} +12.3$ (c 1.06 in $CHCl_3$); IR (cap. film)/ cm^{-1} 3382 (s), 3070 (m), 2966 (s), 1746 (s), 1716 (s), 1616 (w), 1507 (s), 886 (m)

10

δ_H (500 MHz, $CDCl_3$) 1.06 (3H, d, J 7, CH_3CH), 1.45 (9H, s, $C(CH_3)_3$), 1.58 (1H, m, CH_3CH), 1.68 (3H, s, $CH_3C=CH_2$), 1.85 (1H, m, $CH_{2A}CH$), 1.97 (1H, m, $CH_{2B}CH$), 3.73 (3H, s, OCH_3), 4.29 (1H, m, $NHCHCO_2CH_3$), 4.72 (1H, s, $CH_{2A}=CH$), 4.95 (1H, d, J 1.5, $CH_{2B}=CH$) and 5.04 (1H, d, J 7, NH)

15

δ_C (125 MHz, $CDCl_3$) 18.61 ($CH_3C=CH_2$), 21.64 (CH_3CH), 28.32 ($C(CH_3)_3$), 30.79 (CH_3CHCH_2), 38.06 (CH_2CHNH), 52.00 ($NHCHCO_2CH_3$), 52.22 (OCH_3), 79.53 ($C(CH_3)_3$), 110.19 ($CH_2=C(CH_3)$), 144.62 ($CH_2=C(CH_3)$), 155.18 ($OCONH$) and 173.30 (CO_2CH_3).

20 Spectral data obtained for the slow running diastereoisomer: Electrospray-MS m/z 272 (MH^+); $[\alpha]_D^{20} +16.0$ (c 0.60 in $CHCl_3$); IR (cap. film)/ cm^{-1} 3369 (s), 3073 (m), 2969 (s), 1747 (s), 1717 (s), 1617 (w), 1517 (s), 893 (m)

δ_H (500 MHz, $CDCl_3$) 1.04 (3H, d, J 7, CH_3CH), 1.44 (9H, s, $C(CH_3)_3$), 1.55
 25 (1H, m, CH_3CH), 1.67 (3H, s, $CH_3C=CH_2$), 1.91 (1H, m, $CH_{2A}CH$), 2.37 (1H, m, $CH_{2B}CH$), 3.73 (3H, s, OCH_3), 4.26 (1H, m, $NHCHCO_2CH_3$), 4.75 (1H, d, J 1.5, $CH_{2A}=CH$), 4.79 (1H, d, J 1.5, $CH_{2B}=CH$) and 5.46 (1H, d, J 6.1, NH)
 δ_C (125 MHz, $CDCl_3$) 18.51 ($CH_3C=CH_2$), 20.14 (CH_3CH), 28.31 ($C(CH_3)_3$),
 30.55 (CH_3CHCH_2), 37.64 (CH_2CHNH), 52.17 ($NHCHCO_2CH_3$), 52.22
 30 (OCH_3), 79.74 ($C(CH_3)_3$), 111.27 ($CH_2=C(CH_3)$), 147.94 ($CH_2=C(CH_3)$),
 155.36 ($OCONH$) and 173.83 (CO_2CH_3).

These diastereoisomers were not separated routinely and used as a mixture in subsequent reactions.

5 **(b) 2S,4RS-2-*tert*-Butoxycarbonylamino-4,5-dimethyl-hexanoic acid methyl ester (71)**

Following the general procedure for alkene hydrogenation, compounds (69) and compound (70) (130mg, 0.48mmol) yielded a mixture of two diastereoisomers (71) which were not separated, obtained as a colourless oil, yield 128mg, 98%. Analytical HPLC Rt 22.49mins, electrospray-MS m/z 274
10 (MH⁺).

(c) 2S,4RS-2-*tert*-Butoxycarbonylamino-4,5-dimethyl-hexanoic acid (72)

Following the general procedure for methyl ester saponification, compounds (71) (128mg, 0.47mmol) gave an inseparable mixture of compounds (72) as a
15 colourless oil, yield 106mg, 87%. Electrospray-MS m/z 260 (MH⁺). Analytical HPLC Rt = 20.65mins (100%).

(d) 2S,4RS-2-Amino-4,5-dimethyl-hexanoic acid trifluoroacetic acid salt (73)

Following the general procedure of N-Boc removal using TFA, compounds
20 (72) (106mg, 0.41mmol) gave an inseparable mixture of compounds (73) as a solid, yield 107mg, 96% and used directly in the subsequent reaction. Electrospray-MS m/z 160 (MH⁺).


25 **(e) 2S,4RS-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4,5-dimethyl-hexanoic acid (74)**

Following the general procedure for Fmoc protection of an amine, compounds (73) (107mg, 0.39mmol) gave on purification by flash chromatography over silica gel eluting with CHCl₃ / CH₃OH (100:0 to 95:5, v/v) 2S,4RS-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4,5-dimethyl-hexanoic acid (74) as a
30 solid, yield 60mg, 40% as a mixture of two diastereoisomers. Analytical HPLC Rt = 23.83mins (40%) and Rt = 24.06mins (60%). First eluted diastereomer: Electrospray-MS m/z 382 (MH⁺). Later eluted diastereomer: Electrospray-MS m/z 382 (MH⁺).

Example Synthesis 3

Preparation of 2S,5RS-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-5,6-dimethyl-heptanoic acid (80) and 2S-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4,4,5-trimethyl-hexanoic acid (84)

(S)-2-*tert*-butyloxycarbonylamino-5,6-dimethyl-hept-5-enoic methyl ester (**75**) and (S)-2-*tert*-butyloxycarbonylamino-4,4,5-trimethyl-hex-5-enoic methyl ester (**76**) were obtained directly after zinc coupling reaction by flash chromatography.



(a) 2S-2-*tert*-Butyloxycarbonylamino-5,6-dimethyl-hept-5-enoic methyl ester (**75**) and 2S-2-*tert*-butyloxycarbonylamino-4,4,5-trimethyl-hex-5-enoic methyl ester (**76**)

Following the general procedure for zinc coupling reactions, 1-bromo-2,3-dimethylbut-2-ene (163mg, 1.0mmol) was coupled to compound (**61**) (247mg, 0.75mmol) in presence of $\text{CuBr}\cdot\text{SMe}_2$ (20mg, 0.10mmol) to give a residue which on purification by flash chromatography over silica gel eluting with EtOAc/ 40:60 petroleum ether (1:9) gave two regioisomers. The first eluted component compound (**75**) as a colourless oil, yield 60mg, 28% and the second eluted component was compound (**76**) as a colourless oil, yield 51mg, 24%.

Spectral data obtained for compound (**75**); Electrospray-MS m/z 285 (MH^+).

Analytical HPLC R_t = 22.85mins (100%); HRMS $\text{C}_{15}\text{H}_{27}\text{NO}_4$ requires M ,

285.1940, found: M^+ 285.1954 (-4.9 ppm); $[\alpha]_D^{22} +26.1$ (c 1.01 in CH_2Cl_2); elemental analysis $\text{C}_{15}\text{H}_{27}\text{NO}_4$ (req) %C 63.1, %H 9.5, %N 4.9, (fnd) %C 62.4, %H 9.6, %N 5.3; IR (cap. film)/ cm^{-1} 3366 (s), 3154 (m), 2978 (s), 1744 (s), 1718 (s), 1506 (s), 1366 (s), 1164 (s)

5

δ_H (500 MHz, CDCl_3) 1.45 (9H, s, $\text{C}(\text{CH}_3)_3$), 1.62 (9H, m, $(\text{CH}_3)_2=\text{C}(\text{CH}_3)$), 1.87 (1H, m, $\text{CH}_{2A}\text{CH}_2\text{CH}$), 2.03 (1H, m, $\text{CH}_{2B}\text{CH}_2\text{CH}$), 2.09 (1H, dd, J 6, 10.5, $\text{CH}_2\text{CH}_{2A}\text{CH}$), 2.12 (1H, dd, J 6.5, 10.5, $\text{CH}_2\text{CH}_{2B}\text{CH}$), 3.74 (3H, s, OCH_3), 4.29 (1H, m, $\text{NHCHCO}_2\text{CH}_3$) and 5.02 (1H, d, J 7, NH)

10 δ_C (125 MHz, CDCl_3) 18.19 ($(\text{CH}_3)_2\text{C}=\text{C}(\text{CH}_3)$), 20.00 ($(\text{CH}_3)_{2\text{cis}}\text{C}=\text{C}(\text{CH}_3)$), 20.61 ($(\text{CH}_3)_{2\text{trans}}\text{C}=\text{C}(\text{CH}_3)$), 28.33 ($\text{C}(\text{CH}_3)_3$), 30.07 ($\text{CH}_2\text{CH}_2\text{CH}$), 30.92 ($\text{CH}_2\text{CH}_2\text{CH}$), 52.20 ($\text{NHCHCO}_2\text{CH}_3$), 53.47 (OCH_3), 80.00 ($\text{C}(\text{CH}_3)_3$), 95.90 ($(\text{CH}_3)_2\text{C}=\text{C}(\text{CH}_3)$), 96.49 ($(\text{CH}_3)_2\text{C}=\text{C}(\text{CH}_3)$), 155.33 (OCONH) and 173.42 (CO_2CH_3).

15

Spectral data obtained for compound (76); Electrospray-MS m/z 285 (MH^+). Analytical HPLC $R_t = 22.91$ mins (100%); HRMS $\text{C}_{11}\text{H}_{19}\text{NO}_4$ requires M 229.1314, found: $M^+ - \text{C}_4\text{H}_8$ 229.1309 (-2.2 ppm); $[\alpha]_D^{23} +4.8$ (c 1.01 in CH_2Cl_2); elemental analysis $\text{C}_{15}\text{H}_{27}\text{NO}_4$ (req) %C 63.1, %H 9.5, %N 4.9, (fnd) %C 62.5, %H 9.5, %N; IR (cap. film)/ cm^{-1} 3368 (s), 3091 (m), 2934 (s), 1748 (s), 1717 (s), 1516 (s)

20

δ_H (500 MHz, CDCl_3) 1.10 (3H, s, $(\text{CH}_3)_{2A}\text{C}$), 1.12 (3H, s, $(\text{CH}_3)_{2B}\text{C}$), 1.43 (9H, s, $\text{C}(\text{CH}_3)_3$), 1.60 (1H, m, CH_{2A}CH), 1.74 (3H, s, $\text{CH}_3\text{C}=\text{CH}_2$), 1.92 (1H, dd, J 14.5, 4, CH_{2B}CH), 3.70 (3H, s, OCH_3), 4.24 (1H, m, $\text{NHCHCO}_2\text{CH}_3$), 4.79 (1H, s, $\text{CH}_{2A}=\text{C}(\text{CH}_3)$), 4.82 (1H, s, $\text{CH}_{2B}=\text{C}(\text{CH}_3)$) and 4.83 (1H, br d, J 11, NH)

25

δ_C (125 MHz, CDCl_3) 19.38 (CH_3), 27.19 (CH_3), 27.61 (CH_3), 28.34 ($\text{C}(\text{CH}_3)_3$), 38.50 (CH_2CH), 38.95 ($(\text{CH}_3)_2\text{C}$), 51.34 ($\text{NHCHCO}_2\text{CH}_3$), 52.13 (OCH_3), 79.71 ($\text{C}(\text{CH}_3)_3$), 110.95 ($\text{CH}_2=\text{C}(\text{CH}_3)$), 150.62 ($\text{CH}_2=\text{C}(\text{CH}_3)$), 155.00 (OCONH) and 174.24 (CO_2CH_3).

30

(b) 2S,5RS-2-*tert*-Butoxycarbonylamino-5,6-dimethyl-heptanoic acid methyl ester (77)

Following the general procedure for alkene hydrogenation, 2S-2-*tert*-butyloxycarbonylamino-5,6-dimethyl-hept-5-enoic methyl ester (**75**) (60mg, 0.21mmol) yielded compound (**77**) as a colourless oil, yield 54mg, 89%. Electrospray-MS m/z 288 (MH^+). Analytical HPLC R_t = 24.06mins (100%).

5

(c) 2S,5RS-2-*tert*-Butoxycarbonylamino-5,6-dimethyl-heptanoic acid (**78**)

Following the general procedure for methyl ester saponification, compounds (**77**) (54mg, 0.19mmol) gave compounds (**78**) as a colourless oil, yield 54mg, 100%. Electrospray-MS m/z 274 (MH^+). Analytical HPLC R_t = 21.44mins

10 (100%).

(d) 2S,5RS-2-Amino-5,6-dimethyl-heptanoic acid hydrochloride salt (**79**)

Following the general procedure of N-Boc removal using 4M HCl in dioxane, compounds (**78**) (54mg, 0.20mmol) gave compounds (**79**) as a solid, yield 40mg, 97%. Electrospray-MS m/z 174 (MH^+).

15

(e) 2S,5RS-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-5,6-dimethyl-heptanoic acid (**80**)

Following the general procedure for Fmoc protection of an amine, compounds (**79**) (40mg, 0.19mmol) gave on purification by flash chromatography over silica gel eluting with $CHCl_3$ / CH_3OH (100:0 to 95:5, v/v) 2S,5RS-2-(9H-fluoren-9-ylmethoxycarbonylamino)-5,6-dimethyl-heptanoic acid (**80**) as a solid, yield 27mg, 36%. Electrospray-MS m/z 395 (MH^+). Analytical HPLC R_t = 24.52mins (100%), HRMS $C_{24}H_{29}O_4NNa$ requires M 418.1994, found: MNa^+ , 418.1993. (-0.38 ppm)

25

δ_H (500 MHz; $CDCl_3$) 0.73 (6H, m, $(CH_3)_2CH$), 0.82 (3H, d, J 6.5, $(CH_3)_2CHCH(CH_3)$), 1.23 (1H, m, $(CH_3)_2CHCH(CH_3)CH_{2A}$), 1.39 (1H, m, $(CH_3)_2CHCH(CH_3)CH_{2B}$), 1.55 (2H, m, $(CH_3)_2CHCH(CH_3)$ and $(CH_3)_2CHCH(CH_3)CH_{2A}$), 1.63 (1H, m, $(CH_3)_2CHCH(CH_3)$), 1.90 (1H, m, $(CH_3)_2CHCH(CH_3)CH_{2B}$), 4.18 (1H, t, J 6.5, $CH-Fmoc$), 4.40 (3H, m, $NHCHCO_2H$ and CH_2O), 5.30 (1H, br d, J 8, $NH-Fmoc$), 7.27 (2H, m, H-2' and

30

H-7'), 7.37 (2H, m, H-3' and H-6'), 7.56(2H, m, H-1' and H-8') and 7.75 (2H, d, *J* 7, H-4' and H-5')

δ_C (125 MHz; CDCl₃) 14.91 (CH₃)₂CHCH(CH₃), 17.49 and 17.73

- 5 ((CH₃)₂CH), 19.93 and 20.05 ((CH₃)₂CH), 28.08 ((CH₃)₂CH), 29.26 and 29.44 ((CH₃)₂CHCH(CH₃)CH₂CH₂), 30.04 and 30.17 ((CH₃)₂CHCH(CH₃)CH₂CH₂), 31.38 and 31.68 ((CH₃)₂CHCH(CH₃), 37.89 and 38.07 (NHCHCO₂H), 46.88 (CH-1'), 66.84 (CH₂O), 119.72 (CH-5' and CH-10'), 124.80 (CH-4' and CH-11'), 126.81 (CH-6' and CH-9'), 127.46 (CH-3' and CH-12'), 141.05 (C-7' and C-8'), 143.47 (C-2' and C-13') and 155.89 (OCONH). The quaternary signal for the carboxylic acid was not observed.
- 10

(f) 2S-2-*tert*-Butoxycarbonylamino-4,4,5-trimethyl-hexanoic acid methyl ester **(81)**

- 15 Following the general procedure for alkene hydrogenation, 2S-2-*tert*-butoxycarbonylamino-4,4,5-trimethyl-hex-5-enoic methyl ester **(76)** (51mg, 0.18mmol) yielded compound **(81)** as a colourless oil, yield 46mg, 90%. Electrospray-MS *m/z* 288 (MH⁺). Analytical HPLC *Rt* = 22.91mins (100%).

20 (g) 2S-2-*tert*-Butoxycarbonylamino-4,4,5-trimethyl-hexanoic acid **(82)**

Following the general procedure for methyl ester saponification, compound **(81)** (46mg, 0.16mmol) gave compound **(82)** as a colourless oil, yield 44mg, 100%. Electrospray-MS *m/z* 274 (MH⁺).

25 (h) 2S-2-Amino-4,4,5-trimethyl-hexanoic acid hydrochloride salt **(83)**

Following the general procedure of N-Boc removal using 4M HCl in dioxane, compound **(82)** (44mg, 0.16mmol) gave compound **(83)** as a solid, yield 33mg, 99%. Electrospray-MS *m/z* 174 (MH⁺).

30 (i) 2S-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4,4,5-trimethyl-hexanoic acid **(84)**

Following the general procedure for Fmoc protection of an amine, compound **(83)** (33mg, 0.16mmol) gave on purification by flash chromatography over silica gel eluting with CHCl₃ / CH₃OH (100:0 to 95:5, v/v) 2S-2-(9H-fluoren-9-

ylmethoxycarbonylamino)-4,4,5-trimethyl-hexanoic acid (**84**) as a solid, yield 20mg, 32%. Electrospray-MS m/z 396 (MH^+). Analytical HPLC R_t = 24.28mins (100%), HRMS $C_{24}H_{29}O_4NNa$ requires M 418.1994, found: MNa^+ , 418.1993. (δ – 0.38 ppm)

5

δ_H (500 MHz; $CDCl_3$) 0.93 (9H, m, $(CH_3)_2CHC(CH_3)_2A$), 0.98 (3H, s, $(CH_3)_2CHC(CH_3)_2B$), 1.48 (1H, dd, J 14, 10, $(CH_3)_2CHC(CH_3)_2CH_2A$), 1.57 (1H, m, $(CH_3)_2CH$), 1.91 (1H, d, J 14, $(CH_3)_2CHC(CH_3)_2CH_2B$), 4.21 (1H, t, J 6.5, CH -Fmoc), 4.40 (3H, m, $NHCHCO_2H$ and CH_2O), 5.10 (1H, br d, J 7.5, NH -Fmoc), 7.27 (2H, m, H-2' and H-7'), 7.36 (2H, m, H-3' and H-6'), 7.57 (2H, m, H-1' and H-8') and 7.74 (2H, d, J 7, H-4' and H-5')

δ_C (125 MHz; $CDCl_3$) 17.01 ($(CH_3)_2ACH$), 17.16 ($(CH_3)_2BCH$), 23.69 ($(CH_3)_2CHC(CH_3)_2A$), 24.27 ($(CH_3)_2CHC(CH_3)_2B$), 35.27 ($(CH_3)_2CHC(CH_3)_2$), 35.73 ($(CH_3)_2CH$), 41.88 ($(CH_3)_2CHC(CH_3)_2CH_2$), 46.93 (CH-1'), 54.20 ($NHCHCO_2H$), 66.79 (CH_2O), 119.70 (CH-5' and CH-10'), 124.78 (CH-4' and CH-11'), 126.79 (CH-6' and CH-9'), 127.44 (CH-3' and CH-12'), 141.05 (C-7' and C-8'), 143.61 (C-2' and C-13') and 155.68 (OCONH). The quaternary signal for the carboxylic acid was not observed.

20 General Solid Phase procedures

Molecules were assembled using the furanone and pyranone building blocks and novel protected aminoacids described earlier, by solid phase procedures on Chiron multipins following the protocols detailed below.

25

Preparation of Building Block-Linker Constructs

General method for the synthesis of dihydro-3(2H)-furanone or pyranone – Linker Constructs - See Scheme 5 above

30

Dihydro-3(2H)-furanone (**18**, **24-28**), (1.0eq) was dissolved in a mixture of ethanol / water (7:1 v/v, 10mL per mmole compound) containing sodium acetate trihydrate (1.5eq). 4-[[[(hydrazinocarbonyl)amino]methyl]-

cyclohexanecarboxylic acid trifluoro acetate (mw 329.3, 1.0eq) (see Murphy, A. M., *et al*, *J. Am. Chem. Soc.*, **114**, 3156-3157, 1992) was added and the mixture heated under reflux for 2hrs. The mixture was then cooled, poured into dichloromethane (100mL per mmole compound) and water (100mL) added. The organic layer was separated, backwashed with saturated brine (100mL). The organic layer was dried (Na_2SO_4), filtered and evaporated *in vacuo* to yield a white solid. Yield 85 – 105% crude weight. Constructs (29-34) were used without further purification

10 Preparation of Crown Assembly

The compounds were synthesised in parallel fashion using the appropriately loaded Fmoc-Building block-linker-DA/MDA derivatised macrocrowns (see above) loaded at approximately 3.5 – 9.1 μmoles per crown. Prior to synthesis each crown was connected to its respective stem and slotted into the 8 x 12 stem holder. Coupling of the amino acids employed standard Fmoc amino acid chemistry as described in 'Solid Phase Peptide Synthesis', E. Atherton and R.C. Sheppard, IRL Press Ltd, Oxford, UK, 1989.

Removal of N α -Fmoc Protection

20 A 250 mL solvent resistant bath is charged with 200 mL of a 20% piperidine/DMF solution. The multipin assembly is added and deprotection allowed to proceed for 30 minutes. The assembly is then removed and excess solvent removed by brief shaking. The assembly is then washed consecutively with (200 mL each), DMF (5 minutes) and MeOH (5 minutes, 2 minutes, 2 minutes) and left to air dry for 15 minutes.

Quantitative UV Measurement of Fmoc Chromophore Release

A 1cm path length UV cell is charged with 1.2 mL of a 20% piperidine/DMF solution and used to zero the absorbance of the UV spectrometer at a wavelength of 290nm. A UV standard is then prepared consisting of 5.0 mg Fmoc-Asp(OBut)-Pepsyn KA (0.08 mmol/g) in 3.2 mL of a 20% piperidine/DMF solution. This standard gives $\text{Abs}_{290} = 0.55\text{--}0.65$ (at room temperature). An aliquot of the multipin deprotection solution is then diluted as appropriate to give a theoretical $\text{Abs}_{290} = 0.6$, and this value compared with

the actual experimentally measured absorbance showing the efficiency of previous coupling reaction.

Standard Coupling Of Amino Acid Residues

- 5 Coupling reactions are performed by charging the appropriate wells of a polypropylene 96 well plate with the pattern of activated solutions required during a particular round of coupling. MacroCrown standard couplings were performed in DMF (500 μ l).

10 Coupling of an Amino-acid Residue To Appropriate Well

- Whilst the multipin assembly is drying, the appropriate N_α -Fmoc amino acid pfp esters (10 equivalents calculated from the loading of each crown) and HOBt (10 equivalents) required for the particular round of coupling are accurately weighed into suitable containers. Alternatively, the appropriate N_α -
15 Fmoc amino acids (10 equivalents calculated from the loading of each crown), desired coupling agent e.g. HBTU (9.9 equivalents calculated from the loading of each crown) and activation e.g. HOBt (9.9 equivalents calculated from the loading of each crown), NMM (19.9 equivalents calculated from the loading of each crown) are accurately weighed into suitable containers.
20 The protected and activated Fmoc amino acid derivatives are then dissolved in DMF (500 μ l for each macroCrown e.g. for 20 macroCrowns, 20 x 10 eq. x 7 μ moles of derivative would be dissolved in 10 mL DMF). The appropriate derivatives are then dispensed to the appropriate wells ready for commencement of the 'coupling cycle'. As a standard, coupling reactions are
25 allowed to proceed for 6 hours. The coupled assembly was then washed as detailed below.

Washing Following Coupling

- If a 20% piperidine/DMF deprotection is to immediately follow the coupling
30 cycle, then the multipin assembly is briefly shaken to remove excess solvent washed consecutively with (200 mL each), MeOH (5 minutes) and DMF (5 minutes) and de-protected. If the multipin assembly is to be stored or reacted further, then a full washing cycle consisting brief shaking then consecutive

washes with (200 mL each), DMF (5 minutes) and MeOH (5 minutes, 2 minutes, 2 minutes) is performed.

Addition of Capping Group

- 5 Whilst the multipin assembly is drying, the appropriate acid capping group (10 equivalents calculated from the loading of each crown), desired coupling agent e.g. HBTU (9.9 equivalents calculated from the loading of each crown) and activation e.g. HOBt (9.9 equivalents calculated from the loading of each crown), NMM (19.9 equivalents calculated from the loading of each crown)
- 10 are accurately weighed into suitable containers. The acid derivatives / coupling agents are then dissolved in DMF (500 µl for each macrocrown e.g. for 20 macrocrowns, 20 x 10 eq. of derivative would be dissolved in 10 mL DMF) and left to activate for 5 minutes. The appropriate derivatives are then dispensed to the appropriate wells ready for commencement of the 'capping
- 15 cycle'. As a standard, capping reactions are allowed to proceed for 18 hours overnight. The capped assembly was then washed as detailed above.

Acidolytic Mediated Cleavage of Molecule-Pin Assembly

- Acid mediated cleavage protocols are strictly performed in a fume hood. A
- 20 polystyrene 96 well plate (1 mL/well) is labelled and weighed to the nearest mg. Appropriate wells are then charged with a trifluoroacetic acid/water (95:5, v/v, 600 µl) cleavage solution, in a pattern corresponding to that of the multipin assembly to be cleaved.
- The multipin assembly is added, the entire construct covered in tin foil and left
- 25 for 2 hours. The multipin assembly is then added to another polystyrene 96 well plate (1 mL/well) containing trifluoroacetic acid/water (95:5, v/v, 600 µl) (as above) for 5 minutes.

Work up of Cleaved Molecules

- 30 The primary polystyrene cleavage plate (2 hour cleavage) and the secondary polystyrene plate (5 minute wash) are then placed in the GeneVac evaporator and the solvents removed (minimum drying rate) for 90 minutes. The contents of the secondary polystyrene plate are transferred to their corresponding wells on the primary plate using an acetonitrile/water (50: 50 v/v/v) solution (3 x 150

μl) and the spent secondary plate discarded. Aliquots (5-20 L) are taken for analysis. The plate was covered in tin foil, pin-pricked over wells containing compounds, placed into the freezer for 1hr, then lyophilised.

5 Analysis and Purification of Molecules

The (5-20 L) aliquots are analysed by analytical HPLC and electrospray-MS. In virtually all cases, crude purities are >90% by HPLC with the desired m/z. Sample were purified by semi-preparative reverse phase HPLC, using Vydac C₄. Appropriate fractions are combined and lyophilised in tared 10mL glass
10 vials, then re-weighed. Molecules were prepared on a 15-90μmole scale, yielding 2.0-26.0mg of purified products. The purity of each product was confirmed by analytical HPLC at >95% (215nm UV detection) and gave the appropriate [MH]⁺ by electrospray mass spectrometry analysis.

15 Loading of Macrocrowns With Constructs

General method for the loading of multipins with Dihydro-3(2H)-Furanone – Linker Constructs (29-34)

Amino functionalised DA/MDA macrocrowns (ex Chiron Mimotopes, Australia, 9.1μmole loading) or amino functionalised HEMA gears (ex Chiron Mimotopes,
20 Australia, 1.3μmole loading) were used for all loadings and subsequent solid phase syntheses.

Dihydro-3(2H)-Furanone – Linker Construct (29-34) (3eq compared to total surface functionalisation of crowns / gears) was carboxyl activated with 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (3eq), 1-
25 hydroxybenzotriazole (3eq) and N-methylmorpholine (6eq) in dimethylformamide (5mL) for 5mins. This mixture was added to the crowns / gears, additional DMF added to cover the reaction surface and the mixture left overnight.

30 Standard washing and Fmoc deprotection readings (see procedures above) indicated virtually quantitative loading.

Exemplar molecules prepared by the methods using the respective furanone, R3 amino acid and capping group in the method detailed above are shown in
35 Table 1:


Electrospray-MS m/z (MH ⁺)	NAME
385	Benzofuran-2-carboxylic acid [1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)- cyclohexyl]-amide
383	Benzofuran-2-carboxylic acid [1-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-cyclohexyl]-amide
371	Benzofuran-2-carboxylic acid [2-cyclopropyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-ethyl]- amide
398	<i>N</i> -[3-Methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]- 4-pyrrol-1-yl-benzamide
383	Naphthalene-1-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)- butyl]-amide
373	Benzofuran-2-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide
389	Benzo[<i>b</i>]thiophene-2-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide
403	5-Methoxy-benzofuran-2-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide
401	5-Methoxy-benzofuran-2-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-but-3S-enyl]- amide
390	4-Acetylamino- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S- ylcarbamoyl)-butyl]-benzamide
448	4-Hydroxy- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S- ylcarbamoyl)-butyl]-3-morpholin-4-ylmethyl-benzamide
446	4-Hydroxy- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S- ylcarbamoyl)-but-3-enyl]-3-morpholin-4-ylmethyl-benzamide
409	Biphenyl-4-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)- butyl]-amide
389	4- <i>tert</i> -Butyl- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan- 3S-ylcarbamoyl)-butyl]-benzamide
387	4- <i>tert</i> -Butyl- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S- ylcarbamoyl)-but-3-enyl]-benzamide
390	4-Guanidino- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro- furan-3S-ylcarbamoyl)-butyl]-benzamide
388	4-Guanidino- <i>N</i> -[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S- ylcarbamoyl)-but-3-enyl]-benzamide

- 502 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide
- 500 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid [3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-but-3-enyl]-amide

Additional compounds of the invention were prepared as follows:

5

- i) Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-4-pyrrolidin-1-yl-benzamide



Following the procedure of Example 1 step d) except substituting "4-pyrrolidin-1-yl-benzoic acid" for the model carboxylic acid. These acids were prepared by employing two reactions: the initial esters were prepared using Buchwald type chemistry and subsequent standard hydrolysis of the esters provided the required acids.

a. 4-Pyrrolidin-1-yl-benzoic acid methyl ester

An oven-dried reaction tube was charged with cesium carbonate (2.12g, 6.51mmol) that had been finely ground with a pestle and mortar under an atmosphere of argon. Tris(dibenzylideneacetone)dipalladium(0) (42.5mg, 1.5mol%) and (S)-(-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (43.4mg, 1.5mol%) were added and the tube charged with argon. Pyrrolidine (0.39g, 5.58mmol), methyl-4-bromobenzoate (1.00g, 4.65mmol) and toluene (10ml) were added and the mixture heated to 100°C with vigorous stirring until the starting material had been consumed as judged by hplc. The mixture was cooled to room temperature, diluted with ether (20ml), filtered and concentrated. Purification by column chromatography gave the title compound (0.80g, 84%) as a solid. MS (M+H⁺): 206.

b. 4-Pyrrolidin-1-yl-benzoic acid salt


4-Pyrrolidin-1-yl-benzoic acid methyl ester (200mg, 0.98mmol) was dissolved in methanol (4ml) and sodium hydroxide (39mg, 0.98mmol) in water (2ml) was added. The mixture was heated to 60°C until the starting material had been

consumed as judged by hplc. The mixture was cooled to room temperature, diluted with water (20ml), filtered and freeze dried to give the title compound (0.200g, 97%) as a solid. MS (M+H⁺): 192.

An alternative procedure is described below:

- 5 4-Pyrrolidin-1-yl-benzoic acid methyl ester (200mg, 0.98mmol) was dissolved in concentrated hydrochloric acid: water (1:1) (4ml). The mixture was heated at reflux until the starting material had been consumed as judged by hplc. The mixture was cooled to room temperature, diluted with water (10ml), filtered and freeze dried to give the title compound (0.190g, 97%) as a solid. MS (M+H⁺): 192.

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-4-piperidin-1-yl-benzamide



- Following the procedure of Example 1 step d) except substituting "4-piperidin-1-yl-benzoic acid"


4-Piperidin-1-yl-benzoic acid methyl ester

Following the procedure above except substituting "piperidine" for "pyrrolidine" gave the title compound: MS (M+H⁺): 220.

- 20 a. 4-Piperidin-1-yl-benzoic acid salt

Following the procedure above except substituting "4-piperidin-1-yl-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 206.

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-4-morpholin-4-yl-benzamide



Following the procedure of Example 1 step d) except substituting "4-morpholin-4-yl-benzoic acid"


4-Morpholin-4-yl-benzoic acid methyl ester

- 5 Following the procedure above except substituting "morpholine" for "pyrrolidine" gave the title compound: MS (M+H⁺): 222.

a. 4-Morpholin-4-yl-benzoic acid salt

- Following the procedure above except substituting "4-morpholin-4-yl-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the
10 title compound: MS (M+H⁺): 208.

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-4-(4-methyl-piperazin-1-yl)-benzamide



- Following the procedure of Example 1 step d) except substituting "4-methyl-
15 piperazin-1-yl-benzoic acid" for

4-Methyl-piperazin-1-yl-benzoic acid methyl ester


- Following the procedure above except substituting "4-methyl-piperazine" for "pyrrolidine" gave the title compound: MS (M+H⁺): 235.

20

a. 4-Methyl-piperazin-1-yl-benzoic acid salt

Following the procedure above except substituting "4-methyl-piperazin-1-yl-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 221.

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-4-(2-morpholin-4-yl-ethylamino)-benzamide



- 5 Following the procedure of Example 1 step d) except substituting "4-(2-morpholin-4-yl-ethylamino)-benzoic acid"


a. 4-(2-Morpholin-4-yl-ethylamino)-benzoic acid methyl ester

- Following the procedure above except substituting "2-morpholin-4-yl-ethylamine" for "pyrrolidine" gave the title compound: MS (M+H⁺): 265.

b. 4-(2-Morpholin-4-yl-ethylamino)-benzoic acid salt

Following the procedure above except substituting "4-(2-Morpholin-4-yl-ethylamino)-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 251.

- 15 Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-4-piperazin-1-yl-benzamide



Following the procedure of Example 1 step d) except substituting "4-(4-carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester".


- 20 a. 4-(4-Methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester

Following the procedure above except substituting "piperazine-1-carboxylic acid tert-butyl ester" for "pyrrolidine" gave the title compound: MS (M+H⁺): 321.

b. 4-(4-Carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester salt

Following the procedure above except substituting "4-(4-methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 307.

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-3-pyrrolidin-1-yl-benzamide



Following the procedure of Example 1 step d) except substituting "3-pyrrolidin-1-yl-benzoic acid" for "2-benzofuran-carboxylic acid."


a. 3-Pyrrolidin-1-yl-benzoic acid methyl ester

Following the procedure above except substituting "methyl-3-bromobenzoate" for "methyl-4-bromobenzoate" gave the title compound: MS (M+H⁺): 206.

b. 3-Pyrrolidin-1-yl-benzoic acid salt

Following the procedure above except substituting "3-pyrrolidin-1-yl-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 192.

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-3-piperidin-1-yl-benzamide



Following the procedure of Example 1 step d) except substituting "3-piperidin-1-yl-benzoic acid" for "2-benzofuran-carboxylic acid."

a. 3-Piperidin-1-yl-benzoic acid methyl ester


Following the procedure above except substituting "piperidine" for "pyrrolidine" and "methyl-3-bromobenzoate" for "methyl-4-bromobenzoate" gave the title compound: MS (M+H⁺): 220.

b. 3-Piperidin-1-yl-benzoic acid salt

Following the procedure above except substituting "3-piperidin-1-yl-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 206.

5

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-3-morpholin-4-yl-benzamide



Following the procedure of Example 1 step d) except substituting "3-morpholin-4-yl-benzoic acid".

10

a. 3-Morpholin-4-yl-benzoic acid methyl ester

Following the procedure above except substituting "morpholine" for "pyrrolidine" and "methyl-3-bromobenzoate" for "methyl-4-bromobenzoate" gave the title compound: MS (M+H⁺): 222.


15

b. 3-Morpholin-4-yl-benzoic acid salt

Following the procedure above except substituting "3-morpholin-4-yl-benzoic acid methyl ester" for "3-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 208.

20

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-3-(4-methyl-piperazin-1-yl)-benzamide



Following the procedure of Example 1 step d) except substituting "3-methyl-piperazin-1-yl-benzoic acid" for "2-benzofuran-carboxylic acid."


a. 3-Methyl-piperazin-1-yl-benzoic acid methyl ester

- 5 Following the procedure above except substituting "4-methyl-piperazine" for "pyrrolidine" and "methyl-3-bromobenzoate" for "methyl-4-bromobenzoate" gave the title compound: MS (M+H⁺): 235.

b. 3-Methyl-piperazin-1-yl-benzoic acid salt

- Following the procedure above except substituting "3-methyl-piperazin-1-yl-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 221.
- 10

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-3-(2-morpholin-4-yl-ethylamino)-benzamide



Following the procedure of Example 1 step d) except substituting "3-(2-morpholin-4-yl-ethylamino)-benzoic acid" for "2-benzofuran-carboxylic acid."


a. 3-(2-Morpholin-4-yl-ethylamino)-benzoic acid methyl ester

- 20 Following the procedure above except substituting "2-morpholin-4-yl-ethylamine" for "pyrrolidine" and "methyl-3-bromobenzoate" for "methyl-4-bromobenzoate" gave the title compound: MS (M+H⁺): 265.

b. 3-(2-Morpholino-4-yl-ethylamino)-benzoic acid salt

- Following the procedure above except substituting "3-(2-Morpholin-4-yl-ethylamino)-benzoic acid methyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 251.
- 25

Preparation of N-[3-Methyl-1-(2-methyl-4-oxo-tetrahydro-furan-3-ylcarbamoyl)-butyl]-3-piperazin-1-yl-benzamide



Following the procedure of Example 1 step d) except substituting "4-(3-carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester"

b. 3-(4-Methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
Following the procedure above except substituting "piperazine-1-carboxylic acid tert-butyl ester" for "pyrrolidine" and "methyl-3-bromobenzoate" for "methyl-4-bromobenzoate" gave the title compound: MS (M+H⁺): 321.

b. 4-(4-Carboxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester salt
Following the procedure above except substituting "4-(4-methoxycarbonyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester" for "4-pyrrolidin-1-yl-benzoic acid methyl ester" gave the title compound: MS (M+H⁺): 307.

15

Biological Examples

Determination of cathepsin K proteolytic catalytic activity

20

Convenient assays for cathepsin K are carried out using human recombinant enzyme. Standard assay conditions for the determination of kinetic constants used a fluorogenic peptide substrate, typically H-D-Ala-Leu-Lys-AMC, and were determined in either 100 mM Mes/Tris, pH 7.0 containing 1 mM EDTA and 10 mM 2-mercaptoethanol or 100 mM Na acetate, pH 5.5 containing 5 mM EDTA and 20 mM cysteine. The enzyme concentration used was 5 nM. The stock substrate solution was prepared at 10 mM in DMSO. Screens were carried out at a fixed substrate concentration of 60 μ M and detailed kinetic studies with doubling dilutions of substrate from 250 μ M. The total DMSO concentration in the assay was kept below 3%. All assays were conducted at

30

ambient temperature. Product fluorescence (excitation at 390 nm, emission at 460 nm) was monitored with a Labsystems Fluoroskan Ascent fluorescent plate reader. Product progress curves were generated over 15 minutes following generation of AMC product.

5

Inhibition Studies

Potential inhibitors are screened using the above assay with variable concentrations of test compound. Reactions were initiated by addition of
10 enzyme to buffered solutions of substrate and inhibitor. K_i values were calculated according to equation 1

$$v_0 = \frac{VS}{K_M \left(1 + \frac{I}{K_i} \right) + S} \quad (1)$$

where v_0 is the velocity of the reaction, V is the maximal velocity, S is the concentration of substrate with Michaelis constant of K_M , and I is the concentration of inhibitor.

15

In this assay the compounds depicted in Table I have a K_i values at pH 7 in the range 10 nM to 250nM and are thus have utility in the treatment or prophylaxis of disorders in which cathepsin K is implicated, such as osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's
20 disease, hypercalcaemia of malignancy, metabolic bone disease, osteoarthritis, rheumatoid arthritis, and metastatic neoplasias.

Cloning and expression of falcipain II

25 Generation of Falcipain 2

Cloning

The deoxyoligonucleotide primers:

(SEQ ID NO.: 1)

30 5'CGCGGATCCGCCACCATGGAATTAAACAGATTTGCCGAT-3' and

(SEQ ID NO.: 2)

5'CGCGTCTGACTTAATGATGATGATGATGTTCAATTAATGGAATGAAT
GCATCAGT-3' were designed based on sequences deposited at the Sanger
Centre, Cambridge, UK

- 5 (http://www.sanger.ac.uk/Projects/P_falciparum/blast_server.shtml). These
primers were designed to amplify a portion of the cDNA sequence of the
cysteiny proteinase now known as Falcipain 2 and to include relevant
terminal cloning enzymes sites and a carboxy-terminal hexahistidine coding
sequence immediately upstream of the stop codon.

10

- Polymerase chain reaction was performed with the above primers and
Plasmodium falciparum phage library DNA as a template using the following
conditions; 94°C for 2 minutes then 35 cycles of 94°C for 10 seconds, 50°C
for 1 minute, and 60°C for 2 minutes, this was followed by a 60°C 5 minute
15 incubation. The 880bp PCR amplicon was purified and phosphorylated using
T4 polynucleotide kinase. This DNA was then ligated into EcoRV cleaved,
dephosphorylated Bluescript II cloning vector and transformed into DH5 alpha
E.coli. The DNA sequence of the plasmid inserts in isolated recombinant
E.coli clones were determined using an Amersham Megabace sequencing
20 instrument. To create an authentic ORF a three-way ligation was conducted
bringing together the N-terminus of truncated falcipain-2 (NcoI/NdeI), the C-
terminus of falcipain-2 (NdeI/BamHI) and the vector pQE-60 (NcoI/BamHI).

Nucleotide Sequence of TF2.10 (SEQ ID NO.: 3):

25

- CCATGGAATTAAACAGATTTGCCGATTAACTTATCATGAATTTAAAAACA
AATATCTTAGTTTAAGATCTTCAAACCATTAAAGAATTCTAAATATTTATT
AGATCAAATGAATTATGAAGAAGTTATAAAAAAATATAGAGGAGAAGAAA
ATTTCGATCATGCAGCTTACGACTGGAGATTACACAGTGGTGTAACACCT
30 GTAAAGGATCAAAAAAATTGTGGATCTTGCTGGGCCTTTAGTAGTATAGG
TTCCGTAGAATCACAATATGCTATCAGAAAAAATAAATTAATAACCTTAAG
TGAACAAGAATTAGTAGATTGTTCAATTTAAAAATTATGGTTGTAATGGAGG
TCTCATTAATAATGCCTTTGAGGATATGATTGAACTTGGAGGTATATGTCC

AGATGGTGATTATCCATATGTGAGTGATGCTCCAAATTTATGTAACATAG
ATAGATGTACTGAAAAATATGGAATCAAAAATTATTTATCCGTACCAGATA
ATAAATTAAGAAGCACTTAGATTCTTGGGACCTATTAGTATTAGTGTAG
CCGTATCAGATGATTTTGCTTTTACAAAGAAGGTATTTTCGATGGAGAAT
5 GTGGTGATGAATTAAATCATGCCGTTATGCTTGTAGGTTTTGGTATGAAA
GAAATTGTTAATCCATTAACCAAGAAAGGAGAAAAACATTATTATTATATA
ATTAAGAACTCATGGGGACAACAATGGGGAGAAAGAGGTTTCATAAATAT
TGAAACAGATGAATCAGGATTAATGAGAAAATGTGGATTAGGTACTGATG
CATTCATTCCATTAATTGAACATCATCATCATCATTAAGTCGACGCGA
10 TCGAATTCCTGCAGCCCGGGGATCC

Coding for the Protein Sequence (SEQ ID NO.: 4):

MELNRFADLTYHEFKNKYLSLRSSKPLKNSKYLLDQMNYEEVIKKYRGEENF
15 DHAAYDWRLHSGVTPVKDQKNCGSCWAFSSIGSVESQYAIRKNKLITLSEQ
ELVDCSFKNYGCNGLINNAFEDMIELGGICPDGDYPYVSDAPNLCNIDRCT
EKYGIKNYLSVPDNKLKEALRFLGPISISVAVSDDFAFYKEGIFDGECGDELN
HAVMLVGFGMKEIVNPLTKKGEKHYIIKNSWGQQWGERGFINIETDESL
MRKCGLGTDAFIPLIEHHHHHH.

20

The TF2.10 insert was excised from the pQE-60 vector using the restriction enzymes NcoI and BamHI, ligated into NcoI/BamHI cut expression vector pET-11D and transformed into DH5 alpha *E.coli*. The presence of a recombinant expression plasmid (pET-TF2.10) in an isolated *E.coli* colony
25 was confirmed by restriction enzyme digest of plasmid DNA. BL21(DE3) *E.coli* were transformed with pET-TF2.10 and used for expression of the recombinant cysteinyl proteinase.

Protein Expression

30 pET-TF2.10-Transformed BL21(DE3) *E.coli* (BLTF2.10) were grown up overnight at 200 rpm, 37°C in Luria broth containing 100 µg/ml ampicillin. Fresh medium was then inoculated and grown to an OD_{600nm} of 0.8 before protein expression was induced using 1 mM IPTG. Induction was performed

for 3 hours at 200 rpm, 37°C then the bacterial cells harvested by centrifugation and stored at -80°C until protein purification performed.

Protein Purification and Refolding

- 5 An *E.coli* cell pellet equivalent to 250ml culture was lysed by resuspension in solubilisation buffer (6M guanidine hydrochloride, 20mM Tris-HCl, 250mM NaCl, 20mM imidazole, pH8.0) for 30 minutes at room temperature. After centrifugation at 12000g for 10 minutes at 4°C the cleared lysate was applied to 1 ml nickel-NTA agarose, and agitated for 1 hour at room temperature.

10

Protein Refolding Method 1

- The protein bound to nickel-NTA was batch washed with 6M guanidine hydrochloride, 20mM Tris-HCl, pH 8.0, 250mM NaCl then 8M urea, Tris-HCl, pH 8.0, 500mM NaCl then 8M urea, Tris-HCl, pH 8.0 including 30 mM
15 imidazole and protein elution performed using 8M urea, Tris-HCl, pH 8.0 with 1 M imidazole. The eluted protein was then diluted 100 fold in refolding buffer (100mM Tris-HCl, 1mM EDTA, 20% glycerol, 250mM L-arginine, 1mM reduced glutathione, 0.1mM oxidised glutathione, pH8.0) and left stirring overnight at 4°C. The protein could then be concentrated either by filter
20 centrifugation or repurification using a nickel-agarose column (after dialysis to remove the EDTA).

Protein Refolding Method 2

- The protein bound to nickel-NTA was batch washed with 8M urea, Tris-HCl, 250mM NaCl, pH 8.0 then 8M urea, Tris-HCl, pH 8.0 including 20 mM
25 imidazole, then 2M urea, Tris-HCl, pH 8.0. The protein was then refolded on the column by the addition of 100mM Tris-HCl, pH8.0, 250mM L-arginine, 1mM reduced glutathione, 0.1mM oxidised glutathione with incubation at 4°C and protein elution performed using, 100mM Tris-HCl, pH 8.0 with 0.5 M
30 imidazole.

Immediately active (mature) proteinase was obtained using protein refolding method 1 and concentrating the dilute refolded enzyme by filter centrifugation. This method, however, did result in a large degree of enzyme loss due to autoproteolysis. Both concentrating the protein refolded using method 1 by nickel column purification and using refolding method 2 resulted in greater recovery of the enzyme in its stable inactive pro-form. The pro-form could also be used to generate mature active falcipain 2, after incubation at 37°C.

The C-tagged construct outlined above enables rapid concentration and recovery after protein refolding and circumvents problems with autoproteolysis. Unlike the N-tagged constructs described in Shenai et al J Biol Chem 275 37 29000-29010m, the constructs described here can be refolded on the surface of an insoluble matrix, for instance bound to a purification column. Additionally the proregion can act as an enzyme inactivating sequence analogous to the native enzyme making work with the enzyme more predictable ie the stable inactive enzyme can be controllably activated when needed. An N-terminal tag would tend to prevent this normal functioning of the enzyme, as the proregion of the enzyme ought to be able to fold independently to direct the folding state of the mature enzyme domain. The tag described herein allows affinity purification to increase yields and enhance opportunities to isolate stable proforms of the enzyme.

Accordingly there is described an enzymatically active falcipain 2 construct comprising a covalently bonded C-terminal tag. The C-terminal tag may comprise polyhistidine, for example 4-8 residues, preferably 6. The construct described above has the tag at the C terminal of glutamic acid residue, but other constructs can shorten the enzyme by up to 10, for example 6-8 or 2-4 residues and retain a useful screening activity. Preferred constructs comprise the sequence enumerated above, optionally truncated at the C terminal as described herein.

Determination of falcipain 2 proteolytic catalytic activity

Convenient assays for falcipain 2 are carried out using recombinant enzyme prepared above. Alternatively, falcipain is assayed as described in Sijwali et al Prot Exp Purif 22, 128-134 (2001). Standard assay conditions for the
5 determination of kinetic constants used a fluorogenic peptide substrate, typically Boc-Val-Leu-Lys-AMC, and were determined in either 100 mM Mes/Tris/acetate, pH 7.0 containing 1 M NaCl and 10 mM 2-mercaptoethanol or 100 mM Na phosphate, pH 5.5 containing 1 M NaCl and 10 mM 2-mercaptoethanol. The enzyme concentration used was 2 nM. The stock
10 substrate solution was prepared at 10 mM in DMSO. Screens were carried out at a fixed substrate concentration of 80 μ M and detailed kinetic studies with doubling dilutions of substrate from 250 μ M. The total DMSO concentration in the assay was kept below 3%. All assays were conducted at ambient temperature. Product fluorescence (excitation at 390 nm, emission
15 at 460 nm) was monitored with a Labsystems Fluoroskan Ascent fluorescent plate reader. Product progress curves were generated over 15 minutes following generation of AMC product.

Inhibition Studies

20 Potential inhibitors were screened using the above assay with variable concentrations of the compounds in the table below. These compounds were prepared on solid phase using the methodology outlined above. Reactions were initiated by addition of enzyme to buffered solutions of substrate and inhibitor. K_i values were calculated according to equation 1

$$v_0 = \frac{VS}{K_M \left(1 + \frac{I}{K_i} \right) + S} \quad (1)$$

25 where v_0 is the velocity of the reaction, V is the maximal velocity, S is the concentration of substrate with Michaelis constant of K_M , and I is the concentration of inhibitor.

The compounds depicted in the table below above showed K_i values (at pH 7)
30 between 0.5 μ M and 2.7 μ M and are thus useful in the prophylaxis or treatment of parasite infections or infestations, such as malaria.

Naphthalene-2-carboxylic-acid-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide

Benzofuran-2-carboxylic-acid-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide

5-Methoxy-benzofuran-2-carboxylic-acid-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide

4-Acetylamino-*N*-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-benzamide

4-Hydroxy-*N*-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-3-morpholin-4-ylmethyl-benzamide

Biphenyl-4-carboxylic-acid-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide


4-*tert*-Butyl-*N*-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-benzamide

Benzothiazole-5-carboxylic-acid-[3-methyl-1S-(2R-methyl-4-oxo-tetrahydro-furan-3S-ylcarbamoyl)-butyl]-amide

Claims

1. A compound of the formula (IV):

5



where:

R1 = R'C(O) , R' SO2 ,

10 R' = a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or

R' = a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3
15 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b);

a) a cyclic group which may be linked direct to the R' ring or via an alkyl, alkylether, alkylthioether, alkylamine, alkylamide,
20 alkylsulphonamide, alkylsulphone, alkylurea, alkylketone or alkylester linker; or


b) H, C1-7alkyl, C3-6cycloalkyl, OH, SH, NH₂ , NHC1-3alkyl, N(C1-3alkyl)₂, halogen; or

c) O-C1-4alkyl, S-C1-4alkyl, SOC1-4alkyl, SO₂C1-4alkyl, CO₂C0-4alkyl, NHCOC0-4alkyl, CONHC0-4alkyl, COC0-C4alkyl,
25 NHC(=NH)NH₂;

R4 = H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl,;

R3 = C1-7-alkyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar;

30 R5 = C1-7-alkyl, halogen, Ar-C1-7-alkyl, C0-3-alkyl-CONR₃R₄ or R^{iv};

R^{iv} =

where $n = 1-3$, $m = 1-3$;

R^v , R^vi = H, C1-7-alkyl;

5 $A = N, CH$; $B = N, O, S, CH$;

R^{vii} = absent when $B = O, S$; or R^{vii} = H, C1-7-alkyl when $B = N, CH$;

R^{viii} = O, C1-7-alkyl;

H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO₂-R^{ix}, C1-3-alkyl-C(O)-NHR^{ix} or CH₂XAr,

10 R^{ix} is C1-7-alkyl, ArC1-7-alkyl or C3-C6-cycloalkyl;

q is 0 or 1

and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein R₄ and/or R₆ is hydrogen.

15

3. A compound according to claim 1 wherein the R' bicyclic ring is selected from naphthyl, quinolyl, benzofuranyl, benzothienyl, indolyl, indolinyl.

4. A compound according to claim 3, wherein the linkage is the 2 position
20 of the R' ring.


5. A compound according to claim 1 wherein R' is substituted with morpholine or N-methylpiperidine linked through an alkyl or alkylether linkage.

25 6. A compound according to claim 1, wherein R₁ is R'C(O).

7. A compound according to claim 1, wherein R₃ is 2-methylprop-1-enyl, benzyl or especially i-butyl.

8. A compound according to claim 1, wherein the stereochemistry at R3 corresponds to a natural or non natural L-amino acid.

- 5 9. A compound according to claim 1, wherein R5 is CH₃, C₂H₅, CH₂Ar, CH₂CONH₂, (CH₂)₂CONH₂, CH₂OH



- 10 10. A compound according to claim 9, wherein R5 is CH₃, CH₂CH₃, or CH₂OH..

11. A compound according to claim 1, wherein R5 and the C4 bond both have (R) stereochemistry.

15

12. A compound according to claim 1, wherein R5 and the C4 bond both have (S) stereochemistry.

13. A compound according to claim 1 wherein q is 1.

20

14. A compound according to claim 1, wherein q is 0.

15. A compound according to claim 1 wherein R' is a monocyclic ring substituted with a cyclic substituent.

25

16. A compound according to claim 15 wherein the monocyclic ring is pyridyl, pyrimidinyl or phenyl which is preferably substituted in the 3 or 4 position.

17. A compound according to claim 15 wherein the cyclic substituent is non-aromatic.
18. A compound according to claim 17 wherein the non-aromatic cyclic substituent is selected from the group consisting of pyrrolidine-1-yl, piperidine-1-yl, morpholin-4-yl, 4-methylpiperazin-1-yl, 2-morpholin-4-yl-ethylamino, and piperazin-1-yl.
19. A method for the treatment or prophylaxis of disorders dependent upon the activity of cathepsin K comprising the administration of a compound as defined in claim 1 to a mammal in need thereof.
20. A method according to claim 19 wherein the disorder is a bone disorder such as periodontitis or osteoarthritis.
21. A method according to claim 19 wherein the disorder is a cartilage or matrix degradation disorder such as osteoarthritis or rheumatoid arthritis.
22. A method according to claim 19 wherein the disorder is a neoplasia.
23. A method for the treatment or prophylaxis of a parasite infection comprising the administration of a compound as defined in claim 1 to a mammal in need thereof.
24. A method for the control of parasites comprising the administration of a compound as defined in claim 1 to an invertebrate vector and/or to a locus prone to infestation of such a vector.
25. A method for the preparation of a compound as defined in claim 1, comprising the steps of manipulating the protecting groups on a suitably protected carbohydrate derivative to effect deoxygenation at the anomeric position, introducing the R5 substituent via a ketone functionality, for example by Wittig chemistry, introducing the 4-amino group by further manipulation of the C4 secondary alcohol functionality to provide a protected 4-amino-5-

substituted pyranol, N-extending the amine function using peptide chemistry and adding the $R'C(=O)$ or $R'S(=O)_2$ capping group, further comprising the step of oxidising the pyranol before or after the N-terminal extension and/or capping.

5

26. A method for the preparation of a compound as defined in claim 1, comprising the steps of diazotisation of an O-protected, acyclic carboxylic derivative of a suitably derivatised 3-amino-4-substituted lactone, cyclising the diazomethylketone produced to afford a protected 4-amino-5-substituted
10 pyranone, N-extending the amine function using peptide chemistry and adding the $R'C(=O)$ or $R'S(=O)_2$ capping group

1718-196FPCprj.ST25.txt

SEQUENCE LISTING

```

<110> Medivir AB
<120> Cysteine Protease Inhibitors
<130> 1718-196FPC
<141> US 60/252,802
<151> 2000-11-17
<150> US 60/252,840
<161> 2000-11-17
<160> 4
<170> PatentIn version 3.0
<210> 1
<211> 39
<212> DNA
<213> artificial sequence
<220>
<221> primer for cDNA of cysteinyl proteinase (Falcipain 2)
<400> 1
cgcggatccg ccaccatgga attaaacaga ttgccgat
39

<210> 2
<211> 57
<212> DNA
<213> artificial sequence
<220>
<221> Primer for cDNA of cysteinyl proteinase (Falcipain 2)
<400> 2
cgcgtcgact taatgatgat gatgatgatg ttcaattaat ggaatgaatg catcagt
57

<210> 3
<211> 886
<212> DNA
<213> artificial sequence
<220>
<221> PCR product from amplification using primers for the cDNA sequenc
e of cysteinyl proteinase (Falcipain 2)
<222>
<221> CDS
<222> (3)..(848)
<400> 3
cc atg gaa tta aac aga ttt gcc gat tta act tat cat gaa ttt aaa
Met Glu Leu Asn Arg Phe Ala Asp Leu Thr Tyr His Glu Phe Lys
1 5 10 15
aac aaa tat ctt agt tta aga tct tca aaa cca tta aag aat tct aaa
Asn Lys Tyr Leu Ser Leu Arg Ser Ser Lys Pro Leu Lys Asn Ser Lys
20 25 30
tat tta tta gat caa atg aat tat gaa gaa gtt ata aaa aaa tat aga
Tyr Leu Leu Asp Gln Met Asn Tyr Glu Glu Val Ile Lys Lys Tyr Arg
35 40 45
gga gaa gaa aat ttc gat cat gca gct tac gac tgg aga tta cac agt
Gly Glu Glu Asn Phe Asp His Ala Ala Tyr Asp Trp Arg Leu His Ser
50 55 60
ggt gta aca cct gta aag gat caa aaa aat tgt gga tct tgc tgg gcc
Gly Val Thr Pro Val Lys Asp Gln Lys Asn Cys Gly Ser Cys Trp Ala
65 70 75 80

```


1718-196FPCprj.ST25.txt

65	70	75	
ttt agt agt ata ggt tcc gta gaa tca caa tat gct atc aga aaa aat			287
Phe Ser Ser Ile Gly Ser Val Glu Ser Gln Tyr Ala Ile Arg Lys Asn			
80	85	90	95
aaa tta ata acc tta agt gaa caa gaa tta gta gat tgt tca ttt aaa			335
Lys Leu Ile Thr	Leu Ser Glu Gln Glu	Leu Val Asp Cys Ser	Phe Lys
	100	105	110
aat tat ggt tgt aat gga ggt ctc att aat aat gcc ttt gag gat atg			383
Asn Tyr Gly Cys Asn Gly Gly Leu Ile Asn Asn Ala Phe Glu Asp Met			
	115	120	125
gga ggt ata tgt cca gat ggt gat tat cca tat gtg agt			431
Ile Glu Leu Gly Gly Ile Cys Pro Asp Gly Asp Tyr Pro Tyr Val Ser			
	130	135	140
gat ggt cca aat tta tgt aac ata gat aga tgt act gaa aaa tat gga			479
Asp Ala Pro Asn Leu Cys Asn Ile Asp Arg Cys Thr Glu Lys Tyr Gly			
	145	150	155
atc aaa aat tat tta tcc gta cca gat aat aaa tta aaa gaa gca ctt			527
Ile Lys Asn Tyr Leu Ser Val Pro Asp Asn Lys Leu Lys Glu Ala Leu			
	160	165	170
aga ttc ttg gga cct att agt att agt gta gcc gta tca gat gat ttt			575
Arg Phe Leu Gly Pro Ile Ser Ile Ser Val Ala Val Ser Asp Asp Phe			
	180	185	190
gct ttc tac aaa gaa ggt att ttc gat gga gaa tgt ggt gat gaa tta			623
Ala Phe Tyr Lys Glu Gly Ile Phe Asp Gly Glu Cys Gly Asp Glu Leu			
	195	200	205
aat cat gcc gtt atg ctt gta ggt ttt ggt atg aaa gaa att gtt aat			671
Asn His Ala Val Met Leu Val Gly Phe Gly Met Lys Glu Ile Val Asn			
	210	215	220
cca tta acc aag aaa gga gaa aaa cat tat tat tat ata att aag aac			719
Pro Leu Thr Lys Lys Gly Glu Lys His Tyr Tyr Tyr Ile Ile Lys Asn			
	225	230	235
tca tgg gga caa caa tgg gga gaa aga ggt ttc ata aat att gaa aca			767
Ser Trp Gly Gln Trp Gly Glu Arg Gly Phe Ile Asn Ile Glu Thr			
	240	245	250
tat gaa tca gga tta atg aga aaa tgt gga tta ggt act gat gca ttc			815
Asp Thr Ser Gly Leu Met Arg Lys Cys Gly Leu Gly Thr Asp Ala Phe			
	260	265	270
att cca tta att gaa cat cat cat cat cat cat taagtcgacg cgatcgaatt			868
Ile Pro Leu Ile Glu His His His His His His			
	275	280	
cctgcagccc ggggatcc			886
 <210> 4			
<211> 262			
<212> PRT			
<213> artificial			
 <400> 4			
Met Glu Leu Asn Arg Phe Ala Asp Leu Thr Tyr His Glu Phe Lys Asn			
1	5	10	15
Lys Tyr Leu Ser Leu Arg Ser Ser Lys Pro Leu Lys Asn Ser Lys Tyr			
	20	25	30
Leu Leu Asp Gln Met Asn Tyr Glu Glu Val Ile Lys Lys Tyr Arg Gly			
	35	40	45

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number
WO 02/088106 A3

(51) International Patent Classification⁷: **C07D 407/12**,
409/12, 309/14, 307/22, A61K 31/365, 31/343, A61P
19/10

(74) Agent: **SVENSSON, Leonard, R.**; Birch, Stewart, Ko-
lasch & Birch, LLP, P.O. Box 747, Falls Church, VA 22040-
0747 (US).

(21) International Application Number: **PCT/IB01/02906**

(22) International Filing Date:
16 November 2001 (16.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/252,802 17 November 2000 (17.11.2000) US
60/252,840 17 November 2000 (17.11.2000) US

(71) Applicant: **MEDIVIR AB [SE/SE]**; Lunastigen 7, S-141
44 Huddinge (SE).

(72) Inventors: **QUIBELL, Martin**; Medivir UK Ltd., Peter-
house Technology Park, 100 Fulbourn Road, Cambridge
CB1 9PT (GB). **TAYLOR, Steven**; Medivir UK Ltd.,
Peterhouse Technology Park, 100 Fulbourn Road, Cam-
bridge CB1 9PT (GB). **GRABOWSKA, Urszula**; Medivir
UK Ltd., Peterhouse Technology Park, 100 Fulbourn
Road, Cambridge CB1 9PT (GB). **NILSSON, Magnus**;
Medivir UK Ltd., Peterhouse Technology Park, 100 Ful-
bourn Road, Cambridge CB1 9PT (GB). **MORISSON,**
Veronique; Medivir UK Ltd., Peterhouse Technology
Park, 100 Fulbourn Road, Cambridge CB1 9PT (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).


Published:

— with international search report

(88) Date of publication of the international search report:
4 September 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CYSTEINE PROTEASE INHIBITORS



(57) Abstract: In formula (IV) R1 = R'C(O), R'SO₂, R' = a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b), and c) below; or R' = a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b); R4 = H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7-alkenyl; R3 = C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, C0-3-alkyl-CONR3R4 or a bulky amine, R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO₂-R^{1a}, C1-3-alkyl-C(O)-NHR^{1a} or CH₂XAR, q is 0 or 1, have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.

INTERNATIONAL SEARCH REPORT

 Internat. Application No
 PCT/IB 01/02906

A. CLASSIFICATION OF SUBJECT MATTER

 IPC 7 C07D407/12 C07D409/12 C07D309/14 C07D307/22 A61K31/365
 A61K31/343 A61P19/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, CHEM ABS Data, WPI Data, PAJ, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 50533 A (FENWICK ASHLEY EDWARD ;GRIBBLE ANDREW D (GB); SMITHKLINE BEECHAM P) 12 November 1998 (1998-11-12) cited in the application claim 1; tables 1,5	1-26
Y	HANZLIK R P ET AL: "VINYLOGOUS AMINO ACID ESTERS: A NEW CLASS OF INACTIVATORS FOR THIOL PROTEASES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 27, no. 6, 1 June 1984 (1984-06-01), pages 711-712, XP002037365 ISSN: 0022-2623 page 711, left-hand column, last paragraph --- -/--	1-26

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 April 2003

Date of mailing of the international search report

18/06/2003

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Härtinger, S

INTERNATIONAL SEARCH REPORT

Internu Application No
PCT/IB 01/02906

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 29408 A (GRIBBLE ANDREW D ;SMITHKLINE BEECHAM PLC (GB); WITHERINGTON JASON) 25 May 2000 (2000-05-25) examples 1,2 -----	1-26
A	WO 99 53039 A (SMITHKLINE BEECHAM CORP ;TOMASZEK THADDEUS ANTHONY (US); TEW DAVID) 21 October 1999 (1999-10-21) cited in the application page 6, line 7 - line 9 -----	1-26
A	WO 00 49011 A (MARQUIS ROBERT WELLS JR ;SMITHKLINE BEECHAM CORP (US); VEBER DANIE) 24 August 2000 (2000-08-24) *scheme 2* claim 2 -----	1-26
P,A	WO 00 69855 A (TAYLOR STEVEN ;MEDIVIR UK LTD (GB); QUIBELL MARTIN (GB); PEPTIMMUN) 23 November 2000 (2000-11-23) claim 1; examples -----	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 01/02906

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 19-24 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Ir on on patent family members

Intern Application No

PCT/IB 01/02906

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9850533	A	12-11-1998	AU 7562598 A 27-11-1998
			BR 9809306 A 04-07-2000
			CN 1255161 T 31-05-2000
			EP 1003846 A1 31-05-2000
			HU 0002247 A2 28-05-2001
			JP 2001525804 T 11-12-2001
			NO 995434 A 05-11-1999
			NZ 337889 A 28-09-2001
			PL 336856 A1 17-07-2000
			TR 9902766 T2 21-02-2000
			WO 9850533 A1 12-11-1998
			US 2002013360 A1 31-01-2002
			ZA 9803762 A 06-11-1998
WO 0029408	A	25-05-2000	WO 0029408 A1 25-05-2000
WO 9953039	A	21-10-1999	AU 3482099 A 01-11-1999
			CA 2327282 A1 21-10-1999
			CN 1304447 T 18-07-2001
			EP 1068304 A1 17-01-2001
			HU 0101513 A2 28-08-2001
			JP 2002511491 T 16-04-2002
			NO 20005032 A 16-11-2000
			PL 343373 A1 13-08-2001
			TR 200002940 T2 21-02-2001
			WO 9953039 A1 21-10-1999
			US 2002156018 A1 24-10-2002
WO 0049011	A	24-08-2000	AU 3235100 A 04-09-2000
			EP 1153022 A1 14-11-2001
			JP 2002537297 T 05-11-2002
			WO 0049011 A1 24-08-2000
			US 2002165222 A1 07-11-2002
WO 0069855	A	23-11-2000	AU 4772200 A 05-12-2000
			BR 0010553 A 02-07-2002
			CA 2374297 A1 23-11-2000
			EP 1178986 A2 13-02-2002
			WO 0069855 A2 23-11-2000
			JP 2002544274 T 24-12-2002